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Abstract 
The sialic acids represent a structurally and functionally diverse family of nine-carbon keto 
sugars. These compounds, derived structurally from neuraminic acid, are central to many of 
life’s processes at the molecular level. N-Acetylneuraminic acid (NeuNAc) is the most 
naturally abundant of the sialic acids and acts as the terminal residue of mammalian cell 
surface glycoconjugates. The negative charge and exposed location of NeuNAc makes this 
compound intrinsically linked to cellular signalling, recognition and adhesion events. While 
NeuNAc expression is typically restricted to eukaryotic phyla, some pathogenic bacteria have 
evolved to express NeuNAc on their own cell surfaces, allowing them to mimic the surface 
physiology of their mammalian host’s cells and evade detection by the immune system. In 
bacteria, NeuNAc biosynthesis proceeds via the aldol-like condensation reaction of 
phosphoenolpyruvate (PEP) with the sugar-substrate N-acetylmannosamine (ManNAc). 
Alternatively, in mammalian systems ManNAc is first phosphorylated to ManNAc 6-
phosphate (ManNAc 6-P) before undergoing condensation with PEP to give NeuNAc 9-
phosphate (NeuNAc 9-P). These PEP condensation reactions are catalysed by an 
evolutionarily related family of homo-dimeric (βα)8 barrel enzymes (NeuNAc synthase in 
bacteria and NeuNAc 9-P synthase in mammals), referred to collectively as the sialic acid 
synthases.  
In addition to NeuNAc, several pathogenic bacteria synthesise a number of unique ‘bacterial 
sialic acids’, including legionaminic and pseudaminic acid, which are known to be essential 
for the motility and pathogenicity of some species. These alternate sialic acids are again 
biosynthesised via condensation reactions of PEP with variable sugar substrates, catalysed by 
additional members of the sialic acid synthase family.  
In chapter two of this thesis, I report a structural and functional characterisation of human 
NeuNAc 9-P synthase. Modelling and mutagenesis were used to delineate possible sugar-
substrate binding modes, with a number of potentially important phosphate binding residues 
identified. Biophysical analysis reveals the human enzyme adopts a domain-swapped homo-
dimeric conformation in solution, as previously observed for the analogous enzyme from 
Neisseria meningitidis. 
Chapter three details an investigation into the variable sugar-substrate specificity of 
mammalian and bacterial sialic acid synthases, which are apparently selective for their 
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respective sugar-substrates depending entirely upon the presence or absence of the C-6 
phosphate group. Bioinformatic analysis of bacterial and mammalian sequences revealed the 
β2α2 loop of the catalytic barrel as a putative sugar-substrate selectivity element. Substitution 
of the bacterial loop with the mammalian loop sequence however was alone insufficient to 
confer novel activity with the mammalian sugar-substrate.  
In chapter four, the β2α2 loop of the bacterial sialic acid synthases; legionaminic acid synthase 
(LegS) and pseudaminic acid synthase (PseS), was again identified as a structural element 
potentially involved in the sugar-substrate selectivity of these enzymes. Generation of 
chimeric LegS and PseS variants incorporating the β2α2 loop from bacterial NeuNAc 
synthase was unsuccessful at conferring novel NeuNAc synthase activity due to unforeseen 
disruption of PEP binding and quaternary structure.  
The work presented in this thesis provides a starting point from which to pursue a 
comprehensive understanding of the molecular basis of sugar-substrate specificity of the 
sialic acid synthases. An appreciation of how these enzymes achieve precise sugar-substrate 
specificity may provide the basis for their exploitation as therapeutic or biosynthetic targets. 
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Chapter 1: Introduction           
1.1 The sialic acids             
1.1.1 Overview                      
The sialic acids comprise a diverse family of nine-carbon α-keto sugars, the majority of 
which are structural derivatives of neuraminic acid (Figure 1.1).
1
 Neuraminic acid has an 
amino moiety at the C-5 position, and carboxylate at C-2 which confers negative charge at 
physiological pH.
2
 While unsubstituted neuraminic acid is not known to exist in nature, over 
40 substituted variations (classified as sialic acids) have now been described.
2
 Common 
modifications to the core neuraminic acid framework include O-acetylation and esterification 
of the hydroxyl moieties, namely at positions C-7, C-8 and C-9 (Figure 1.1).
3
 Multiple 
substitutions at these positions allow further diversification of sialic acid structure. Other 
modifications include glycolation (e.g. N-glycolylneuraminic acid) and deamination (e.g. 2-
keto-3-deoxy-D-glycero-D-galacto-nononic acid) of the C-5 amino group.
3
 N-Acetylation at 
position C-5 yields N-acetylneuraminic acid (NeuNAc), which is by far the most prevalent 
sialic acid in nature and has become synonymous with the term sialic acid (which more 
correctly refers to the collective family of compounds structurally derived from the nine-
carbon neuraminic acid framework). 
2
 
 
 
 
 
 
Figure 1.1. The family of naturally occurring sialic acids, structurally derived from neuraminic acid (shown 
left). Figure adapted from Schauer (2004).
3
        
   
The structural diversity of the sialic acids allows these molecules to facilitate a wide range of 
biological functions, however sialic acid expression is not ubiquitous in nature.
2, 4
 Sialic acids 
are commonly expressed in members of the animal kingdom, particularly in higher organisms 
(echinoderms upwards). NeuNAc is prevalent in mammalian systems, where it acts as the 
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terminal residue of cell surface glycoconjugates and thus plays central roles in cell signalling, 
recognition and adhesion events.
1-2, 4
  
In addition to mammalian systems, biosynthesis of NeuNAc has been detected in insects, 
including larval stage Drosophila melanogaster.
5
 Unlike animals, plants and prokaryotes 
typically lack NeuNAc expression. A definitive NeuNAc biosynthetic pathway is yet to be 
elucidated for any plant species however there is some evidence to suggest such pathways 
exist.
6
 Prokaryotic expression of sialic acids is uncommon, however there are exceptions, and 
a number of gram-negative bacteria synthesise certain sialic acids.
7
 By integrating NeuNAc 
into their own cell surface glycoconjugates, pathogenic bacteria are able to effectively mimic 
the surface physiology of their mammalian host’s cell and evade detection by the immune 
system.
1, 7
 Additionally, expression of the “bacterial sialic acids”; 5,7-diacetamido-3,5,7,9-
tetradeoxy-L-glycero-L-manno-nonulosonic acid (pseudaminic acid) and 5,7-diacetamido-
3,5,7,9-tetradeoxy-D-glycero-D-galacto-nonulosonic acid (legionaminic acid) has been 
reported for a number of gram-negative bacteria.
8-10
 These compounds are apparently unique 
to bacteria and microorganisms, and are essential for the development of cell surface 
structures which aid in motility and pathogenicity.
9, 11
 
1.1.2 N-Acetylneuraminic acid   
 
NeuNAc contains an N-acetyl functionality at position C-5 (Figure 1.2) and is the most 
abundant sialic acid in nature.
2
 In mammalian systems, NeuNAc is incorporated as the 
terminal residue of glycoconjugates which decorate the cell’s surface.4 Because of this 
exposed terminal position, and the molecule’s negative charge at physiological pH, NeuNAc 
is involved in cellular recognition and adhesion events, notably during immune and 
inflammatory responses.
2-3
 Sialic acid binding lectins presented on the surface of immune 
effector cells mediate immune-responses via interaction with sialic acid ligands expressed by 
other cells.
12
 
 
         
                       
 
Figure 1.2. N-Acetylneuraminic acid is a nine-carbon amino-sugar. The C-1 carboxylate confers negative 
charge at physiological pH.         
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Under some circumstances, NeuNAc is implicated in inter-cellular repulsion via 
concentration of negative charge at the cell surface. This repulsive effect is thought to 
contribute to the metastatic potential of certain cancer cells, driving separation of cells from 
the bulk of the tumor mass.
13-14
 The negative charge of NeuNAc may also function to mask 
certain recognition sites, and protect underlying glycoconjugate regions from cellular 
degradation.
2
  
Sialic acids are expressed in nearly all mammalian tissue types, however the highest 
concentrations are found in the central nervous system (CNS).
15
 Gangliosides, being lipid 
based glycoconjugates, contain terminal NeuNAc residues in their oligosaccharide portion. 
These gangliosides are important for brain development and neuronal function.
16
 Increased 
NeuNAc concentration in brain gangliosides has been associated with enhanced neuritic 
growth, and neuro-protection from glutamate toxicity.
17
 Polymeric NeuNAc is also an 
important constituent carbohydrate of the CNS glycoprotein, neuronal cell adhesion molecule 
(NCAM), which is known to be important for cellular adhesion processes pertaining to 
cognition and neural plasticity.
18
 Proper sialylation of NCAM is required for its function, and 
has been shown to be essential for the foetal development of mice.
19
  
Because of the abundance of exposed NeuNAc in the CNS, neuroinvasive pathogenic 
bacteria such as Neisseria meningitidis and Escherichia coli K1 express NeuNAc on their 
own cell surfaces, allowing them to mimic the exterior of mammalian cells, and thus appear 
immunologically silent within their hosts.
7, 20
 This molecular mimicry makes it difficult for 
the immune system to identify and clear pathogenic invaders, and has hindered the 
development of polysaccharide vaccines against such pathogens.
21
 
NeuNAc presented on mammalian cell surfaces also facilitates the recognition and binding of 
certain viruses to host cells prior to internalisation.
22
 For this reason, structural analogues of 
NeuNAc have applications as anti-viral therapeutics, including the frontline influenza drugs 
Zanamavir (Relenza™) and Oseltamivir (Tamiflu®).23 These NeuNAc analogues are potent 
inhibitors of the influenza neuraminidase enzyme which functions to hydrolyse the terminal 
NeuNAc residue from cell surface glycoconjugates.
24
 By cleaving this terminal sugar moiety, 
nascent viral particles are able to be released from the surface of the infected cell.
24
 
Neuraminidase inhibitors prevent cleavage of the NeuNAc residue which binds the virus 
particle to the cell surface, thus preventing distribution of the virus.
25
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1.1.3 N-Acetylneuraminic acid biosynthesis 
 
The biosynthetic pathways of NeuNAc from both mammalian and bacterial systems are well 
documented (Figure 1.3).
26-31
 Both pathways begin with the activated sugar-substrate uridine 
diphosphate (UDP) N-acetylglucosamine (UDP-GlcNAc). Epimerisation and hydrolysis of 
this metabolite, catalysed by the enzyme UDP-GlcNAc 2-epimerase, generates the amino 
sugar N-acetyl mannosamine (ManNAc).
30
 The bacterial pathway utilises ManNAc directly 
in an aldol-like condensation reaction with phosphoenolpyruvate (PEP) to form NeuNAc, a 
reaction catalysed by the enzyme NeuNAc synthase (NeuNAcS).
28, 32
 Interestingly, the 
mammalian pathway involves an additional step in which ManNAc is first phosphorylated 
via ManNAc kinase activity to ManNAc 6-phosphate (ManNAc 6-P).
29
  
 
 
 
 
 
 
 
Figure 1.3. The NeuNAc biosynthetic pathway from bacterial and mammalian systems. The bacterial pathway 
utilises ManNAc directly for condensation with PEP to yield NeuNAc (blue arrow). The mammalian pathway 
includes an additional two steps in which the precursor metabolite ManNAc is phosphorylated at C-6, and then 
following condensation with PEP, the product NeuNAc 9-P is dephosphorylated to yield NeuNAc (red arrows).  
ManNAc 6-P is the substrate for mammalian NeuNAc 9-phosphate synthase (NeuNAc 9-PS) 
which catalyses the aldol-like condensation of PEP with ManNAc 6-P to yield NeuNAc 9-
phosphate.
4, 27, 33
 This step is analogous to that catalysed by NeuNAcS in bacterial systems.
4
 
NeuNAc 9-P is subsequently dephosphorylated to form NeuNAc.
1
 A final step in both 
bacterial and mammalian systems generates ‘activated’ NeuNAc via conjugation to cytidine-
monophosphate (CMP), which acts as the glycosyl donor for incorporation into cell surface 
glycoconjugates.
31, 34
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1.1.4 2-Keto-3-deoxy-D-glycero-D-galacto-nononic acid  
 
Deaminated neuraminic acid 2-keto-3-deoxy-D-glycero-D-galacto-nononic acid (KDN) is 
another commonly occurring sialic acid in nature, but lacks the C-5 amine functionality of 
neuraminic acid (Figure 1.4).
35
 KDN, first discovered in trout egg glycoprotein, is widely 
expressed in animals and bacteria, however highest expression levels are seen within the 
lower-vertebrates.
36-37
  
 
 
 
Figure 1.4. Molecular structure of 2-keto-3-deoxy-D-glycero-D-galacto-nononic acid (KDN). 
Like NeuNAc, KDN is incorporated into the terminal position of almost all types of vertebral 
glycoconjugates.
35
 Common structural properties shared by these two sialic acids allow a 
degree of functional overlap; however biological roles unique to KDN arise through loss of 
the N-acetyl group. KDN is known to act as a capping residue of certain vertebral polysialic 
acid chains, preventing further sialylation of the glycan, and protecting against degradation 
by bacterial sialidases which specifically recognise terminal NeuNAc residues.
35, 38
 KDN is 
also a component of cell wall polysaccharides in some pathogenic bacteria.
39
 Elevated levels 
of free KDN have been detected in human foetal red blood cells with comparison to maternal 
red blood cells, and also in ovarian cancer cells, suggesting that KDN may play roles 
involved in normal development and tumor malignancy.
40
  
The biosynthesis of KDN is largely unresolved, and remains a contentious topic. KDN 
biosynthesis is thought to proceed via a de-novo pathway from mannose 6-phosphate (Man 6-
P) and PEP, in a process analogous to mammalian NeuNAc biosynthesis.
41
 Purified fractions 
from trout tissue were shown to contain KDN 9-phosphate (KDN 9-P) synthase activity. The 
authors postulate that this activity was separate to that of NeuNAc 9-PS, which in humans, 
has secondary KDN 9-P synthase activity.
37, 41
 The ability to additionally utilise Man 6-P in 
catalysis, albeit with far lower efficiency than ManNAc 6-P, gives human NeuNAc 9-PS a 
unique bi-functional character not yet observed in other mammalian orthologues.
37
 To date, 
no genes encoding a distinct KDN 9-P synthase have been identified, making it difficult to 
delineate the enzymes of KDN biosynthesis from those involved in NeuNAc biosynthesis.  
 6 
 
1.1.5 Legionaminic acid 
 
Legionaminic acid (5,7-diacetamido-3,5,7,9 tetradeoxy-D-glycero-D-galacto-nonulosonic 
acid; Leg) is one of several sialic-acid like sugars often referred to as “bacterial sialic 
acids”.20 Such compounds are apparently unique to microorganisms and bacteria.10 Leg is N-
acetylated at positions C-5 and C-7, and lacks the C-9 hydroxyl of the neuraminic acid core 
(Figure 1.5). Stereochemically, Leg retains the same absolute configuration as NeuNAc.
10
 
Leg is a constituent of the lipopolysaccharides (LPS) of gram-negative pathogenic bacteria 
including Legionella pneumophila, the bacterial pathogen responsible for the acute 
respiratory condition Legionnaire’s disease.42-43 Leg residues have also been detected within 
the glycan portion of flagellar glycoproteins from the pathogen Campylobacter coli.
44
 Heavy 
post-translational glycosylation of flagellar proteins is known to be critical for bacterial 
motility and pathogenicity.
45-47
 
 
 
 
Figure 1.5. Molecular structure of 5,7-diacetamido-3,5,7,9 tetradeoxy-D-glycero-D-galacto-nonulosonic acid 
(legionaminic acid). 
A full biosynthetic pathway of Leg has been reported for Campylobacter jejuni (Figure 1.6), 
and was suggested to proceed via unique guanosine-diphosphate (GDP) linked intermediates, 
differing from the previously described sialic acid biosynthetic pathways which utilise UDP-
linked intermediates.
10
 The proposed legionaminic acid biosynthetic pathway begins with the 
glycolytic intermediate fructose 6-phosphate. Seven subsequent reactions yield the metabolite 
GDP-2,4-diacetamido-2,4,6-trideoxy-gluco-pyranose. Simultaneous hydrolysis of the C-1 
nucleotide diphosphate (NDP) and epimerisation at C-2 is catalysed by the enzyme GDP-
sugar hydrolase/2-epimerase, generating the sugar-substrate 2,4-diacetamido-2,4,6-trideoxy-
D-manno-pyranose. This compound undergoes condensation with PEP to form legionaminic 
acid, a reaction catalysed by legionaminic acid synthase (LegS), an enzyme thought be 
analogous to those that catalyse the PEP condensation reactions of the NeuNAc and KDN 
biosynthetic pathways.
10
 As for NeuNAc and KDN, a final step in the pathway conjugates 
Leg to CMP, activating it for incorporation into glycoconjugates.
10
 It should be noted that in 
contrast to the proposed Leg biosynthetic pathway described above, Glaze et al previously 
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identified a pathway which instead utilises UDP-linked intermediates.
42
 It is likely that more 
than one NDP is capable of fulfilling this role.  
 
 
 
 
 
 
 
Figure 1.6. The biosynthetic pathway of legionaminic acid as proposed by Schoenhofen et al.
10
 
1.1.6 Pseudaminic acid 
 
Another common “bacterial sialic acid” is Pseudaminic acid (5,7-diacetamido-3,5,7,9-
tetradeoxy-L-glycero-L-manno-nonulosonic acid; Pse). This compound is a diastereomer of 
Leg, with inversion of stereochemistry at C-5, C-7 and C-8 (Figure 1.7).
9
  
 
 
 
 
Figure 1.7. Molecular structure of 5,7-diacetamido-3,5,7,9-tetradeoxy-L-glycero-L-manno-nonulosonic acid 
(pseudaminic acid). 
Much like Leg, Pse is an important sugar-component of the glycoproteins that make up 
bacterial flagella.
48
 In particular, Pse has been shown to be essential for the proper 
development of flagella in the gastrointestinal pathogens C. jejuni, C. coli and Helicobacter 
pylori.
11, 49-51
 Functional flagella are required for motility in these organisms, and motility is 
directly related to their capacity for virulence.
9, 11
 Mutant variants of C. jejuni and H. pylori 
unable to produce Pse were shown to be aflagellate, highlighting the fundamental role of 
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glycosylation in flagellar development.
11, 50
 This link to bacterial virulence has spurred 
interest in the pseudaminic acid biosynthesis pathway as a target for novel antibiotics.
9
 
The biosynthetic pathway of pseudaminic acid, elucidated first from H. pylori, begins with 
the activated sugar UDP-N-acetylglucosamine (UDP-GlcNAc) (Figure 1.8).
7
 Three further 
enzymatic conversions yield UDP-2,4-diacetamido-2,4,6-trideoxyaltrose. A UDP-sugar 
hydrolase catalyses the cleavage of UDP at C-1, forming 2,4-diacetamido-2,4,6-
trideoxyaltrose, which then undergoes a condensation reaction with PEP to form pseudaminic 
acid and inorganic phosphate.
9
 This PEP condensation reaction is catalysed by the enzyme 
pseudaminic acid synthase (PseS), again thought to be analogous to the PEP utilising 
enzymes of the previously described sialic acid biosynthesis pathways.
9
 CMP-pseudaminic 
acid synthase conjugates the product to CMP, activating the sugar for transfer to and 
incorporation into glycoconjugates.
9, 34
 
 
 
 
 
 
 
 
 
Figure 1.8. The pathway of CMP-pseudaminic acid biosynthesis. 
1.2 The sialic acid synthases         
       
The biosynthetic pathways leading to several commonly occurring sialic acids have been 
described in a number of organisms, as outlined previously. Common to all of these pathways 
is the central reaction step in which a sugar metabolite undergoes a condensation reaction 
with PEP to yield the respective sialic acid product. The PEP utilising aldolases which 
catalyse this reaction can be broadly classified as sialic acid synthases.
1, 52
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1.2.1 N-Acetylneuraminic acid synthase 
 
The most well understood of the sialic acid synthases is N-acetylneuraminic acid synthase 
(NeuNAcS), which has been rigorously characterised from a number of sources.
4, 32, 53-55
 In 
bacterial systems, NeuNAcS catalyses the aldol-like condensation reaction of ManNAc with 
PEP, forming NeuNAc and inorganic phosphate.
32
 In mammals (and a number of other 
animal phyla), an analogous enzyme catalyses the aldol-like condensation of ManNAc 6-P 
with PEP, yielding NeuNAc 9-P, and thus this enzyme is referred to as NeuNAc 9-P synthase 
(NeuNAc 9-PS).
4
 
NeuNAcS from the neuroinvasive pathogen N. meningitidis is the most highly characterised 
of the sialic acid synthases.
28, 32, 56
 While its identity was unknown at the time, NeuNAcS 
from N. meningitidis (NmeNeuNAcS) was first purified from crude cell lysate in 1962, and 
shown to irreversibly catalyse the condensation reaction of ManNAc and PEP to form 
NeuNAc.
28
  In 1983 a set of genes located within the 17 kilobase “kps cluster” of the E. coli 
K1 genome was identified as being necessary for the biosynthesis of the bacteria’s polysialic 
acid capsule.
57
 A number of mutations to the genes within this cluster resulted in acapsular 
mutants and complementation with functionally intact kps fragments was able to restore 
capsulation.
57
 One gene located within the kps cluster, NeuB, was shown to encode NeuNAc 
synthase activity in E. coli K1.
58
 Subsequently, the NeuB gene was successfully cloned and 
the gene product purified to homogeneity.
53
 NeuNAc synthase activity was then confirmed 
via a coupled enzymatic assay with CMP-NeuNAc synthetase, which resulted in formation of 
the end product CMP-NeuNAc.
53
 Purified E. coli K1 NeuNAcS was shown to be highly 
specific for the sugar-substrate ManNAc, with a range of alternate hexose and hexosamine 
sugars not able to be utilised by this enzyme for catalysis.
53
 
A gene sequence homologous to NeuB from E. coli K1 was then identified within the genome 
of Streptococcus agalactiae following a BLAST search of the EMBL/GenBank/DDBJ 
database.
55
 The gene product was purified to homogeneity and shown to facilitate the highly 
specific condensation of ManNAc and PEP to form NeuNAc. Furthermore, the authors 
demonstrated that this enzyme adopts a homo-dimeric structure in solution, and has an 
absolute requirement for divalent metal ions in catalysis, with manganese and magnesium the 
most activating of those tested.
55
 The identification of a NeuB homolog within the genome of 
N. meningitidis suggested that a common biosynthetic method may exist between many 
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species of gram-negative bacteria, and that the NeuNAcS activity originally isolated from N. 
meningitidis cell lysate was likely encoded by this NeuB sequence homolog.
59
   
1.2.2 Structure of N-acetylneuraminic acid synthase 
 
The molecular structure of NmeNeuNAcS (PDB: 1XUZ) was solved in 2005 using X-ray 
crystallography, and to date remains the only variant of any sialic acid synthase to have its 
complete structure solved and published.
32
 The initial structure was obtained from 
NmeNeuNAcS co-crystallised with Mn
2+
, PEP and a reduced open chain analogue of 
ManNAc (rManNAc), all of which are bound within the active site of the protein (Figure 
1.9).
32
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.9. The crystal structure of NmeNeuNAcS (PDB: 1XUZ). Each monomeric chain (top) consists of an 
AFPL domain (grey), flexible linker (yellow) and catalytic (βα)8 barrel domain (blue). Two identical chains 
associate to form a domain-swapped homo-dimer arrangement (bottom). 
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The monomeric chain of NmeNeuNAcS was shown to consist of a catalytic N-terminal (βα)8 
barrel domain (residues 1-273) and a C-terminal antifreeze protein like (AFPL) domain 
(residues 285-349) joined via a flexible linker region (Figure 1.9). Both of these domains 
were previously predicted to occur in NmeNeuNAcS based on sequence homology with 
previously solved protein folds, and while the (βα)8 barrel fold is common to PEP utilising 
enzymes (albeit with low sequence identity), the AFPL domain is entirely unique to the sialic 
acid synthases.
60-62
 The AFPL domain is named for its structural homology with the 
functional type III antifreeze proteins found in arctic fish.
63
 These small globular proteins 
facilitate the inhibition of ice crystal formation, and thus are involved in the freeze-tolerance 
and freeze-avoidance strategies required for the survival of these organisms in sub-zero 
environments.
63
 Like the type III antifreeze proteins, the AFPL domain of NmeNeuNAcS 
consists of four short β-strands, arranged to generate two-fold symmetry of two identical 
four-stranded motifs.
32
  
Consistent with in vitro analysis in solution, NmeNeuNAcS was shown to form a homo-
dimeric arrangement within the crystals asymmetric unit.
4, 32
 Interestingly, the dimer adopts a 
conformation in which the AFPL domain of one monomer interacts with the (βα)8 barrel 
domain of the other, forming a “domain-swapped” homo-dimer which has since been proven 
to be critical for catalysis (Figure 1.9).
64
 The active site of NmeNeuNAcS is housed at the C-
terminal face of the (βα)8 barrel domain, as is typical for enzymes of the (βα)8 barrel fold.
65
 
The AFPL domain of the opposing monomer effectively caps the active site from solvent, 
and additionally contributes a key arginine residue (Arg-314) which functions to steer 
ManNAc into a catalytically favoured orientation within the active site.
64
  
The active site of NmeNeuNAcS is defined largely by residues from β-strands two and four at 
the C-terminal of the (βα)8 barrel, however the linker region and AFPL domain also 
contribute residues to the active site (Figure 1.10).
32
 NmeNeuNAcS is known to be active 
only in the presence of divalent metal ions, and as such a single manganese ion is present 
within the active site of the NmeNeuNAcS structure.
4, 32
 The active site metal ion is 
coordinated with octahedral geometry by the imidazole moieties of His-215 and His-236, O-
2-P of PEP, O-1 of rManNAc and two water molecules.
32
 The C-1 hydroxyl of rManNAc 
coordinates the metal in this structure suggesting that the aldehyde which is present in the 
native substrate ManNAc may similarly coordinate the metal thus allowing activation of the 
carbonyl centre for nucleophilic attack by PEP.
32
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Figure 1.10. Active site depiction of NmeNeuNAcS with rManNAc (yellow), PEP (orange) and Mn
2+
 (pink 
sphere) bound (PDB: 1XUZ). Note the side-chain of Arg-314 (blue) from the opposite monomer extending into 
the active site where it forms critical interactions with the sugar-substrate via water molecules (blue spheres). 
The substrate analogue rManNAc forms interactions with the highly conserved active site 
residues Asn-74, Asp-247, Gln-55 and Tyr-186 of NmeNeuNAcS. Interestingly, Arg-314 
from the AFPL domain of the adjacent monomer extends into the active site and forms 
hydrogen bonding interactions with the N-acetyl group of rManNAc via active site water 
molecules.
32
 Deletion of this highly conserved residue renders NmeNeuNAcS catalytically 
inert.
64
 PEP also makes a number of interactions within the active site. The phosphate group 
of PEP forms hydrogen bonds with three conserved serine residues (Ser-132, Ser-154 and 
Ser-213) and Asn-184, while the PEP carboxylate is shown to form electrostatic interactions 
with two nearby lysine residues (Lys-129 and Lys-53).
32
  
1.2.3 Proposed catalytic mechanism of N-acetylneuraminic acid synthase 
 
NeuNAcS catalyses the aldol-like condensation reaction of PEP with the sugar-substrate 
ManNAc, to form NeuNAc.
28, 32
 Preliminary mechanistic studies on NeuNAcS from C. jejuni 
using deuterated substrates demonstrated that the enzyme catalysed reaction is stereospecific 
for nucleophilic attack of the si face of PEP with the si face of the aldehydic (open-chain) 
form of ManNAc.
54
 Subsequent labelling studies with NmeNeuNAcS showed that 
isotopically labelled 
18
O (bridging C-2 and P atoms)
 
from PEP is released as free phosphate 
through the course of the catalytic cycle.
32
 This observation has important implications for 
the proposed reaction mechanism. The loss of labelled 
18
O
 
as free phosphate suggests a 
mechanism which proceeds via a tetrahedral intermediate.
32
 Based on the results of their 
18
O
 
Helix 2 
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labelling studies, Gunawan et al proposed a C-O cleavage mechanism (Figure 1.11).
32
 
Electrons from the enol group of PEP initially attack the C-1 aldehyde of ManNAc, yielding 
an oxocarbenium ion intermediate. Catalytic water present in the active site then attacks the 
electrophilic oxocarbenium carbonyl centre, generating a tetrahedral intermediate which 
spontaneously releases free phosphate (containing the labelled bridging oxygen atom) via C-
O bond cleavage. The elimination of phosphate yields open chain NeuNAc which will cyclise 
to its stable pyranose form in solution. This C-O bond cleavage mechanism is well 
documented in related PEP utilising enzymes including 3-deoxy-D-arabino-heptulosonate 7-
phosphate synthase (DAH7PS) and 2-keto-3-deoxy-D-manno-octulosonate-8-phosphate 
synthase (KDO8PS).
66-67
 
 
 
 
 
Figure 1.11. The proposed catalytic mechanism of NmeNeuNAcS proceeds via oxocarbenium ion and 
tetrahedral intermediates. 
For this reaction mechanism to be plausible, the C-1 carbonyl of ManNAc requires activation 
to promote nucleophilic attack by PEP in the first step. Similarly the nucleophilicity of the 
catalytic water must be increased to promote attack of the oxocarbenium ion in the 
subsequent step. The rManNAc bound crystal structure of NmeNeuNAcS (PDB: 1XUZ) 
shows the active site divalent metal ion occupies a position proximal to the C-1 hydroxyl of 
the ManNAc analogue.
32
 It could be argued that the active site metal may coordinate the 
aldehyde oxygen of the native substrate, activating the aldehydic carbon to nucleophilic 
attack by PEP. Several suggestions for the identity of the species responsible for activating 
water have been made. A glutamate residue (Glu-134) within close proximity of the active 
site water may act as a base, deprotonating the water and thereby promoting attack on the 
proximal oxocarbenium ion intermediate.
32
 In addition, divalent metal ion coordination of the 
catalytically relevant water molecule may assist its deprotonation.
32
  
The catalytic activity of the sialic acid synthases is widely dependent on the presence of 
divalent metal ions.
4, 32, 54-55 
This metal dependency can be rationalised if the metal is 
involved in such roles as activation of the ManNAc aldehyde, and the catalytic water. 
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Crystallisation of NmeNeuNAcS in the presence of a stable de-oxy analogue of the supposed 
tetrahedral intermediate (Figure 1.12) provides strong evidence for a dual role of the divalent 
metal ion in catalysis.
56
  
 
 
 
 
 
 
Figure 1.12. NmeNeuNAcS active site depiction with putative (R)-configuration tetrahedral intermediate 
analogue (yellow) and Mn
2+
 (pink sphere) bound. 
The orientation of the tetrahedral intermediate analogue within the active site strongly implies 
the role of metal in both activation of the ManNAc aldehyde and delivery of water to the 
oxocarbenium ion in the following step of catalysis.
56
 This inhibitor bound crystal structure 
also provides rationalisation for the stereochemical preference of the C-2 (R) isomer, which 
was shown to inhibit NmeNeuNAcS more potently than its respective (S)-diastereomer.
56
 In 
its (R) configuration, the C-2 hydrogen projects towards the active site metal ion suggesting 
that the C-2 hydroxyl of the natural intermediate may coordinate to the metal ion.
56
 
Preferential binding of the C-2 (R) isomer suggests that this is the likely stereochemistry at C-
2 of the actual intermediate.
56
 The formation of this tetrahedral configuration would require a 
reaction mechanism that proceeds via the facial attack of catalytic water onto the si-face of 
the oxocarbenium ion intermediate.
56
  
Decomposition of the tetrahedral intermediate in the final step of catalysis releases free 
phosphate and NeuNAc to solution. The driving force behind the collapse of the tetrahedral 
intermediate is thought to be ionisation of the C-2 hydroxyl group.
32
 Promoting deprotonation 
of the C-2 hydroxyl may be a third role for the coordinated metal ion, or instead the function 
of a nearby basic residue.
32
 
There exists little experimental mechanistic data for any of the other sialic acid synthases, 
however sequence similarity implies that PEP and sugar-substrate condensation may proceed 
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via the same mechanism as is now well established for NmeNeuNAcS. Glu-25 and Glu-234 
are postulated catalytic residues involved in decomposition of the tetrahedral intermediate, 
these, along with the metal coordinating residues, are almost entirely conserved across phyla, 
suggesting a mechanistic commonality.
6, 32
 Furthermore, the metal dependency of all known 
sialic acid synthases suggests a common metallo-catalytic cycle. Further elucidation of the 
precise mechanism of the other sialic acid synthases will be made possible when high 
resolution crystal structures of these enzymes become available.  
The kinetic parameters of the NmeNeuNAcS catalysed reaction have been characterised using 
a number of alternative approaches. Hao et al (2005) reported steady-state kinetic parameters 
for NmeNeuNAcS based on a stopped thiobarbituric acid assay (TBA).
4
 NmeNeuNAcS was 
shown to have a KM (ManNAc) of 11.6 mM, suggestive of weak substrate binding. The 
catalytic turnover number (kcat) of this enzyme was reported as 49.8 catalytic cycles per 
second.
4
 A continuous coupled-assay monitoring the consumption of NADH (a by-product of 
coupling to NeuNAc lyase and lactate dehydrogenase) at 340 nm was then used to derive the 
same kinetic parameters.
32
 Using this method a KM (ManNAc) of 9.4 mM and a KM (PEP) of 
0.25 mM were calculated. More recently a continuous UV-visible assay directly monitoring 
the loss of PEP at 232 nm gave KM (ManNAc) of 2.9 mM, KM (PEP) of 0.028 mM and a kcat 
of 3.1 s
-1
.
64
 These values are lower than those previously reported, and perhaps reflect the 
increased sensitivity of the continuous assay employed.  
1.2.4 N-Acetylneuraminic acid 9-phosphate synthase 
 
The biosynthetic source of NeuNAc in animals was originally thought to be NeuNAc lyase, 
an enzyme which reversibly catalyses the cleavage of NeuNAc to ManNAc and pyruvate.
26
 
With equilibrium in favour of the reverse reaction, NeuNAc is formed preferentially. The 
distinct lack of NeuNAc lyase activity in tissues secreting NeuNAc containing glycoproteins 
however suggested an alternative route to NeuNAc biosynthesis may operate in animal 
systems. Indeed, a de-novo biosynthetic pathway for NeuNAc was identified in fractions 
purified from rat liver and bovine submaxillary glands.
29
 This pathway consists of three 
enzymes; a kinase responsible for phosphorylation of ManNAc, an aldolase and a 
dephosphorylating enzyme. The equilibrium of all three reactions was shown to greatly 
favour NeuNAc formation. The identified aldolase activity was confirmed in pig 
submaxillary gland extracts and shown to irreversibly catalyse the formation of NeuNAc 9-P 
from ManNAc 6-P and PEP, via a proposed condensation reaction mechanism.
27
 The aldolase 
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responsible was tentatively named N-acylneuraminic acid synthetase, but is now referred to 
as N-acetylneuraminic acid 9-phosphate synthase (NeuNAc 9-PS), and is known to be the 
primary facilitator of NeuNAc biosynthesis in animals.
1, 4
  
A homology search of the human gene database using the E. coli NeuB gene as the search 
entry identified a homologous sequence (36.1% identity at the amino acid level) encoding a 
359 amino acid protein with NeuNAc 9-PS activity.
37
 The recombinant gene sequence was 
shown to restore sialic acid synthase activity in NeuB-negative E.coli mutants and facilitate 
NeuNAc formation in insect cells.
37
 Interestingly, the same recombinant gene was also shown 
to cause in vivo production of 2-keto-3-deoxy-D-glycero-D-galacto-nononic acid (KDN).
37
 In 
humans, NeuNAc 9-PS has a unique bi-functional character, utilising both ManNAc 6-P and 
Man 6-P as sugar-substrates for the formation of NeuNAc 9-P and KDN 9-P respectively.
4, 6, 
37
 It should be noted however that human NeuNAc 9-PS (HsaNeuNAc 9-PS) shows far 
greater activity in the presence of ManNAc 6-P than Man 6-P and thus is primarily 
considered a NeuNAc 9-PS.
4
            
      
The steady-state kinetic parameters of various mammalian orthologues of NeuNAc 9-PS have 
been determined, and the reported parameters vary significantly between studies. The KM of 
ManNAc 6-P has been reported as 35 μM, 0.69 mM and 1.04 mM for rat, hog and human 
NeuNAc 9-PS respectively.
4, 33, 68
 The source of such disparity in values may be in the use of 
relatively insensitive stopped-assay methodologies, or the purity of the enzyme used. The KM 
for PEP has been reported as 105 μM for rat NeuNAc 9-PS, and is unreported for any other 
orthologue.
33
 Interestingly, human NeuNAc 9-PS is the only mammalian orthologue to also 
exhibit activity with Man 6-P, although this secondary activity has been observed in other 
animals including Drosophila melanogaster.
5
 The KM for Man 6-P has been reported as 2.6 
mM for HsaNeuNAc 9-PS.
4
 It is well accepted that Man 6-P is a far poorer substrate than 
ManNAc 6-P with respect to the human enzyme (with specificity constants, kcat/KM, of 4.3 
and 21 s
-1
 M
-1
 respectively).
4
 It is likely that the absence of the N-acetyl group attenuates 
binding affinity through reduced active site interactions. 
 
NeuNAc 9-PS from a number of sources has been purified and characterised (as outlined 
above), yet there remains no resolved full length crystal structure of any NeuNAc 9-PS. 
Considerable sequence homology strongly suggests that HsaNeuNAc 9-PS consists of the 
same overall folds as elucidated for NmeNeuNAcS, a catalytic (βα)8 barrel domain and C-
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terminal AFPL domain. This enzyme is known to exist as a functional dimer in solution and 
is expected to form the same domain-swapped homo-dimer arrangement as observed for 
NmeNeuNAcS.
4, 69
 
 In 2005, the structure of the small C-terminal AFPL domain of HsaNeuNAc 9-PS was 
solved in solution using NMR spectroscopy (PDB: 1WVO, Figure 1.13).
70
  This structure 
shows overall similarity to the bacterial AFPL domain from NmeNeuNAcS with a backbone 
root-mean-square deviation (RMSD) value of 0.90 Å relative to residues 7-66 from the 
solved human domain (Figure 1.13).
70
 Interestingly the human AFPL domain lacks the 
conserved residue Arg-314 that enters the active site in the bacterial enzyme. Instead, nearby 
conserved lysine residues may facilitate the required recognition and stabilisation of the 
mammalian substrate.
70
 Evolutionary analysis of the AFPL domain of human NeuNAc-9-PS 
and type III antifreeze proteins from both bacteria and vertebrates suggests that the sialic acid 
synthase domain may be the evolutionary precursor to type III antifreeze proteins in 
vertebrates.
70
 An antifreeze function of the ancestral sialic acid synthase domain may have 
evolved in response to changes in environmental temperature.
70
  
 
 
 
 
 
 
Figure 1.13. Structure of the HsaNeuNAc 9-PS AFPL domain (green, PDB: 1WVO) and structural alignment 
with the AFPL domain of NmeNeuNAcS (blue, PDB: 1XUZ).  
1.2.5 Legionaminic acid synthase  
 
The sialic acid synthases responsible for the production of sialic acids other than NeuNAc 
(i.e. the bacterial sialic acids) are generally lacking in characterisation, with only a handful of 
studies dedicated to these enzymes. The lack of a commercial supply of the complex sugar-
substrates, and the extensive organic synthesis protocol required to arrive at these products 
has been a major hurdle in the study of the bacterial sialic acid synthases. 
The bacterial sialic acid synthase, legionaminic acid synthase (LegS), catalyses the 
condensation of PEP with 2,4-diacetamido-2,4,6-trideoxy-D-manno-pyranose, analogous to 
the central condensation reaction catalysed by NeuNAcS as previously described.
10
 LegS has 
 18 
 
been minimally characterised from two bacterial sources (C. jejuni and L. pneumophila), and 
was proven to catalyse the aforementioned reaction by NMR, via a metal dependent C-O 
bond cleavage mechanism similar to that elucidated for NmeNeuNAcS.
10, 32, 42
 Interestingly, 
the characterised LegS from C. jejuni was also shown to exhibit low levels of NeuNAcS 
activity suggesting it may be bi-functional in nature.
11
  
1.2.6 Pseudaminic acid synthase  
 
Pseudaminic acid synthase (PseS) catalyses the condensation of PEP with 2,4-diacetamido-
2,4,6-trideoxyaltrose to form pseudaminic acid (Pse) in certain bacteria.
9, 48
 PseS has been 
characterised from C. jejuni and shown to catalyse the formation of Pse by 
1
H and 
31
P NMR 
via the metal dependent C-O bond cleavage mechanism common to the known sialic acid 
synthases.
48
 Kinetic analysis using a coupled enzymatic assay gave a KM (PEP) value of 6.5 
μM, and KM (2,4-diacetamido-2,4,6-trideoxyaltrose) of 9.5 μM, with a kcat of 0.65 s
-1
.
48
 
Unlike LegS, PseS does not exhibit observable secondary NeuNAcS activity.
11
  
The C. jejuni genome possesses at least three genes encoding sialic acid synthase 
functionality, NeuB1, NeuB2 and NeuB3. The first of these has been characterised as a 
NeuNAcS, and is 34% identical to E. coli NeuNAcS at the amino acid level.
54
 NeuB2 was 
shown to encode low levels of both LegS and NeuNAcS activity (as described above), and 
the NeuB3 gene product has been characterised as a PseS.
42, 48
 The fact that this organism 
contains genes for all three of these related sialic acid synthases makes it an extremely useful 
system for studying the determinants of sugar-substrate specificity between these enzymes. 
Understanding the structural basis for selection of one sugar-substrate over another may assist 
with the design of modified enzymes which could be used to selectively generate sialic acids 
of novel structure. Furthermore, understanding the ways in which these bacterial enzymes 
preferentially select and bind their sugar-substrates will assist in the development of potent 
active-site inhibitors as novel antibiotics. 
1.3 Sialic acid synthases as therapeutic targets                
                                                                                                                                                                                                                                          
Now begins a period of time which will be defined by the distinct threat posed by bacterial 
infections once treatable with common over-the-counter antibiotics. The rapid emergence of 
bacterial strains resistant to existing antibacterial compounds, coupled with a dwindling 
pharmaceutical interest in novel antibiotic development, means the return to a pre-antibiotic 
era has become a very real possibility.
71
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Antibiotic resistance is not a new phenomenon, nor is it the product of human intervention. In 
fact, antibiotic resistance genes in bacteria have been present and evolving for more than two 
billion years.
72
 Human interference has however altered the rate at which antibiotic resistance 
arises. The anthropogenic introduction of massive quantities of antibiotic compounds to the 
biome via treatment of patients and agricultural livestock provides the strong selection 
pressures necessary for the development of resistance mechanisms.
71 
A classic example is the now widespread methicillin-resistant Staphylococcus aureus 
(MRSA). MRSA was originally considered the archetypal hospital-superbug, but now exists 
as a community-acquired pathogen, and additional multi-drug resistant variants are 
commonplace.
73
 Widespread respiratory tract pathogens including Mycobacterium 
tuberculosis and Streptococcus pneumonia also exist abundantly in multidrug resistant forms, 
requiring treatment with drugs previously reserved for last-resort cases.
73
 The chief causative 
agent of bacterial meningitis in children, N. meningitidis, is also known to exist as entirely 
penicillin-resistant forms in some areas and poses an enormous threat, particularly to the parts 
of Sub-Saharan Africa in which infection is prevalent.
74
 So widespread and severe is the 
emergence of resistance that even last-resort drugs, such as vancomycin and the 
carbapenems, are ineffective against extremely drug resistant strains. The discovery of a β-
lactamase in the enterobacteriaceae species Klebsiella pneumonia, which specifically cleaves 
the lactam-ring of carbapenems, demonstrates the constant and unrelenting emergence of 
resistant bacteria, and the ever diminishing supply of drugs with which to treat them.
75
 
 The development of antibiotic compounds with novel mechanisms of action has never been 
more important. Circumventing the existing pathways of drug-resistance requires the 
identification and exploitation of new and unique bacterial targets. 
The sialic acid synthases potentially represents a family of novel therapeutic targets for the 
treatment of bacterial infections otherwise resistant to current therapies. Inhibition of 
bacterial NeuNAcS activity with high-affinity active site inhibitors would result in reduced 
NeuNAc expression at the bacterial cell surface, effectively exposing these cells to the host’s 
immune effectors. In this way, sialic acid synthase inhibitors could be considered secondary 
antibiotics, functioning to destroy the pathogen’s molecular disguise, and subsequently 
facilitating natural clearance by the immune system. Because sialic acid biosynthesis is 
central to normal human cell function, inhibitors must be entirely bacterio-specific and have 
no inhibitory effect on NeuNAc 9-PS activity. It is therefore important that we understand the 
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molecular determinants of substrate specificity between bacterial and mammalian sialic acid 
synthases to guide the design of inhibitors that will leave the mammalian pathway 
unperturbed. 
The bacterial sialic acid synthases, PseS and LegS, may also provide a unique opportunity for 
the exploitation of bacterial metabolism by novel drug compounds. Importantly, these 
enzymes are mostly exclusive to pathogenic gram-negative bacteria and their function is 
central to motility and virulence.
9-11
 Disruption of bacterial cell surface glycoconjugate 
structures (e.g. LPS and flagella), via inhibition of sialylation, would render these organisms 
unable to infect their host. Again, the development of inhibitors against these targets first 
requires an extensive understanding of the enzyme-catalysed reactions and the mode of 
natural substrate binding.  
In addition to this, human NeuNAc 9-PS may hold promise as a novel anti-cancer target. 
There is significant evidence to suggest that development of malignancy in cancer cells is 
linked to changes in cellular glycosylation, notably the composition of carbohydrate 
structures at the cell surface.
76
 A number of cancer types including Wilms tumor, colonic 
carcinoma and small cell lung carcinoma express elevated levels of cell-surface polysialic 
acid, which may contribute to the overall metastatic potential of these cells.
13
 The negative 
charge conferred by polysialylation of cancer cells may provide the cellular repulsion 
required to initially detach from the original tumor mass.
13
 Once mobile in the blood-stream, 
polysialic acid rich metastatic cancer cells may interact with sialic acid binding cell-adhesion 
molecules (e.g. E-selectin) at metastatic sites, facilitating infiltration of the endothelium, and 
establishment of a nascent metastatic tumor.
13, 76
 Furthermore, changes in the sialylation and 
expression of neuronal cell adhesion molecule promotes metastasis of cancer cells through 
modulated cell-adhesion processes.
13
  
Down-regulation of sialic acid expression at the cell surface through targeted inhibition of the 
NeuNAc biosynthesis pathway in cancer cells may provide a route to prevention or reduction 
of tumor metastasis. Further elucidation of the mechanisms linking polysialic acid over-
expression and malignancy/metastasis is necessary in order to design effective treatment 
strategies. 
Interestingly, a positive correlation was also detected between levels of free KDN, the 
alternate product of the HsaNeuNAc 9-PS catalysed reaction, and the malignant state of 
ovarian adenocarcinomas.
40
 Although the link between increased free KDN and tumor 
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malignancy remains unresolved, KDN levels may find use as a marker of malignant 
progression of certain ovarian cancers. It has also been suggested that free KDN levels may 
be an oncofetal antigen for early detection of ovarian cancer and potentially other types of 
human cancer.
40
  
1.4 Research aims          
      
The research undertaken during the course of this study had the general goal of elucidating 
the molecular basis of substrate specificity of the known sialic acid synthases. By 
understanding the structural elements which underpin the ability to specifically select for one 
or more sugar-substrates, we may gain insight into how these enzymes could be exploited as 
novel therapeutic targets and increase our understanding of how the family of sialic acid 
synthases have evolved to synthesise the diverse range of compounds we observe in nature. 
Additionally, modification of the enzyme’s structure to accommodate non-natural substrates 
in catalysis may allow the production of novel complex sialic acids with potentially useful 
applications.  
Before beginning to examine the determinants of sugar-substrate selectivity, I sought to 
further characterise wild-type human NeuNAc 9-PS, as structural and functional data 
pertaining to this important enzyme is relatively sparse. This section of research constitutes 
the second chapter of this thesis and includes: in vitro characterisation of the kinetic and 
thermodynamic parameters of the native reactions catalysed by HsaNeuNAc 9-PS; structural 
elucidation using homology modelling and mutagenesis; biophysical analysis of the protein’s 
functional arrangement in solution. 
In chapter three, I report an attempt to delineate the molecular basis of substrate specificity 
between NmeNeuNAcS and HsaNeuNAc 9-PS, which utilise the substrates ManNAc and 
ManNAc 6-P respectively. Identification of the structural elements and active site residues 
which allow the human and bacterial enzymes to select between substrates differing only by 
phosphorylation at C-6 may provide a basis for the design of bacterio-specific inhibitors 
which selectively target the bacterial enzyme, whilst leaving the human pathway unperturbed. 
A bioinformatic approach was taken to identify conserved putative sugar-substrate binding 
elements from each clade. A number of chimeric proteins combining structural elements from 
both NmeNeuNAcS and HsaNeuNAc 9-PS were then designed and generated in an attempt to 
interchange the sugar-substrate specificity of these enzymes.  
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In an extension of the work described in chapter three, the sugar-substrate specificity of two 
bacterial sialic acid synthases, LegS and PseS, was investigated as detailed in chapter four. 
The generation of chimeric proteins incorporating a NeuNAcS-like β2α2 loop sequence into 
these alternative sialic acid synthases was completed in an attempt to confer (or improve) 
activity with ManNAc, thereby assessing the relative importance of this loop for substrate 
selectivity. The aim of this work was to identify key sugar-substrate binding motifs which 
may aid in tracing the evolutionary changes which have occurred allowing these enzymes to 
utilise alternative sugar-substrates in catalysis and thus become specialised in their biological 
roles. 
Taken together, these three areas of focus aim to provide an increased understanding of the 
ways in which the sialic acid synthases specifically recognise and bind their appropriate 
sugar-substrates and provide future direction for the exploitation of these enzymes as either 
therapeutic targets, or as sources of complex novel sialic acids. 
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Chapter 2: Structural and functional characterisation of human N-
acetylneuraminic acid 9-phosphate synthase 
2.1 Overview 
                
In mammals, NeuNAc biosynthesis proceeds via the aldol-like condensation of ManNAc 6-P 
with PEP (Figure 2.1). This central reaction step, catalysed by NeuNAc 9-PS, yields NeuNAc 
9-P which is subsequently dephosphorylated to give the final product NeuNAc. This pathway 
differs from that utilised by bacterial systems, in which unphosphorylated ManNAc 
undergoes condensation with PEP to give NeuNAc directly. Bacterial NeuNAcS from a 
number of sources have been characterised in considerable depth however data pertaining to 
mammalian NeuNAc 9-PS remains relatively sparse.
4, 32, 54-55
  
 
 
 
Figure 2.1. The mammalian pathway to NeuNAc biosynthesis. 
This chapter details a structural and functional characterisation of human NeuNAc 9-PS 
(HsaNeuNAc 9-PS). Given that there is currently no full length crystal structure of any 
NeuNAc 9-PS orthologue available, we report here the generation of a HsaNeuNAc 9-PS 
homology model based on the structure of NmeNeuNAcS, and prediction of the sugar-
substrate binding mode, using induced-fit substrate docking. Site-directed mutagenesis was 
then used to validate the role of predicted active site residues in sugar-substrate binding. 
Furthermore, a range of biophysical techniques were used to corroborate the overall fold and 
native quaternary structure of wild-type HsaNeuNAc 9-PS, as predicted by the model. 
2.2 Homology modelling of wild-type HsaNeuNAc 9-PS     
           
As there is currently no full length crystal structure of HsaNeuNAc 9-PS, a homology model 
was generated by Dr. Wanting Jiao, using the PDB coordinates of the solved NmeNeuNAcS 
structure (PDB: 1XUZ) as a template (Figure 2.2). NmeNeuNAcS and HsaNeuNAc 9-PS 
share 29% sequence identity at the amino acid level (Appendix A). The homology model 
closely resembles the crystal structure of NmeNeuNAcS, with root-mean-squared deviation 
(RMSD) of 0.47 Å, and is predicted to form the same overall fold (Figure 2.3). 
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Figure 2.2. Homology model of HsaNeuNAc 9-PS showing domain-swapped homo-dimeric arrangement. 
 
 
 
 
 
 
 
Figure 2.3. Alignment of HsaNeuNAc 9-PS homology model with NmeNeuNAcS structure (PDB: 1XUZ). 
 
90˚ 
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2.3 Induced-fit substrate docking and rationale for mutagenesis     
  
In order to examine the possible interactions between the substrate ManNAc 6-P and the 
active site residues of HsaNeuNAc 9-PS, induced-fit docking was conducted by Dr. Jiao, for 
both chains in the dimer of the model, due to the difference in conformation of the predicted 
β2α2 loop in both subunits. The induced fit docking in chain A produced 11 output poses, the 
best scored of which was that with the shortest distance between the reaction centres of PEP 
and ManNAc 6-P (3.2 Å). Induced-fit docking of ManNAc 6-P into the chain B active site 
produced four output poses. The difference in the number of output poses between chains is 
likely due to differences in starting conformations of the active sites in both monomers. The 
best pose of ManNAc 6-P in chain B has a distance between the two reaction centres of 3.3 
Å. 
The best poses for both chains predict that PEP and the bound manganese ion form the same 
interactions as observed in the solved NmeNeuNAcS structure, which is not surprising given 
the conservation of the PEP and metal binding residues across phyla.
6, 32
 The active site Mn
2+
 
ion is coordinated with octahedral geometry by the imidazole side-chains of His-217 and His-
238, the O2P of PEP, O-1 of ManNAc 6-P and two water molecules.
32
 
The best ManNAc 6-P binding pose from chain A  predicts that the aldehyde oxygen and C-2 
acetamide hydrogen bond with the side-chain of Tyr-188 while Gln-54 hydrogen bonds with 
the C-3 and C-4 hydroxyl groups of ManNAc 6-P (Figure 2.4). The C-4 hydroxyl moiety 
additionally forms a hydrogen bond with Gln-54 via its amide side-chain. The anionic 
phosphate group is positioned closely to the positively charged residue Lys-290, with which 
it is predicted to form an electrostatic interaction. Intriguingly, Lys-290 is inserted into the 
active site from the AFPL domain of the other monomer, extending across the dimer interface 
to access the active site of the opposite chain. The phosphate group is also predicted to form 
hydrogen bonds with His-84 and Thr-80 from the catalytic barrel’s β2α2 loop. Overall, this 
pose of ManNAc 6-P is similar to the binding pose of rManNAc in the crystal structure of 
NmeNeuNAcS (PDB: 1XUZ), with respect to the positions of the N-acetyl and aldehyde 
groups (Figure 2.5). 
 
 
 
 26 
 
 
 
 
 
 
 
Figure 2.4. Stereo view of the best pose of docked PEP (orange) and ManNAc 6-P (yellow) from chain A. 
Residues contributed by chain A are shown in green, while residues contributed by chain B are shown in blue. 
 
 
 
 
 
 
 
Figure 2.5. Stereo view overlay of Chain A best pose active site residues (green) with NmeNeuNAcS (PDB: 
1XUZ) active site residues (purple). Mammalian substrates are shown in yellow, while bacterial substrates are 
coloured blue. 
The best output pose for Chain B predicts that the nitrogen of the C-2 acetamide group forms 
a hydrogen bonding interaction with Tyr-188, the C-3 hydroxyl group forms a hydrogen bond 
with Gln-54, and the carboxylate side-chain of Asp-247 hydrogen bonds with both the C-2 
and C-3 hydroxyl groups of ManNAc 6-P (Figure 2.6). The C-6 phosphate of the mammalian 
substrate is once again predicted to interact with the positively charged primary amine side-
chain of Lys-290, and additionally forms hydrogen bonds with Thr-72. 
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Figure 2.6. Stereo view of the best pose of docked PEP (orange) and ManNAc 6-P (yellow) from chain B. 
Residues contributed by chain B are shown in blue, while residues contributed by chain A are shown in green. 
Again, Lys-290 from the AFPL domain of the opposite chain is predicted to form an interaction with the 
phosphate group of ManNAc 6-P. 
 
 
 
 
 
 
 
 
Figure 2.7. Stereo view overlay of Chain B best pose active site residues (blue) with NmeNeuNAcS (PDB: 
1XUZ) active site residues (purple). ManNAc 6-P is shown in yellow, while ManNAc is shown in pink. 
In summary, the ManNAc 6-P binding residues, as predicted by induced-fit docking, are 
largely the same between the two chains of the homology model. Tyr-188, Gln-55 and Lys-
290 are predicted to form bonding interactions in both chains. Additionally, one of two 
threonine residues (Thr-72 or Thr-80) is predicted to form an interaction with the phosphate 
group of ManNAc 6-P, and both may contribute some degree of interaction. Of these 
residues, only Lys-290 and the variable threonine residues are predicted to interact with the 
C-6 phosphate group which is unique to the mammalian sugar-substrate. Furthermore, these 
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predicted residues are highly conserved and unique to mammalian NeuNAc 9-PS suggesting 
involvement in selection for and stabilisation of the phosphorylated sugar-substrate. 
In order to verify the role of predicted sugar binding residues, a selection of these were 
chosen for mutagenesis. The putative phosphate binding residues Lys-290 and Thr-80 were 
substituted for alanine (which has no capacity for hydrogen bonding) to probe the importance 
of the respective side-chain functionalities at these positions in sequence. Lys-290 provides a 
particularly appealing target for mutagenesis, considering it is located on the AFPL domain 
of the opposite monomer and apparently extends across the dimer interface to form an 
interaction with the unique phosphate group of the mammalian substrate. This interaction, if 
real, would have implications for the formation of the domain-swapped homo-dimeric 
arrangement we predict for HsaNeuNAc 9-PS. 
In addition to these two predicted phosphate binding residues, Lys-74 from the β2α2 loop was 
also chosen for mutagenesis to alanine. While not predicted to form a phosphate binding 
interaction by substrate docking, this cationic residue occupies a position in sequence which is 
potentially suggestive of involvement in binding the anionic phosphate group of ManNAc 6-
P. Lys-74 aligns closely with Asn-74 from NmeNeuNAcS, which is shown to anchor the C-6 
hydroxyl of rManNAc in the solved crystal structure. Due to the inherent flexibility of the 
β2α2 loop, the side-chain of Lys-74 may in-fact be able to adopt an orientation which allows 
electrostatic interaction with the charged phosphate group of ManNAc 6-P. Such a 
conformational reorientation may be too large to calculate with the induced-fit docking 
method used here. 
2.4 Cloning, expression and purification of wild-type HsaNeuNAc 9-PS and variants 
  
An E. coli codon optimised synthetic gene encoding wild-type HsaNeuNAc 9-PS (GenBank 
accession No. NP061819) was purchased (Life Technologies) as a Gateway® entry vector 
pDONR
TM
221 clone. The target gene was then successfully sub-cloned into the Gateway® 
expression vector pDEST
TM
17 which encodes an N-terminal histidine (His) tag as described 
in section 6.3.3. 
The aforementioned variants of HsaNeuNAc 9-PS (K290A, K74A, T80A) were generated by 
polymerase chain-reaction (PCR) site-directed mutagenesis (Section 6.3.6). The sequences of 
mutagenic primers used are shown in table 6.5. All mutagenesis was completed using the 
pDEST
TM
17 vector bearing the wild-type HsaNeuNAc 9-PS gene as the template, with 
 29 
 
PfuUltra DNA polymerase (Agilent). Successful amplification of the mutagenic products was 
determined by agarose gel electrophoresis, and all mutagenic genes were then sequence 
verified.   
Sequence verified pDEST
TM
17 vectors bearing wild-type and variant HsaNeuNAc 9-PS 
genes were then transformed into E. coli One Shot TOP10 cells (Invitrogen). Propagated 
plasmid from a selected transformant was then purified and used for transformation into E. 
coli BL21 (DE3) Star cells and E.coli BL21 (DE3) pBB540/pBB542 (Chaperone 3) cells for 
comparative expression testing. In order to test inducible expression of the target proteins, an 
induced culture (containing 0.5 mM IPTG) and non-induced culture of each cell line was 
grown overnight in lysogeny broth (LB). The best yield of soluble protein for wild-type 
HsaNeuNAc 9-PS and all variants was achieved when expressed in Chaperone 3 cells, and 
thus this cell line was chosen for up-scaled expression and purification of the desired 
proteins.  
All proteins were expressed and purified using the protocol outlined in section 6.4. Cells 
over-expressing the target proteins were harvested from 2 L of LB culture by centrifugation, 
and lysed using sonication. The soluble fraction of the resulting crude lysate was separated by 
centrifugation, and the His-tagged protein then separated from other soluble cellular protein 
using immobilized metal-affinity chromatography (IMAC). The N-terminal His-tag was then 
cleaved by overnight incubation with TEV protease. The cleaved His-tags and TEV protease 
were then separated from the target protein with another round of IMAC. Size-exclusion 
chromatography was then used as a final purification step, and the pure fractions pooled, 
flash frozen and stored at -80˚C. Protein purity was assessed using SDS-PAGE (Figure 2.8A).  
Following purification, mass spectrometry was used to confirm the correct molecular weights 
of wild-type and variant proteins (Appendix B).  Circular dichroism (CD) was used to ensure 
that variant proteins retained wild-type like secondary structure, and were correctly folded in 
solution (Figure 2.8B). 
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Figure 2.8. A) SDS-PAGE gel showing kDa molecular weight markers (M), purified wild-type HsaNeuNAc 9-
PS (1), purified HsaK290A (2), purified HsaK74A (3), and purified HsaT80A (4). B) CD spectra of wild-type 
HsaNeuNAc 9-PS and variants, showing retention of native secondary structure. 
2.5 Steady-state kinetics of wild-type HsaNeuNAc 9-PS and variants   
  
The kinetic parameters of purified HsaNeuNAc 9-PS and all mutant variants thereof were 
determined using a continuous UV-Vis assay monitoring PEP consumption at 232 nm as 
described in section 6.5.2 (Figure 2.9). 
Wild-type HsaNeuNAc 9-PS was shown to have a Michaelis constant (KM) of 45 ± 3 μM, 
and kcat of 1.5 ± 0.1 s
-1 
with respect to the sugar-substrate ManNAc 6-P (Table 2.1). The same 
enzyme was shown to have a significantly lower catalytic efficacy with its alternate substrate 
Man 6-P. A KM of 7.3 ± 1 mM and kcat of 0.13 s
-1 
±
 
0.01 gives a calculated Man 6-P 
specificity constant 2000-fold lower than that for ManNAc 6-P (Table 2.1). The absence of 
the C-2 N-acetyl functionality in Man 6-P means substrate-active site interactions are fewer, 
making it a relatively poor substrate. Furthermore, the measured specificity constant of 
HsaNeuNAc 9-PS for ManNAc 6-P is more than 300-fold greater than that reported for 
NmeNeuNAcS with ManNAc under similar conditions.
32 Maximal velocities were recorded 
for HsaNeuNAc 9-PS with PEP concentrations as low as 10 μM (at saturating concentrations 
of ManNAc 6-P), however an accurate KM value for PEP could not be determined due to 
constraints of the assay. 
A B 
M 1 2 3 4 
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Figure 2.9. Michaelis-Menten plots of wild-type and variant forms of HsaNeuNAc 9-PS at variable 
concentrations of ManNAc 6-P. 
KM (ManNAc 6-P) of the K290A variant was shown to be considerably increased 
(approximately 14-fold) over wild-type suggesting attenuated ManNAc 6-P binding, while 
KM (PEP) remained less than 10 μM. Similarly, a four-fold reduction in kcat was observed for 
K290A. Together, an increased KM (ManNAc 6-P) and reduced kcat results in a >50-fold 
decrease in the enzymes specificity constant with respect to its native substrate (Table 2.1).  
Unlike K290A, the K74A variant displayed near wild-type kinetic parameters (Table 2.1).                                                
Loss of the Thr-80 functionality, predicted to hydrogen bond with the C-6 phosphate group of 
ManNAc 6-P in chain A of the model, results in a two-fold increase in KM (ManNAc 6-P), 
and a resultant decrease in the enzymes specificity constant for this substrate (Table 2.1).  
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Table 2.1. Kinetic parameters of wild-type HsaNeuNAc 9-PS and mutant variants 
 
2.6 PEP binding studies of wild-type HsaNeuNAc 9-PS and variants   
  
Given that KM (PEP) is apparently very low (< 10 μM) and was not accurately quantifiable 
using the standard continuous assay, isothermal titration calorimetry (ITC) was employed to 
determine the dissociation constants (Kd) and binding enthalpies of PEP for wild-type 
HsaNeuNAc 9-PS and variants thereof (Table 2.2). It was observed that PEP binds with a 1:1 
molar ratio, as expected given each monomer of HsaNeuNAc 9-PS contains a single PEP 
binding site (Figure 2.10A). PEP binding is exothermic for HsaNeuNAc 9-PS, with an 
overall enthalpic change (∆H) of -2380 ± 13 cal/mol suggesting favourable hydrogen bond 
formation. Furthermore, PEP binding is associated with a favourable entropic change (-T∆S) 
of -5250 cal/mol, which may be indicative of displacement of solvent from the binding site. 
Interestingly, NmeNeuNAcS also exhibits entropically favoured PEP binding, but lacks the 
favourable enthalpic component shown here for HsaNeuNAc 9-PS (Section 3.9). This 
additional favourable enthalpy change may account for the lower dissociation constant (and 
therefore higher binding affinity) of PEP observed for HsaNeuNAc 9-PS over 
NmeNeuNAcS. 
 
 
 
 
                                            
Kinetic Parameter 
 
                               
Wild-type 
 
                           
K290A 
 
                            
K74A 
                            
T80A 
                                                  
KM (ManNAc 6-P) μM 
 
                             
45 ± 3 
                             
650 ± 50 
                                     
35 ± 1 
                                 
92 ± 10 
kcat (ManNAc 6-P) s
-1 1.5 ± 0.1 0.4  ± 0.1 1.6 ± 0.1 
 
 
1.4 ± 0.1 
                                            
kcat/KM  (ManNAc 6-P)  s
-1M-1 
 
 
                             
34000 ± 4000 
 
                                  
590 ± 60 
 
                            
46000 ± 1600 
                              
14700 ± 2500 
KM (Man 6-P) mM 7.3 ± 1    
kcat (Man 6-P) s
-1 0.13 ± 0.01    
kcat/KM  (Man 6-P)  s
-1M-1 
 
18  ± 2    
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Figure 2.10. (A-D) Raw ITC thermograms and model-fitted data for 2mM PEP titrations into 90 µM wild-type 
HsaNeuNAc 9-PS and variants. (E) Raw ITC thermogram and integrated data for 5mM ManNAc 6-P titration 
into 90 µM wild-type HsaNeuNAc 9-PS. 
 The Kd (PEP) for wild-type HsaNeuNAc 9-PS was measured as 2.6 ± 0.1 μM, consistent 
with a KM of less than 10 μM. All mutant variants exhibited Kd values consistent with the 
wild-type enzyme, suggesting introduction of these specific mutations has not significantly 
perturbed PEP binding (Table 2.2). It is interesting to note that while HsaT80A retains a near 
wild-type dissociation constant for PEP, the thermodynamic parameters of PEP binding are 
apparently altered for this variant (Table 2.2). It should be noted however that the full 
sigmoidal binding curve was not observed for HsaT80A and so the calculated 
         A. Wild-type                  B. K290A         C. K74A 
         D. T80A                      E. Wild-type 
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thermodynamic parameters should be viewed with scepticism (Figure 2.10D). Titration of 5 
mM ManNAc 6-P into HsaNeuNAc 9-PS, in the absence of PEP, did not elicit an observable 
binding event (Figure 2.10E) suggesting PEP is required for the subsequent binding of 
ManNAc. 
Table 2.2. Calculated thermodynamic parameters of PEP binding to wild-type HsaNeuNAc 9-PS and variants. 
2.7 Thermal stability          
  
The thermal stability of wild-type HsaNeuNAc 9-PS and variants was assessed using 
differential scanning fluorimetry (DSF) in the presence (and absence) of metal and ligands 
(Figure 2.11). Wild-type HsaNeuNAc 9-PS was shown to have a melt temperature of 43 ˚C, 
the same as that reported previously for wild-type NmeNeuNAcS.
77
  
 
 
 
 
 
 
                                                                                                                                                                                                         
            
                      
Figure 2.11. The effect of ligands on the thermal stability of wild-type HsaNeuNAc 9-PS and variants.  
All variant proteins exhibited similar melting temperatures to wild-type HsaNeuNAc 9-PS 
under each set of conditions. While no significant thermal shift was observed upon the 
addition of metal alone, the addition of 1 mM metal and 1 mM PEP results in a substantial 
 Wild-type HsaNeuNAc 9-PS 
 
 
 
 
 
K290A K74A T80A 
     
Kd (PEP) μM 
 
2.6 ± 0.1 3.2 ± 0.3 2.4 ± 0.3 9.2 ± 0.1 
∆H cal/mol -2380 ± 13 -2010 ± 30 -1880 ± 30 -14870 ± 55 
∆S cal/mol/deg 17.6 ± 2 18.4 ± 2 19.4 ± 2 -26.8 ± 3 
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increase in the thermal stability of both wild-type and variants. This result is consistent with a 
structural rearrangement upon PEP binding, possibly related to pre-organisation of the sugar 
binding site for ManNAc 6-P binding. Interestingly, the combination of Mn
2+
 and PEP 
confers almost twice the degree of thermal stabilisation as Mg
2+
 and PEP. No thermal 
stabilisation was observed when the protein was supplemented with metal and ManNAc 6-P. 
This is likely indicative of the inability of ManNAc 6-P to bind in the absence of PEP, 
corroborating the lack of ManNAc 6-P binding observed by ITC. 
2.8 Structural studies          
  
A number of in-solution techniques were used to validate the overall fold and quaternary 
structure predicted for HsaNeuNAc 9-PS by homology modelling. It has been previously 
reported that the wild-type enzyme exists predominantly as a native dimer in solution.
69
 The 
quaternary structure of all variants of HsaNeuNAc 9-PS was also assessed to ensure that any 
loss of functionality observed was not the result of disrupted oligomerisation. 
The native quaternary structure of wild-type HsaNeuNAc 9-PS and variants was assessed in 
solution by analytical gel filtration on a Superdex 200 10/300 column. Protein standards of 
known molecular weights were first used to generate a semi-logarithmic calibration curve of 
elution volume/void volume (Ve/Vo) versus molecular weight (Figure 2.12).  
 
 
 
 
 
 
 
Figure 2.12. Semi-logarithmic plots showing elution volume of target proteins relative to molecular weight 
standards. Standards used for calibration include at least five of the following: thyroglobulin (669 kDa), beta 
amylase (200 kDa), alcohol dehydrogenase (150 kDa), ovalbumin (43 kDa), conalbumin (75 kDa) and carbonic 
anhydrase (29 kDa). 
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The elution volume of His-tagged wild-type HsaNeuNAc-9-PS was measured and converted 
to molecular mass by substitution into the equation describing the linear calibration curve. 
The His-tagged wild-type enzyme elutes as a single species at 13.5 mL, with a calculated 
molecular weight of ~94 kDa (Table 2.3). This value is consistent with that of a dimeric 
species in solution (theoretical dimeric mass: 87.7 kDa), and corroborates a previous study 
suggesting HsaNeuNAc 9-PS exists primarily as a functional dimer.
69
 All mutant variants of 
HsaNeuNAc 9-PS were also shown to exist as dimeric species by analytical gel filtration 
under the experimental conditions used, confirming that introduction of respective sugar 
binding site mutations has not perturbed the enzymes quaternary structure. 
Table 2.3. Experimental parameters determined by analytical gel filtration 
 
Small angle X-ray scattering (SAXS) was then used to probe the solution structure of 
HsaNeuNAc 9-PS, and visualise any conformational change associated with PEP binding. 
Given the thermal stabilisation induced by PEP, and the observation that ManNAc 6-P does 
not bind in the absence of PEP, it was hypothesised that PEP binding induces a 
conformational active site rearrangement which primes the enzyme for ManNAc 6-P binding. 
A PEP induced conformational change has been described previously for NmeNeuNAcS, 
with a marked change in the SAXS profile observed upon PEP binding.
77
  
SAXS data was collected for HsaNeuNAc 9-PS at approximately 10 mg/mL, in the presence 
and absence of 1mM MnCl2 and PEP. Experimental scattering data was then compared to the 
theoretical scattering profile of the HsaNeuNAc 9-PS homology model using CRYSOL.
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Figure 2.13 shows the experimental scattering data for both unliganded and liganded 
HsaNeuNAc 9-PS overlaid with the theoretical homology model scattering. Samples were 
 Elution 
volume (mL) 
Elution vol/void 
vol 
Calculated molecular 
mass (Da) 
Theoretical 
dimeric mass (Da) 
Error 
(%) 
HsaNeuNAc 9-PS wild-
type (His-tagged) 
13.5 1.71 93800 87732 6.4 
HsaK290A (His-tagged) 13.6 1.72 90900 87619 3.6 
HsaK74A (His-tagged) 13.3 1.76 93300 87619 6.1 
HsaT80A 13.4 1.78 89100 80931 9.2 
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devoid of an increase in intensity at low q (indicative of aggregation) with Guinier plots 
linear for qRg < 1.3. 
Both apo and liganded protein data sets are in good agreement with the predicted homology 
model scattering, with chi-square values of 1.1 and 1.2 respectively. There is however no 
significant change in the scattering profiles of apo and PEP bound HsaNeuNAc 9-PS. 
 
 
 
 
 
 
 
 
 
 
Figure 2.13. Small angle X-ray scattering (SAXS) profiles of apo (blue) and PEP bound (red) HsaNeuNAc 9-
PS, fit to the predicted homology model scattering profile (black line).  
Using the structural parameters derived from SAXS experiments (Table 2.4), we are able to 
estimate overall volume and molecular mass of the protein in solution. The porod volume 
(VP) estimate obtained from scattering data is 106300 ± 11000 Å
-3
 and 115600 ± 12000 Å
-3
 
for liganded and unliganded wild-type HsaNeuNAc 9-PS respectively. This consistent with 
the theoretical volumes calculated from sequence. Using the online server MoW, this volume 
can be used to calculate the approximate molecular mass of the protein in solution.
79
 The 
calculated molecular mass of both liganded and unliganded HsaNeuNAc 9-PS is 
approximately twice the theoretical monomeric mass, confirming dimerisation in solution. 
Close agreement of the experimental scattering profiles with the predicted model scattering 
strongly implies HsaNeuNAc 9-PS forms the domain-swapped homo-dimeric arrangement 
that is predicted by the homology model, and has been observed previously for 
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NmeNeuNAcS.
32
 Such domain-swapping would allow the previously identified phosphate 
binding residue Lys-290 to extend into the active site from the AFPL domain of the opposite 
chain as predicted. 
Table 2.4. Experimental parameters obtained by small angle X-ray scattering (SAXS). 
Structural parameters HsaNeuNAc 9-PS + MnCl2  + PEP HsaNeuNAc 9-PS + MnCl2 
I(0) (cm
-1
) [from P(r)] 0.07 ± 0.01 0.05 ± 0.01 
Rg (Å) [from P(r)] 34.3 ± 1 34.8 ± 1 
I(0) (cm
-1
) (from Guinier) 0.07 ± 0.01 0.05 ± 0.01 
Dmax (Å) 118 ± 6 119 ± 6 
Rg (Å) (from Guinier) 33.8 ± 0.3 34.3 ± 0.3 
Porod volume estimate (Å
3
) 106300 ± 11000 115600 ± 12000 
Dry dimeric volume calculated from 
sequence (Å
3
) 
97,540  97,540  
Calculated monomeric molecular 
mass from sequence (Da) 
40495 40495 
Molecular mass from Porod volume 
(Da) (from MoW) 
88260  95940  
 
2.9 Crystallisation trials         
  
Extensive crystallisation trials were conducted for wild-type HsaNeuNAc 9-PS and variants. 
These trials included screening commercial crystallisation conditions (PACT premier, Clear 
Strategy I & II and JCSG Plus) at variable protein concentrations in the presence and absence 
of metal and PEP. While no crystals of sufficient diffraction quality were obtained from these 
trials, a number of positive leads were identified: 
1) Poor quality plate-like crystals formed after approximately seven days when fresh 
HsaNeuNAc 9-PS (6.95 mg/mL) was crystallised by hanging drop vapour diffusion method 
in the presence of 0.2 M sodium bromide, 0.1 M bis-tris propane (pH 7.5), 20 % w/v PEG 
3350, 1 mM PEP and 1 mM MgCl2 (Figure 2.14A). Similar crystals were obtained with 
alternate sodium salts (sodium nitrate, sodium formate, sodium acetate trihydrate). Diluting 
the entire condition to 85% of the original concentration yielded significantly improved 
crystals, but they continued to lack three-dimensionality (Figure 2.14B). Hanging drop 
vapour diffusion was completed in 24-well plates with a total reservoir volume of 500 µL and 
drop volume of 2 µL. 
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2) Needle-like crystals were observed after several days when fresh HsaNeuNAc 9-PS (6.95 
mg/mL) was crystallised by sitting drop vapour diffusion method with conditions from Clear 
Strategy I (well E1) and PACT premier (well C5) from 96-well plates (Figures 2.14C, 2.14D 
respectively). The latter diffracted to 3.4 Å but were not cryo-protected and did not survive 
90% attenuation. 96-well plates were screened using a TTP Labtech Mosquito screening 
robot, with final drop volumes of 400 nL. Optimisation of the aforementioned crystal leads 
was not completed, given time constraints. 
  
 
 
 
 
 
 
 
 
 
 
Figure 2.14. Initial crystallisation leads for wild-type HsaNeuNAc 9-PS. A) Plate-like crystals grown in 0.2 M 
sodium bromide, 0.1 M bis-tris propane (pH 7.5), 20 % w/v PEG 3350, 1 mM PEP and 1 mM MgCl2 (2 µL 
drop). B) Improved plate-like crystals grown in 85% final concentration of the condition used in A (2 µL drop). 
C) Needles grown in conditions from Clear Strategy I - E1 (400 nL drop). D) Needles grown in conditions from 
PACT premier - C5 (400 nL drop). 
2.10 Discussion           
  
Unlike bacterial NeuNAcS, which utilise the neutral amino sugar ManNAc in catalysis, 
mammalian NeuNAc biosynthesis proceeds via condensation of PEP with the phosphorylated 
substrate ManNAc 6-P. By utilising a charged, phosphorylated sugar-substrate, the 
mammalian enzyme gains increased substrate specificity over its bacterial counterpart. This is 
evident in the massive reduction of the human enzymes KM (ManNAc 6-P), and subsequent 
A B C 
D 
D 
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rise in specificity constant for ManNAc 6-P, relative to that of NmeNeuNAcS for ManNAc.
32, 
64
 The high affinity interactions afforded by the additional phosphate group allows the 
mammalian enzyme to be more specific for its substrate, which is particularly important in a 
cellular environment rich in alternate hexose and hexosamine sugars, and contributes to the 
overall precision of sialic acid metabolism in mammalian systems. 
Lys-290, from the AFPL domain of the opposite monomer, in part contributes to the 
selectivity for this unique mammalian substrate, by forming a high affinity interaction with 
the C-6 phosphate group. Given the abundance of cationic residues present on the proximal 
β2α2 loop, it is interesting to discover that electrostatic stabilisation of the sugar-substrate 
phosphate group is achieved partially through interaction with this lysine residue from the 
adjacent monomer. Insertion into the active site from a location distant in sequence is 
reminiscent of Arg-314, a conserved bacterial NeuNAcS AFPL domain residue known to be 
critical for catalysis in NmeNeuNAcS. The insertion of Lys-290 into the active site from the 
AFPL domain of the adjacent monomer provides rationalisation for the formation of the 
functional domain swapped homo-dimeric arrangement. It is likely that monomeric variants 
of HsaNeuNAc 9-PS would have reduced or abolished catalytic ability through lack of this 
‘borrowed’ active site residue.   
The binding mode of ManNAc 6-P, shown here to rely on a Lys/Thr pair for phosphate 
binding shares some commonality with related PEP utilising aldolases. 3-deoxy-D-arabino-
heptulosonate 7-phosphate synthase (DAH7PS) for example utilises the phosphorylated 
sugar-substrate erythrose 4-phosphate, and a conserved Arg/Thr or Arg/Ser pair, also located 
on the β2α2 loop of the enzymes catalytic (βα)8 barrel domain, fulfils the phosphate binding 
role.
67, 80-81
 The key difference however is that the conserved pair of phosphate binding 
residues in DAH7PS are adjacent in sequence. In HsaNeuNAc 9-PS, Thr-80 is indeed 
adjacent in sequence to a lysine residue, but this lysine is not predicted to interact with the 
phosphate group. Instead, Lys-290, distant in sequence to the functional threonine, is 
apparently recruited for ManNAc 6-P binding.   
Substrate binding to HsaNeuNAc 9-PS appears to be sequential, with no ManNAc 6-P 
binding event observable in the absence of PEP. It is possible that PEP binding drives pre-
organisation of the active site, which promotes subsequent sugar-substrate binding, as 
previously observed for NmeNeuNAcS.
77
 The thermal stabilisation conferred by PEP 
provides some evidence for an induced conformational rearrangement or structural 
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rigidification, however the lack of change between liganded and unliganded SAXS profiles 
suggests that any such rearrangement does not significantly affect the average global 
structure of the enzyme. The favourable entropic change associated with PEP binding (also 
observed for NmeNeuNAcS) is likely to involve displacement of water from the active site 
upon binding. The entropic gain achieved by solvent exclusion would potentially compensate 
any entropically disfavoured conformational rearrangement associated with PEP binding. 
Interestingly, PEP binding to the human enzyme is also driven by an enthalpic component not 
observed for NmeNeuNAcS. 
To conclude, we have identified a number of key residues likely to be involved in the 
selection and stabilisation of the phosphorylated sugar-substrate of HsaNeuNAc 9-PS. 
Further elucidation of the specific substrate binding interactions will require access to a high 
resolution crystal structure. 
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Chapter 3: Determinants of the sugar-substrate specificity of bacterial and 
mammalian sialic acid synthases  
3.1 Overview           
  
As previously described, the pathways of NeuNAc biosynthesis differ between mammalian 
and bacterial systems.
1, 4
 In bacteria, NeuNAcS catalyses the aldol-like condensation of 
ManNAc and PEP to form NeuNAc directly.
32
 The mammalian PEP condensing enzyme, 
NeuNAc 9-PS, is however unable to utilise ManNAc in catalysis. Instead, ManNAc must first 
undergo phosphorylation to ManNAc 6-P by ManNAc kinase.
29
 This product is the substrate 
for NeuNAc 9-PS, which catalyses condensation with PEP to give NeuNAc 9-P. 
Dephosphorylation in a subsequent step forms the functional product NeuNAc.  
 
 
 
 
 
Figure 3.1. The condensation reactions catalysed by bacterial and mammalian sialic acid synthases. 
Most remarkably, there is no sugar-substrate ambiguity between the bacterial and mammalian 
forms, with all characterised bacterial NeuNAcS exclusively utilising ManNAc as sugar-
substrate, and likewise the mammalian NeuNAc 9-PS utilising only ManNAc 6-P in catalysis 
(Figure 3.1).
33, 68
 It is apparent that the sugar-substrate specificity of the bacterial and 
mammalian sialic acid synthases is dependent entirely upon the presence or absence of the C-
6 phosphate group. It is important to reiterate here that human NeuNAc 9-PS is also able to 
utilise mannose 6-phosphate as an alternate substrate.
6, 37
 This compound lacks the C-2 N-
acetyl functionality of ManNAc, but retains the C-6 phosphate group which is apparently an 
absolute requirement for sugar-substrates of the mammalian enzymes. Understanding the 
structural determinants which underpin this differential sugar-substrate selectivity is pertinent 
to the development of novel antibiotic compounds which exclusively target the bacterial 
enzyme, whilst leaving the human enzyme unperturbed.  
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In this chapter, I report the details of a bioinformatic analysis of bacterial and mammalian 
sequences conducted in order to identify elements which are highly conserved within 
bacterial and mammalian clades, but poorly conserved between them. Such elements may 
correspond to structural motifs involved in recognising and stabilising the phosphorylated or 
unphosphorylated forms of ManNAc. Following the elucidation of two regions of distinct 
sequence variability between bacterial and mammalian sialic acid synthases, a number of 
chimeric proteins incorporating structural elements from both NmeNeuNAcS and 
HsaNeuNAc 9-PS were generated and characterised. 
3.2 Sequence alignment of NeuNAcS and NeuNAc 9-PS     
  
A selection of 15 bacterial NeuNAcS and 13 mammalian NeuNAc 9-PS sequences were 
obtained from the KEGG database 
82
 and input for multiple alignment using Clustal Omega 
(Figure 3.2).
83-84
 While all but one of the mammalian sequences used in this alignment were 
359 residues in length, the bacterial sequences vary between 343-352 residues. The additional 
length of the mammalian enzymes typically arises from an extended C-terminus, with an 
extra 6-8 residues from the AFPL domain. Furthermore, the β2α2 loop of the bacterial 
sequences (as defined by the crystal structure of NmeNeuNAcS, PDB: 1XUZ) is typically 
two residues shorter than the corresponding mammalian loop sequence.  
 
 
 
 
 
 
 
 
 
 
Catalytic domain β2α2 loop 
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Figure 3.2. Multiple sequence alignment of mammalian NeuNAc 9-PS (green) and bacterial NeuNAcS (blue). 
Domains and active site residues are annotated according to the NmeNeuNAcS crystal structure (PDB: 1XUZ), 
and sequences coloured using the ClustalX colour scheme (Jalview). Sugar-substrate binding residues are 
marked by red circles, PEP binding residues by yellow circles and metal binding residues by green circles.  
From the multiple sequence alignment it is apparent that the residues comprising the catalytic 
barrel domain are largely conserved between bacterial and mammalian forms. Of the six 
Linker AFPL domain 
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active site residues shown to interact with PEP in the solved NmeNeuNAcS structure (PDB: 
1XUZ), five are conserved across all bacterial and mammalian sequences analysed (Lys-53, 
Lys-129, Ser-132, Ser-154 and Ser-213). Furthermore the metal coordinating residues (His-
215 and His-236) are entirely conserved. The sugar binding residues Tyr-186, Asp-247 and 
Gln-55 are conserved between bacterial and mammalian sequences, but conserved bacterial 
sugar binding residues Arg-314 and Asn-74 are conserved as valine and threonine residues 
respectively in mammals.  
While the catalytic barrel domain residues are mostly conserved between bacterial and 
mammalian forms of this enzyme, there are two regions which display poor sequence 
homology. The β2α2 loop of the catalytic barrel (residues 57-79 in NmeNeuNAcS) is one such 
region, and displays poor sequence conservation with the corresponding mammalian loop 
(Figure 3.2). This loop contains a number of small secondary structural elements (one 4 
residue α-helix and one 5 residue 3/10 helix), but shall be referred to purely as the β2α2 loop 
from here onwards. Residues 69-79 represent the flexible portion of the loop.  
Interestingly, the bacterial and mammalian β2α2 loop sequences are highly conserved within 
their own clades (Figure 3.2). This high degree of intra-clade conservation but poor overall 
conservation suggests that these loop regions may have evolved to provide an alternate 
function in bacteria and mammalian forms of the enzyme. Given the proximity of the β2α2 
loop to the sugar binding site, and the fact that Asn-74 from this loop anchors the C-6 
hydroxyl of rManNAc in NmeNeuNAcS (Figure 3.3), it could be predicted that this loop 
plays an important role in selecting for, and stabilising the respective bacterial and 
mammalian sugar-substrates, which differ only by the C-6 substituent.
32
  
 
 
 
 
 
 
Figure 3.3. The β2α2 loop (blue) of NmeNeuNAcS forms direct interactions with the C-6 hydroxyl of ManNAc 
(yellow) through the side-chain of Asn-74. 
rManNAc 
PEP 
Asn-74 
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What makes this hypothesis more compelling is the abundance of conserved residues with 
positively charged side-chains within the mammalian loop and flanking regions (Figure 3.4). 
These residues are largely conserved as non-cationic amino acids in bacterial sequences 
(Figure 3.2). Given the mammalian sugar-substrate contains a polyanionic C-6 phosphate 
group which orients toward the β2α2 loop as shown in chapter two, the cationic residues of the 
loop may provide electrostatic stabilisation of ManNAc 6-P.  
 
 
 
Figure 3.4. Partial sequence alignment of HsaNeuNAc-9-PS and NmeNeuNAcS showing the β2α2 loop 
sequence and major secondary structural elements. Cationic residues are indicated by red circles. 
 
Comparison of the surface electrostatics of the HsaNeuNAc 9-PS model and NmeNeuNAcS 
structure shows a clear difference in the distribution of surface charge across the β2α2 loop 
region (Figure 3.5). While the β2α2 loop of NmeNeuNAcS is predominantly negatively 
charged at physiological pH, the corresponding region of HsaNeuNAc 9-PS appears to have 
considerable electropositive surface charge, consistent with the involvement of this loop in 
binding an anionic phosphorylated substrate.  
 
 
  
 
 
 
 
Figure 3.5.  PyMOL vacuum electrostatics calculation shows a notable difference in the charge distribution 
between the β2α2 loop (circled) of NmeNeuNAcS (left, PDB: 1XUZ) and modelled HsaNeuNAc 9-PS (right). 
The β2α2 loop of NmeNeuNAcS has considerable negative surface charge (red) whereas the β2α2 loop of 
HsaNeuNAc 9-PS exhibits a high degree of electropositive charge (blue). Note: this electrostatic calculation is 
not quantitative and provides an approximate representation of the charge-smoothed surface only.  
α1 α2 β3 β2 
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Within the conserved mammalian β2α2 loop are three residues (Gly-78, Lys-79 & Thr-80), 
which are reminiscent of a partial “Walker phosphate binding motif” [GXXXXGK(T/S)].85 
From induced-fit substrate docking (Section 2.3) we know that Thr-80 of this motif is a likely 
phosphate binding residue and thus implicates the β2α2 loop in phosphate binding directly. It 
seems likely that variability in loop sequence between bacterial and mammalian enzyme 
dictates the strict sugar-substrate specificity seen in nature.  
A second region of poorly conserved sequence within the entire sialic acid synthase family is 
the flexible linker region (Residues 272-282) which connects the catalytic barrel and C-
terminal AFPL domains (Figure 3.2). Furthermore, the AFPL domain itself (Residues 282-
349) has relatively low sequence conservation between bacterial and mammalian 
orthologues. HsaNeuNAc 9-PS and NmeNeuNAcS share only 21.8% identity across the 
combined linker and AFPL region (Residues 272-349) and 22.4% for the AFPL domain alone 
(Figure 3.6). Comparatively, the catalytic barrel domain (Residues 1-272) of these enzymes 
share 30.7% identity at the amino acid level. Again, the AFPL domain and linker sequences 
are almost entirely conserved within mammalian sequences.  
It is established that the AFPL domain is essential for the catalytic function and stability of 
both bacterial and mammalian enzymes.
4, 77
 Truncation of the AFPL domain has been shown 
to totally abolish the activity of both NmeNeuNAcS and HsaNeuNAc 9-PS. The conserved 
bacterial residue Arg-314 from the AFPL domain is known to be essential for catalysis in 
NmeNeuNAcS, and functions to steer the sugar-substrate ManNAc into a catalytically 
favourable orientation within the active site.
64
 The guanidinium side-chain of Arg-314 
extends into the active site of one chain, from the AFPL domain of the second chain. We 
have shown that the conserved mammalian AFPL domain residue Lys-290 plays a similar 
role, extending into the active site to form specific interactions with the C-6 phosphate group 
of ManNAc 6-P (Section 2.3). The lack of sequence homology, and observed roles of both 
bacterial and mammalian AFPL domain residues in sugar-substrate binding, suggests that this 
C-terminal domain may additionally contribute toward the sugar-substrate selectivity of the 
bacterial and mammalian sialic acid synthases. Furthermore, the flexible linker region of 
NmeNeuNAcS comes within close proximity of the β2α2 ManNAc binding loop, highlighting 
the possibility of interplay between these two putative sugar-substrate selectivity elements.
32
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Figure 3.6. Partial alignment of HsaNeuNAc 9-PS and NmeNeuNAcS sequences showing the linker region 
(red) and AFPL domain (blue). Residues implicated in sugar-substrate binding (HsaLys-290, NmeArg-314) are 
indicated by black circles. 
3.3 Chimera design and generation        
           
Bioinformatic analyses reveals the sequences corresponding to both the β2α2 loop of the 
catalytic domain, and the AFPL domain/linker are poorly conserved between bacterial 
NeuNAcS and mammalian NeuNAc 9-PS, but maintain a high degree of conservation within 
their own clades. This suggests potential involvement in the differentiation and stabilisation 
of these enzymes alternate sugar-substrates. In an attempt to convert the sugar-substrate 
specificity of the bacterial enzyme towards that of the mammalian enzyme, a number of 
chimeric proteins were generated in which the aforementioned structural elements from 
HsaNeuNAc 9-PS were engineered into the respective positions of the NmeNeuNAcS protein 
scaffold.  
3.4 β2α2 loop-swap chimera          
  
In NmeNeuNAcS, the β2α2 loop effectively caps the active site, and forms a hydrogen bond 
with the C-6 hydroxyl of ManNAc via the side-chain of the conserved bacterial residue Asn-
74 (Figure 3.3). In mammalian NeuNAc 9-PS, residues of the β2α2 loop have been shown to 
form similar interactions with the C-6 phosphate group of ManNAc 6-P (Section 2.3). 
Interestingly, the β2α2 loop of HsaNeuNAc 9-S is two residues longer than NmeNeuNAcS, 
and contains a number of lysine and arginine residues with positively charged side-chains at 
physiological pH (Figure 3.4). These cationic residues are otherwise absent from the bacterial 
sequence and may be responsible for providing an electrostatic environment which favours 
binding of a charged substrate.  
Because of the postulated involvement of the β2α2 loop in determining sugar-substrate 
specificity, a loop-swap chimera was generated in which 14 residues constituting the flexible 
portion of the HsaNeuNAc 9-PS β2α2 loop (residues 67-80, as predicted by homology 
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modelling) were engineering into the corresponding position of the NmeNeuNAcS (βα)8 
barrel (Figure 3.7). It was envisaged that insertion of the human β2α2 loop residues into the 
bacterial enzyme may confer the ability to utilise ManNAc 6-P in catalysis, a novel activity 
not seen in wild-type bacterial NeuNAcS.
28
  
 
 
 
 
 
 
Wild-type NmeNeuNAcS       61-DEMSDEAKQVIPGNA---DVSIYEIMER-85 
      
 
 
 
 
 
 
 
 
 
 
 
 
Nme/Hsa loop-swap chimera 61-DEMSDEALER-PYTSKHSWGKTYEIMER-87 
 
Figure 3.7. A loop-swap chimera was generated in which 12 residues comprising the flexible β2α2 loop of 
NmeNeuNAcS (red) were replaced with 14 analogous residues from the HsaNeuNAc 9-PS β2α2 loop sequence 
(green). Residues with positively charged side-chains are indicated by red circles. 
The gene construct encoding the Nme/Hsa loop-swap chimera was successfully generated 
using a 7-step overlap extension PCR methodology as shown in Figure 3.8. Forward and 
reverse primers, each encoding half of the 14 HsaNeuNAc 9-PS loop residues to be inserted 
into the NmeNeuNAcS scaffold, were designed and used to amplify a short ‘pre-loop’ N-
terminal fragment and a longer ‘post-loop’ C-terminal fragment from the NmeNeuNAcS 
wild-type gene (serotype B strain MC58, neuB) in the pDEST
TM
17 vector. The resulting 
linear fragments were effectively blunt end constructs containing each half of the new loop 
sequence (Figure 3.8; Steps 1 & 2).  
 51 
 
Forward and reverse ‘bridging’ primers were designed with complementarity to the central 30 
base pairs of the human loop sequence, and used to extend each fragment, thereby 
introducing an overlap of 30 base pairs between the two fragments (Figure 3.8; steps 3 & 4). 
The overlapping fragments were then extended using forward and reverse gene primers in the 
final two PCR reactions to generate the complete construct with the 14 human loop residues 
in situ (Figure 3.8; steps 5 & 6).  
An additional PCR step using generic Gateway® primers was required to introduce 
Gateway® 5’ and 3’ flanking sequences containing an N-terminal TEV protease cleavage site 
into the final loop-swap gene construct (Figure 3.8; step 7). The forward and reverse gene 
primers used for all chimera construction steps contain the generic extensions required to 
facilitate this step. Gel electrophoresis was used at each stage of cloning to ensure successful 
amplification of the correct constructs. 
Following extension with generic Gateway® sequences, the linear construct was ligated into 
pDONR
TM
221 entry vector, using the Gateway® protocol outlined in section 6.3.5. The 
successfully sequence verified pDONR
TM
221 vector bearing the loop-swap chimera construct 
was then transformed into E. coli One Shot TOP10 cells (Invitrogen) and propagated for 
plasmid extraction (Section 6.3.8). Purified plasmid from a resulting transformant was ligated 
into the expression vector pDEST
TM
17 which encodes an N-terminal His-tag using the 
protocol described in section 6.3.4. All primers used for chimera cloning are listed in Table 
6.3. 
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       REV gene primer  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.8. Assembly of the linear gene construct encoding the Nme/Hsa loop-swap chimera 
      FWD  loop primer 
    FWD gene primer    REV loop primer 
   Pre-loop fragment 
      Post-loop fragment 
   Pre-loop fragment 
   Post-loop fragment 
  FWD gene primer 
 REV gene primer    FWD bridging primer 
REV bridging primer 
  FWD gene primer 
 REV gene primer 
Complete loop swap construct 
Steps 1 & 2 
Steps 3 & 4 
Steps 5 & 6 
Step 7 
  FWD gateway primer  REV gateway primer 
= NmeNeuNAcS sequence 
= NmeNeuNAcS loop sequence 
= HsaNeuNAc-9-PS sequence 
 
= Generic sequence encoding N-terminal TEV cleavage site 
= Gateway sequence encoding N-terminal His-tag 
 
5’ 
5’ 
5’ 
5’ 
5’ 
3’ 
3’ 
5’ 
5’ 
3’ 
3’ 
3’ 
3’ 
3’ 
5’ 
5’ 
3’ 
3’ 
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3.5 AFPL domain-swap chimera         
  
Considering the relatively low sequence homology of bacterial and mammalian AFPL 
domains (22% identity between NmeNeuNAcS and HsaNeuNAc 9-PS), and the fact that the 
AFPL domain contributes residues which interact with sugar-substrates directly in both 
NmeNeuNAcS and HsaNeuNAc 9-PS, it is possible that the AFPL domains are involved in 
differentiating between and stabilising the respective unphosphorylated or phosphorylated 
sugars. To this end, an AFPL domain-swap chimera was designed and generated by Dr. 
Joseph, in which the AFPL domain of HsaNeuNAc 9-PS was engineered into the respective 
position of the NmeNeuNAcS scaffold, in an attempt to confer activity with ManNAc 6-P 
(Figure 3.9).
86
 
 
 
 
 
 
Wild-type NmeNeuNAcS           
261-KQGAHALKLARGGKKDTIIAGEKPTKDFAFASVVADKDIKKGELLLSGDNLWVKRPGNGD  
FSVNEYETLFGKVAACNIRKGAQIKKTDIE-349 
 
 
 
 
 
Nme/Hsa AFPL domain-swap chimera                       
261-KQGAHALKLARGSPTKQLLPCEMACNEKLGKSVVAKVKIPEGTILTMDMLTVKVGEPKGY 
PPEDIFNLVGKKVLVTVEEDDTIMEELVDNHGKKIKS-359 
Figure 3.9. An AFPL domain-swap chimera was generated by Dr. Joseph in which 79 residues comprising the 
AFPL domain of NmeNeuNAcS (red) were replaced with 86 residues from the HsaNeuNAc 9-PS AFPL domain 
sequence (green). The conserved residue Gly-272 was chosen as the point of interchange, and thus the entire 
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AFPL domain and linker region was substituted with that from HsaNeuNAc 9-PS. Residues implicated in sugar-
substrate binding (HsaLys-290, NmeArg-314) are indicated by black circles. 
The aforementioned AFPL domain-swap chimera was generated using a similar overlap 
extension PCR method to that described in section 3.4. For full details of the AFPL domain-
swap chimera cloning protocol please refer to the thesis of Dr. Dmitri Joseph.
86
 
3.6 β2α2 loop-swap/AFPL domain-swap double chimera     
         
Both the β2α2 loop and AFPL domain/linker potentially play roles in sugar-substrate binding 
and selection. As described previously, the AFPL domain linker region comes within close 
proximity of the β2α2 loop of NmeNeuNAcS.
32
 It is therefore possible that these elements are 
interconnected, and that the structural basis for substrate selection may rely on synergistic 
operation of both elements. In order to determine if the combination of the β2α2 loop and the 
AFPL domain/linker functions in substrate selection, a double-chimera incorporating both 
structural elements was generated. Generation of the construct encoding this double-chimera 
was achieved using the same overlap extension method described in section 3.4.  
 
 
 
 
 
 
 
 
 
 
Figure 3.10. A double-chimera was constructed in which both the β2α2 loop and AFPL domain/linker from 
NmeNeuNAcS (red) were replaced with the corresponding residues from HsaNeuNAc 9-PS (green) in an 
attempt to confer activity with the mammalian substrate ManNAc 6-P. The human loop residues were installed 
on top of the existing AFPL domain-swap chimera using the original loop-swap chimera primers. 
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The primers encoding the HsaNeuNAc 9-PS β2α2 loop residues, previously used for 
generation of the β2α2 loop-swap chimera (Table 6.3), were employed to install the same 14 
human enzyme loop residues into the existing AFPL domain-swap chimera construct. This 
allowed effective insertion of the HsaNeuNAc 9-PS loop sequence on top of the existing 
AFPL chimera, to produce a final construct with both the human enzyme loop and AFPL 
domain/linker. All primers used for cloning this chimera are listed in table 6.3. 
Generation of the double-chimera construct proceeded as for the β2α2 loop-swap chimera, 
however the AFPL-domain swap chimera construct (in pDEST
TM
17) vector was used as the 
template instead of the wild-type NmeNeuNAcS gene (Figure 3.11). Because this template 
encodes the NmeNeuNAcS N-terminal catalytic barrel and HsaNeuNAc 9-PS C-terminal 
AFPL domain, the combination of forward NmeNeuNAcS and reverse HsaNeuNAc 9-PS 
gene primers was used for extension of linear fragments, and final ligation (Figure 3.11). 
These gene primers, used for all cloning steps, encode the small generic extensions required 
for final elongation with Gateway® sequences (Table 6.3).  
The complete double-chimera gene construct was successfully amplified and sequence 
verified. The linear construct was then sub-cloned into the Gateway® expression vector 
pDEST
TM
17 using the protocols described in sections 6.3.3 and 6.3.5.  
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       REV Hsa gene primer  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.11. Assembly of the linear gene construct encoding the double-chimera using the existing AFPL 
domain-swap chimera as template. 
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3.7 Expression and purification of Nme/Hsa chimeras     
   
The pDEST
TM
17 vectors bearing the β2α2 loop-swap chimera and double-chimera constructs 
were transformed into E. coli BL21 (DE3) Star cells and E. coli BL21 (DE3) 
pBB540/pBB542 (Chaperone 3) cells for expression testing. In order to test inducible 
expression of the target proteins, an induced culture (containing 0.5 mM IPTG) and non-
induced culture of each cell line was grown overnight. Both chimeras were shown (by SDS-
PAGE) to be over-expressed following induction with IPTG, and soluble in both cell lines.  
The best yield of soluble protein for both chimeras was achieved when expressed in 
Chaperone 3 cells, and thus this cell line was chosen for upscaled expression and purification. 
The expressed proteins were purified (Figure 3.12A) using a similar protocol as described for 
wild-type HsaNeuNAc 9-PS (Section 2.4). Expression and purification of the AFPL domain-
swap chimera was completed by Dr. Joseph, as detailed in his thesis.
86
 
Following purification, mass spectrometry was used to confirm the correct molecular weights 
of all chimeras (Appendix B), and circular dichroism (CD) used to ensure the retention of 
wild-type like secondary structure, and correct folding in solution (Figure 3.12B). 
 
 
 
 
 
 
 
 
 
 
Figure 3.12. A) SDS-PAGE gel showing kDa molecular weight markers (M), purified loop-swap chimera (1) 
and purified double-chimera (2). B) CD spectra of wild-type NmeNeuNAcS and chimeras showing retention of 
native secondary structure and folding. 
A B 
M 1 2 
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3.8 Chimera activity assessment with ManNAc and ManNAc 6-P    
  
Following successful purification, the β2α2 loop-swap chimera and double-chimera were 
assayed for activity with both ManNAc and ManNAc 6-P across a range of conditions, using 
the continuous UV-Vis assay described in section 6.5.2. The β2α2 loop-swap chimera was 
shown to retain activity with ManNAc, but at such low levels as to not be quantifiable using 
this assay. No activity was observable in the presence of the mammalian substrate ManNAc 
6-P, even with high concentrations of enzyme (up to 1 mg/mL). No activity was detectable 
for the double-chimera with either ManNAc or ManNAc 6-P under the experimental 
conditions used. The AFPL domain-swap chimera was assayed for activity by Dr. Joseph, 
who concluded there was no observable activity with either ManNAc or ManNAc 6-P, even 
with protein concentrations as high as 1 mg/mL.
86
  
Assaying for low levels of activity by UV-Vis was found to be extremely difficult. Because 
high enzyme concentrations were required to observe activity, the experimental absorbance 
values were very high leading to a poor signal to noise ratio, and overall reduction in the 
accuracy of the assay. Furthermore, it was difficult to differentiate between enzymatic 
consumption of PEP and non-enzymatic hydrolysis over long periods of time. To circumvent 
this problem, an NMR assay was developed to screen for very low levels of activity (as 
described in section 6.5.3). By using NMR, high enzyme concentrations could be used, while 
retaining the ability to clearly detect product formation. In order to follow enzymatic 
reactions by 1D proton NMR in an H2O/D2O mixture, water suppression using pre-saturation 
(PRESAT) was required to reduce the otherwise overwhelming solvent signal.  
Enzyme activity was determined by monitoring the disappearance of substrate proton 
resonance, and the proportional appearance of product proton resonances. Specifically, the 
resonances associated with the α/β forms of the anomeric proton of ManNAc and ManNAc 6-
P were monitored throughout the reaction. These proton signals are observable as distinct 
standalone peaks at 5.0 and 4.9 ppm for α and β protons respectively (Figure 3.13). The axial 
and equatorial C-3 protons of NeuNAc/NeuNAc 9-P could be observed appearing as the 
product was formed. In order to verify the assay conditions, wild-type NmeNeuNAcS was 
used as positive control. Total conversion of equi-molar PEP and ManNAc to NeuNAc was 
observed under the developed assay conditions, validating the methodology (Figure 3.13). 
Similarly, wild-type HsaNeuNAc 9-PS was used to validate the assay using ManNAc 6-P as 
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a substrate (not shown). The C-3 proton peaks of NeuNAc 9-P appear in the same position as 
those of NeuNAc. 
 
 
 
 
 
 
 
 
Figure 3.13. PRESAT NMR experiment monitoring the NmeNeuNAcS catalysed condensation of 5 mM PEP 
and 5 mM ManNAc. The appearance of NeuNAc C-3 proton peaks at ~1.7 and 2.1 ppm confirms product 
formation. Total substrate to product conversion was achieved within ~1hour. 
This NMR assay was used to test for low levels of activity for both the β2α2 loop-swap 
chimera and double-chimera as the lack of activity observable by UV-Vis is not necessarily 
indicative of complete inactivity, given the constraints of the assay.  
The β2α2 loop-swap chimera was confirmed as retaining activity with ManNAc, with distinct 
peaks consistent with the product NeuNAc, appearing after approximately three hours (Figure 
3.14). The rate of turnover however was extremely poor, with approximately 2/3 of substrate 
converted to product over a period of 24 hours. No product formation was observed when 
ManNAc 6-P was supplied as the sugar-substrate (Figure 3.15). 
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Figure 3.14. PRESAT NMR activity assay for β2α2 loop-swap chimera with 5 mM PEP and 5 mM ManNAc. 
The appearance of NeuNAc C-3 proton peaks at ~1.7 and 2.1 ppm confirms retention of activity with ManNAc. 
 
 
 
 
 
 
 
 
Figure 3.15. PRESAT NMR activity assay for β2α2 loop-swap chimera with 5 mM PEP and 5 mM ManNAc 6-
P. No product formation is detectable after 24 hours. 
The double-chimera was shown by NMR to be inactive with respect to both ManNAc (Figure 
3.16) and ManNAc 6-P (Figure 3.17), with no detectable product formation after 24 hours. It 
should be noted that in the NMR spectra for the double-chimera with ManNAc 6-P, there is 
an obvious change in size of the peaks corresponding to the substrates over time (Figure 
3.17). This is most likely an artefact of water suppression which may also influence solute 
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peak sizes from one experiment to the next. The absence of any product resonances provides 
sufficient evidence to conclude that no substrate turnover is occurring. 
 
 
 
 
 
 
 
 
Figure 3.16. PRESAT NMR activity assay for Nme/Hsa double-chimera with 5 mM PEP and 5 mM ManNAc. 
No product formation was detectable after 24 hours. 
 
 
 
 
 
 
 
 
 
Figure 3.17. PRESAT NMR activity assay for Nme/Hsa double-chimera with 5 mM PEP and 5 mM ManNAc 
6-P. No product formation was detectable after 24 hours. 
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3.9 PEP binding studies of Nme/Hsa chimeras      
  
The purified Nme/Hsa chimeras were shown to have very poor or entirely abolished activity 
in vitro. Only the β2α2 loop-swap chimera retained any activity, with a slow turnover of 
ManNAc and PEP observed. Unfortunately, none of the resulting chimeras were able to 
utilise the mammalian substrate ManNAc 6-P in catalysis. In order to assess the nature of this 
inactivity, ITC was used to determine whether PEP binding was affected by introduction of 
the respective structural elements from HsaNeuNAc 9-PS.  
The binding interaction of wild-type NmeNeuNAcS with PEP was first characterised for 
comparison with the generated chimeras (Figure 3.18A). Unlike HsaNeuNAc 9-PS, PEP 
binding is an endothermic binding process for NmeNeuNAcS, with an overall ∆H of 5350 ± 
140 cal/mol. PEP binding is also associated with a favourable entropic change (T∆S) of -
11840 cal/mol. Unexpectedly, when a PEP titration was carried out with the β2α2 loop-swap 
chimera under identical conditions to that used for wild-type NmeNeuNAcS, only a very 
weak PEP binding event was observable (Figure 3.18B). This binding data could not be fit to 
a single-site binding model. It is obvious that PEP binding has been significantly impacted by 
substitution of the β2α2 loop residues, which may account for the considerable reduction in 
activity observed for this chimera with ManNAc.  
 
 
 
 
 
 
 
 
Figure 3.18. Raw ITC thermograms and integrated data for 1 mM PEP titrations into: A) 150 µM wild-type 
NmeNeuNAcS, B) 150 µM β2α2 loop-swap chimera, and C) 150 µM double-chimera.  
Similarly, only a very poor PEP binding signal was observed for the double-chimera when a 
PEP titration was completed under the same conditions as used for wild-type NmeNeuNAcS 
A B C 
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(Figure 3.18C). PEP binding has apparently been significantly attenuated, potentially via the 
same mechanism of perturbation as for the β2α2 loop-swap chimera. 
While the AFPL domain-swap chimera was initially thought to retain wild-type like PEP 
binding affinity, it has since been shown that the experimental conditions under which the 
titration was completed may have resulted in a false-positive binding signal.
86
 While this has 
not yet been corroborated, it is possible that the AFPL domain-swap chimera also has 
compromised PEP binding affinity. 
3.10 Thermal stability of the Nme/Hsa chimeras      
  
DSF was used to determine the relative thermal stabilities of the chimeric proteins with 
comparison to wild-type NmeNeuNAcS in the presence and absence of ligands (Figure 3.19). 
The unliganded β2α2 loop-swap chimera was shown to have a melt temperature of 46.1 ˚C 
which is slightly higher than that measured previously for wild-type NmeNeuNAcS (42.6 ˚C), 
while the AFPL domain-swap chimera was shown to have a native melt temperature of 43.6 
˚C.86  
 
 
 
 
 
 
 
Figure 3.19. Effect of ligands on the thermal stability of wild-type NmeNeuNAcS and Nme/Hsa chimeras. Data 
marked with an asterix (*) was collected by Dr. Dmitri Joseph and published in his thesis.
86
 
Wild-type NmeNeuNAcS is known to undergo significant thermal stabilisation upon Mn
2+
 
binding (+6.4 ˚C), and even more-so upon PEP binding (+13.6 ˚C).77 The β2α2 loop-swap 
chimera retains stabilisation in the presence of Mn
2+
 (+5.4 ˚C) but unlike wild-type 
NmeNeuNAcS, the presence of PEP affords no additional stabilisation over that already 
conferred by the metal. The absence of PEP induced stabilisation is consistent with the 
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observation that this chimera has an attenuated binding affinity for PEP as determined by ITC 
(Section 3.9). Similarly, the AFPL domain-swap chimera is stabilised in the presence of Mn
2+
 
(+4 ˚C), but no additional stabilisation is conferred by PEP. This supports the previously 
stated hypothesis that this chimera may have a reduced capacity for PEP binding.  
Unfortunately, thermal stability data could not be obtained for the double-chimera due to 
unresolved technical problems with the DSF thermal cycler. 
3.11 Structural studies         
        
Analytical gel filtration was used to determine the native molecular masses of the Nme/Hsa 
chimeras (Figure 3.20). The gel filtration column was initially calibrated with a range of 
known molecular weight standards, and semi-logarithmic plots of elution volume/void 
volume (Ve/Vo) versus molecular weight were then used to calculate the molecular masses of 
the chimeras. The β2α2 loop-swap chimera eluted from the column as a single species at 13.7 
mL, giving a calculated molecular mass of 85.8 kDa (Table 3.1). This value is closest to that 
of the theoretical dimeric mass (78.1 kDa), suggesting retention of the wild-type multimeric 
state under these conditions. The His-tagged double-chimera similarly elutes as a single 
species at 13.8 mL giving a calculated molecular mass of 73.8 kDa, again closest to that of 
the theoretical dimer (86.8 Da). 
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Figure 3.20. Semi-logarithmic plots showing elution volume of target proteins relative to molecular weight 
standards. Standards used for calibration include at least five of the following: thyroglobulin (669 kDa), beta 
amylase (200 kDa), alcohol dehydrogenase (150 kDa), ovalbumin (43 kDa), conalbumin (75 kDa) and carbonic 
anhydrase (29 kDa). 
Table 3.1. Experimental parameters determined for Nme/Hsa chimeras by analytical gel filtration 
 
The AFPL domain-swap chimera was also shown to exist as a single dimeric species by 
analytical gel filtration.
86
 The quaternary structure of this chimera was then investigated 
further by analytical ultracentrifugation (AUC).
86
 Sedimentation velocity experiments 
revealed that a concentration dependant equilibrium exists between monomeric and dimeric 
species, with dissociation of the dimer observed at concentrations less than 1 mg/mL.
86
 
Analytical gel filtration was completed at concentrations above this threshold, and therefore 
only the dimeric species was observed. Wild-type NmeNeuNAcS is known to form a stable 
dimer even at very low concentrations and thus Dr. Joseph concluded that exchange of the 
AFPL domains had somehow destabilised the native quaternary structure.
86
  
 Elution volume 
(mL) 
Elution 
vol/void vol 
Calculated 
molecular mass (Da) 
Theoretical dimeric 
mass (Da) 
Error 
(%) 
β2α2 loop-swap chimera 13.7 1.74 85800 78138 8.9 
Double-chimera (His-
tagged) 
13.8 1.84 73800 86759 14.9 
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Small-angle X-ray scattering (SAXS) was used to verify the quaternary structure of these 
chimeras in solution. Scattering data was collected for the β2α2 loop-swap chimera in the 
presence of 1 mM MnCl2 and 1 mM PEP (Figure 3.21A). Scattering data for both the 
unliganded and PEP bound double-chimera was also obtained (Figure 3.21B).  
 
    
 
 
 
 
 
Figure 3.21. A) SAXS profile of β2α2 loop-swap chimera in the presence of 1 mM Mn
2+
 and 1 mM PEP (blue) 
fit to the theoretical scattering profile of NmeNeuNAcS (black line). B) SAXS profiles of ligand-free (red) and 
PEP bound (blue) double-chimera fit to the theoretical scattering profile of NmeNeuNAcS (black line). 
The SAXS profile of the ligand bound β2α2 loop-swap chimera is in reasonable agreement 
with the theoretical scattering predicted for ligand bound NmeNeuNAcS based on 
crystallographic coordinates (PDB: 1XUZ), with a chi-square value of 1.725. This indicates 
probable retention of the domain-swapped arrangement seen for wild-type NmeNeuNAcS. 
The scattering profile of liganded β2α2 loop-swap chimera resembles more closely that of 
ligand bound wild-type NmeNeuNAcS than the apo-enzyme, but lacks the distinct troughs at 
0.2 and 0.32 Å
-1
 which are characteristic of the liganded wild-type enzyme.
77
 This may 
suggest the enzyme adopts a less globular conformation, possibly associated with reduced 
affinity for PEP. As previously described, PEP binding induces a conformational shift toward 
a more compact species, which facilitates subsequent sugar-substrate binding.
77
 The 
structural parameters derived from SAXS indicate the presence of a dimer under these 
experimental conditions, consistent with the results of analytical gel filtration (Table 3.2).  
The SAXS data obtained for the double-chimera similarly demonstrates dimerisation under 
the aforementioned experimental conditions. The SAXS derived porod volume for the 
double-chimera gives a calculated molecular mass of approximately twice the monomeric 
A B 
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mass, and furthermore the radius of gyration (Rg) values are consistent with those calculated 
for NmeNeuNAcS which is known to form a stable dimer in solution (Table 3.2).
86
 Both apo 
and liganded forms show poorer correlation to the predicted NmeNeuNAcS profile than 
observed for the β2α2 loop-swap chimera (Chi-square values of 2.8 and 2.1 respectively). This 
is unsurprising given the extent of structural disparity from the original wild-type enzyme. 
While these fits are poor, the improvement of chi-square value, and decrease in the enzymes 
radius of gyration (Rg) upon PEP addition may suggest a minor shift in the average structural 
conformation, to something more representative of the liganded wild-type enzyme.  
Table 3.2. Experimental parameters obtained by small angle X-ray scattering (SAXS).  
 
The solution structure of the AFPL domain-swap chimera was assessed by SAXS in the 
presence of Mn
2+
 and PEP.
86
 Dr. Joseph reported a good fit of the experimental scattering 
data to the theoretical scattering of the NmeNeuNAcS crystal structure, with a chi-square 
value of 1.56.
86
 Furthermore, the SAXS profile of the AFPL domain-swap chimera was more 
similar to experimental scattering obtained for PEP bound NmeNeuNAcS, than for 
unliganded NmeNeuNAcS. This may suggest the retention of at least some degree of PEP 
binding ability, and the ability to undergo (to some extent) the conformational change 
associated with PEP binding in the wild-type enzyme.
86
 The liganded AFPL domain-swap 
chimera scattering is in better agreement with the scattering profile of liganded wild-type 
NmeNeuNAcS, than the liganded double-chimera. This suggests that the extra substitution of 
Structural parameters 
β2α2 loop-swap chimera 
+ MnCl2 + PEP 
Double-chimera  
+ MnCl2 
Double-chimera 
+ MnCl2 + PEP 
I(0) (cm
-1
) [from P(r)] 0.11 ± 0.01 0.06 ± 0.01 0.06 ± 0.01 
Rg (Å) [from P(r)] 34.7 ± 1 35.5 ± 1 34.2 ± 1 
I(0) (cm
-1
) (from Guinier) 0.11 ± 0.01 0.06 ± 0.01 0.06 ± 0.01 
Dmax (Å) 118 ± 6 124 ± 6 118 ± 6 
Rg (Å) (from Guinier) 33.8 ± 0.3 35.4 ± 0.4 33.7 ± 0.6 
Porod volume estimate (Å
3
) 112500 ± 11000 118300 ± 12000 109500 ± 11000 
Dry dimeric volume calculated 
from sequence (Å
3
) 
92990  96190  96190 
Calculated monomeric molecular 
mass from sequence (Da) 
38797 39751 39751 
Molecular mass from Porod 
volume (Da) (from MoW) 
93350 98210 90880 
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the β2α2 loop may have had an additional effect on PEP binding over and above the effect of 
AFPL domain substitution alone. 
3.12 Attempted crystallisation        
       
The Nme/Hsa chimeras were screened for crystals using the conditions previously described 
for NmeNeuNAcS,
32
 and with commercially available screening conditions (Molecular 
Dimensions PACT, JCSG and Clear Strategy I & II). Protein was screened at a range of 
concentrations (2, 5 10 mg/mL) in the presence and absence of ligands, however crystals of 
diffraction quality were not obtained.  
3.13 Discussion           
          
Bacterial and mammalian NeuNAc biosynthesis differs primarily in the sugar-substrates 
which undergo condensation with PEP in the central step of the pathway. Bacterial NeuNAcS 
catalyses the condensation of ManNAc with PEP, whereas the analogous mammalian 
enzyme, NeuNAc 9-PS, uses the C-6 phosphorylated derivative ManNAc 6-P. Intriguingly, 
the aforementioned enzymes are wholly specific for their own substrates, which differ only 
by the substituent at C-6. As described in chapter two, the human enzyme gains a 
considerable catalytic advantage over its bacterial counterpart by utilising a phosphorylated 
substrate with an inherently higher affinity.  
Multiple sequence alignment of bacterial and mammalian orthologues identified two distinct 
structural elements which have reduced sequence homology between bacterial and 
mammalian forms, but are highly conserved within their own clades. The first of these, the 
β2α2 loop of the catalytic domain, is known to contribute sugar-substrate binding residues in 
both NmeNeuNAcS and HsaNeuNAc 9-PS (Section 2.3).
32
 Interestingly, the human 
enzyme’s loop sequence contains a much higher proportion of conserved residues with 
positively charged side-chains than that of the bacterial loop. This has potential implications 
in binding and stabilisation of the polyanionic phosphate group, which is present only in the 
mammalian substrate. The second identified region is the AFPL domain and the short linker 
which connects it to the catalytic barrel. The sequence of this unique C-terminal domain is 
poorly conserved between bacterial and mammalian forms, and similarly contributes residues 
known to participate directly in sugar-substrate binding.
64
 The linker region, consisting of 
approximately 10 residues, comes within close proximity of the aforementioned putative 
sugar-substrate binding loop upon formation of the functional domain swapped homo-
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dimer.
32
 This proximity alludes to potential cross-talk between these two putative sugar-
substrate selectivity elements. 
A number of chimeric proteins were generated in order to probe the importance of these 
clade-specific sequences, and as an attempt to convert the activity of a bacterial NeuNAcS to 
that of mammalian NeuNAc 9-PS by conferring the ability to utilise the phosphorylated 
substrate ManNAc 6-P in catalysis. The first of these involved the introduction of 14 residues 
from the β2α2 loop of HsaNeuNAc 9-PS into the corresponding position of the NmeNeuNAcS 
catalytic domain. Dr. Joseph then generated a complementary chimera in which the AFPL 
domain of HsaNeuNAc 9-PS was fused to the catalytic domain of NmeNeuNAcS.
86
 Finally, a 
double-chimera was generated in which both β2α2 loop and AFPL domain sequences from the 
human enzyme were installed into the NmeNeuNAcS scaffold simultaneously.  
The aforementioned chimeras were expressed as soluble proteins and purified to 
homogeneity. Furthermore, all were shown to be correctly folded in solution and retain wild-
type like dimeric quaternary structure. Unfortunately none of the resulting chimeras had 
adopted the ability to utilise ManNAc 6-P in catalysis. The loop-swap chimera was unique in 
the fact that it retained low levels of activity with the native substrate ManNAc, while the 
remaining two chimeras were entirely inactive with ManNAc. 
Gross reduction of activity with ManNAc upon substitution of the β2α2 loop is not at all 
unexpected, as this substitution removes the functional side-chain of Asn-74, a residue known 
to bind the C-6 hydroxyl of ManNAc in the wild-type enzyme (Figure 3.3).
32
 The fact that the 
loop-swap chimera retains any activity with the bacterial substrate is remarkable, and 
suggests the substituted human loop sequence is capable of maintaining the ManNAc binding 
function in part. The conserved human residue Thr-72, predicted to interact with the C-6 
phosphate of ManNAc 6-P (Section 2.3), may be able to fulfil the role of Asn-74 in the loop-
swap chimera. Because the side-chain of Thr-72 is shorter than that of Asn-74, this 
interaction may be weaker and/or transient and therefore provide less efficient stabilisation of 
the sugar-substrate.  
Inactivity of the double chimera may arise for the same reasons given the loop is also 
substituted. Furthermore, substitution of the NmeNeuNAcS AFPL domain with that of 
HsaNeuNAc 9-PS is likely to abolish activity with ManNAc through loss of the critical 
residue Arg-314.
64
 The corresponding human residue is a conserved valine, which could 
provide no such function as that described for Arg-314. Of course it is likely that other, more 
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global, factors resulting from substitution of these structural elements are also implicated in 
loss of activity. A subtle change in protein dynamics for example, could potentially destroy 
the catalytic function of these modified enzymes. 
The inability of these chimeras to successfully turnover the mammalian substrate ManNAc 6-
P may be due to a number of factors. Substitution with the putative human sugar-binding loop 
alone is apparently not sufficient to confer activity with ManNAc 6-P. Only 14 residues (of 
the flexible portion of the loop) were substituted and therefore additional mammalian 
structural elements which may facilitate functional positioning of the loop, are absent in the 
resulting chimera. Substitution of a larger portion, perhaps incorporating the entire β2α2 loop, 
may increase the likelihood of ManNAc 6-P binding. Incorporation of the human AFPL 
domain in addition to the β2α2 loop sequence should be expected to provide a greater chance 
of conferring activity with ManNAc 6-P, given what we know about the importance of Lys-
290 from the AFPL domain (Section 2.3). This combination of human protein elements is 
however apparently still insufficient to prompt catalysis with the human substrate.  
The leading cause of loss or reduction of activity is almost certainly the inadvertent 
perturbation of PEP binding which was observed by ITC and/or DSF for all three chimeras. 
This confounding result makes it difficult to delineate the effect of substituted sequence 
elements on activity. Perhaps the chimeras would exhibit novel activity with ManNAc 6-P if 
only PEP binding was retained? For the loop-swap chimera this is probably not the case 
given retention of activity with ManNAc, however for the AFPL domain-swap and double-
chimera proteins this possibility should not be excluded.  
There is no obvious connection between the β2α2 loop and the conserved PEP binding 
residues, however previously reported molecular-dynamics simulations demonstrated that 
PEP binding results in a reduction of the flexibility of the β2α2 loop of NmeNeuNAcS.
77
 As 
this loop occupies a position which partially occludes entrance to the active site, change in 
the sequence here may alter the sampled conformationals of the loop, thus preventing access 
of substrates. The relatively poor sequence identity between NmeNeuNAcS and HsaNeuNAc 
9-PS may mean the human loop sequence is largely incompatible with the bacterial scaffold, 
and unable to undergo the same range of motion as that of the wild-type enzyme. Repeating 
the molecular-dynamics simulations conducted for NmeNeuNAcS, with the human enzyme 
loop residues in situ, may expose any change in flexibility of the loop that could be 
responsible for occlusion of PEP from the active site. 
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Thermal stability data suggests that substitution of the bacterial AFPL domain also affects 
PEP binding. In NmeNeuNAcS, a hydrogen bonding network links PEP binding to 
rearrangement of the AFPL domain, a process thought to be essential for establishing a 
competent catalytic site.
77
 Only one of the AFPL domain residues involved in the bacterial 
hydrogen bonding network (Glu-282) is retained in the AFPL domain-swap chimera as this 
glutamate is also conserved in mammals. Within this hydrogen bonding network is Asn-184, 
which is known to bind the phosphate group of PEP.
32
 Disruption of the hydrogen bonding 
network through introduction of the human AFPL domain may prevent Asn-184 from 
maintaining a functional PEP binding orientation within the active site. 
Loss of interactions between the AFPL domain and main barrel may also be responsible for 
destabilisation of the quaternary structure of the AFPL-domain swap chimera (and by 
analogy, the double-chimera). The AFPL domain-swap chimera was shown to exist in both 
dimeric and monomeric states at low concentrations, a property not observed for wild-type 
NmeNeuNAcS, which exists predominantly as a stable dimer.
86
 Two key interactions 
identified between the AFPL domain and catalytic barrel of NmeNeuNAcS are lost upon 
substitution with the human enzyme AFPL domain. Arg-314 and Glu-134 form a salt bridge 
across the dimer interface, however in the AFPL domain-swap chimera, Arg-314 is 
substituted by the HsaNeuNAc 9-PS residue Val-316, which is incapable of forming such 
interaction. Similarly, the NmeNeuNAcS residues Asp-296 and Arg-114 are shown to form a 
high-occupancy interaction across the dimer interface, anchoring the globular portion of the 
AFPL domain of one chain, to the main barrel of the other.
86
 Asp-296 is conserved as Lys-
298 in mammals, and thus substitution with the mammalian AFPL domain introduces 
electropositive repulsion at this point. Loss of the aforementioned dimer interface contacts 
would result in increased mobility of the AFPL domain and promote dimer dissociation. Site-
directed mutagenesis could be used to reinstall these original contacts, thereby stabilising the 
dimer interface and potentially assisting with the transfer of novel activity. 
It is apparent that interconverting the activity of bacterial NeuNAcS is no trivial task. The 
substitution of large regions of sequence gives rise to a plethora of confounding effects, 
including unintentional disruption of PEP binding and quaternary structure. A more strategic 
approach to inter-converting activity might be to remodel the bacterial enzyme’s active site 
residues individually, interchanging conserved bacterial residues to the corresponding 
conserved mammalian residues. The key sugar-substrate binding interactions identified in 
chapter two would assist in guiding this process. Alternatively, a directed evolution approach 
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using random mutagenesis and/or gene recombination would provide a powerful route for 
conferring novel activity. This would however rely on the development of a selection assay 
that could be used to screen for ManNAc 6-P positive mutants. The resulting ManNAc 6-P 
active mutants could then be sequenced to verify the specific nature of the protein 
modification, however because ManNAc 6-P and ManNAc are part of the same biosynthetic 
pathway to NeuNAc, it would be difficult to distinguish any novel ability to utilise ManNAc 
6-P in catalysis from residual activity with ManNAc. 
Mammalian and bacterial orthologues of this enzyme are the products of divergent evolution, 
having undergone remodelling to accommodate the alternate sugar-substrates that they utilise 
in catalysis. This remodelling is particularly apparent in the sequences of the β2α2 loop and 
AFPL domain/linker where amino acid conservation drops significantly between bacterial 
and mammalian clades. These elements are likely to provide the necessary differentiation 
between ManNAc 6-P and ManNAc. Because the bacterial biosynthetic pathway to NeuNAc 
lacks the additional kinase and phosphatase catalysed steps of the mammalian pathway, it 
could be assumed that bacterial NeuNAcS would not be exposed to ManNAc 6-P and 
therefore would need not be selective against this metabolite. In reality, many 
microorganisms express ManNAc kinase, however this functions primarily as a catabolic 
enzyme.
7, 87
 In addition to a key cell surface decoration, NeuNAc is utilised as a rich source 
of carbon, nitrogen and energy by a number of pathogenic microbes.
7, 88
 Sialidase activity 
facilitates the scavenging of free NeuNAc from mammalian host cells, and subsequent 
cleavage by specific lyase activity releases ManNAc (Figure 3.22) and pyruvate (not shown).  
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Figure 3.22. The bacterial pathways of NeuNAc biosynthesis (green arrows) and catabolism (blue arrows).  
ManNAc is then phosphorylated by ManNAc kinase to give ManNAc 6-P.
7
 Unlike in 
mammalian systems, ManNAc 6-P is destined for catabolism in bacteria, and is epimerised to 
GlcNAc 6-P which eventually enters the glycolytic pathway.
87
 It is not known how bacteria 
maintain the balance between anabolic and catabolic commitment of ManNAc.
7
 What is 
apparent however is that bacterial NeuNAcS is required to be selective only for non-
phosphorylated ManNAc otherwise ManNAc 6-P destined for catabolic pathways would be 
perpetually returned to the NeuNAc pool (Figure 3.22). By utilising only ManNAc in 
NeuNAc biosynthesis, ManNAc 6-P becomes a committed catabolic metabolite.  
Because the initial UDP-GlcNAc 2-epimerase and kinase steps of mammalian NeuNAc 
biosynthesis are catalysed by a bi-functional enzyme, metabolite channelling would 
presumably prevent NeuNAc 9-PS from frequent exposure to unphosphorylated ManNAc.
88
 
It is therefore possible that this enzyme has lost the ability to utilise ManNAc through active 
site remodelling to accommodate the phosphorylated substrate, rather than active exclusion of 
the unphosphorylated amino-sugar. Regardless, by utilising ManNAc 6-P in catalysis, the 
human enzyme gains improved catalytic efficiency, at the expense of an additional two 
biosynthetic steps. Because NeuNAc biosynthesis is a core metabolic process in mammals, it 
is unsurprising that the pathway to NeuNAc has become significantly refined. Bacteria 
however, utilise NeuNAc expression primarily for host immune evasion, a process not 
immediately central to survival and proliferation. NeuNAc biosynthesis may therefore be 
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subject to weaker selection pressures in bacterial systems, and so a less efficient route to 
NeuNAc is sufficient for meeting cellular demands. 
To conclude, a number of sequence elements likely to be involved in sugar-substrate 
selection by bacterial NeuNAcS and mammalian NeuNAc 9-PS were identified. An attempt 
to interconvert the sugar-substrate specificity of NmeNeuNAcS via the installation of human 
sequence elements was unsuccessful due to the unforeseen and unintentional disruption of 
PEP binding. Furthermore, the complex interplay between the AFPL domain, β2α2 loop and 
catalytic site make this a highly challenging task. The resulting chimeras, while inactive with 
ManNAc 6-P, may provide promising scaffolds from which to further pursue the transfer of 
novel activity. 
                                                          
 
 
 
 
 
 
 
 
 
 
 
 
 75 
 
Chapter 4: Sugar-substrate specificity of non-NeuNAcS bacterial sialic acid 
synthases 
4.1 Overview           
             
Microorganisms synthesise a number of unique sialic acid like compounds not observed in 
higher organisms.
7
 Pseudaminic acid (5,7-diacetamido-3,5,7,9-tetradeoxy-L-glycero-L-
manno-nonulosonic acid) and legionaminic acid (5,7-diacetamido-3,5,7,9 tetradeoxy-D-
glycero-D-galacto-nonulosonic acid) are two such compounds and are known to be important 
components of bacterial cell surface structures.
11, 46
 Heavy post-translational glycosylation of 
flagellar proteins with the aforementioned ‘bacterial sialic acids’ is apparently essential for 
the motility and virulence of a number of pathogenic bacteria, including species of the 
Campylobacter genus.
11, 44
  
Pseudaminic acid is biosynthesised in bacteria by condensation of PEP with 2,4-diacetamido-
2,4,6-trideoxyaltrose, catalysed by pseudaminic acid synthase (PseS) (Figure 1.8). Similarly, 
legionaminic acid is the product of condensation of PEP with 2,4-diacetamido-2,4,6-trideoxy-
D-mannopyranose, a reaction catalysed by yet another member of the sialic acid synthase 
family; legionaminic acid synthase (LegS) (Figure 1.6). The sugar-substrates of the PseS and 
LegS catalysed reactions are stereoisomers, and differ by inversion of stereochemistry at C-2, 
C-4 and C-5. These reactions are analogous to the PEP condensation reactions catalysed by 
NeuNAcS and NeuNAc 9-PS however the bacterial sialic acid precursor sugars differ from 
the canonical sialic acid precursor ManNAc through additional N-acetylation at C-4 and loss 
of the C-6 hydroxyl group. Unlike NeuNAcS and NeuNAc 9-PS, which are selective for 
sugar-substrates based on phosphorylation (or lack thereof) at C-6, these bacterial sialic acid 
synthases specifically recognise and bind their appropriate sugar-substrates based on 
variations in stereochemistry and substitution. 
The genome of C. jejuni contains three genes encoding sialic acid synthase functionality.
11
 
Cj1141 has been characterised as a NeuNAcS, Cj1317 as a PseS and Cj1327 as a LegS.
42, 48, 
54
 The presence of genes encoding all three primary sialic acid synthases makes C. jejuni an 
excellent model from which to study the structural and functional variation which defines 
these enzymes. Elucidation of the molecular basis of the alternate sugar-substrate specificity 
of these bacterial sialic acid synthases may form the basis for the exploitation of these 
enzymes for therapeutic advantage. Furthermore, understanding the specific active site 
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architectures that facilitate the recognition and catalysis of structurally variable sugar-
substrates may assist with re-engineering such enzymes as sources of novel and complex 
sialic acids with useful applications. 
In the studies described in this chapter, sequence alignment of the aforementioned bacterial 
sialic acid synthase orthologues with other sialic acid synthase clades was used in an attempt 
to identify putative sugar binding motifs that may provide insight into how these enzymes 
recognise and bind substrates with variable stereochemistry and functional group substitution. 
Using the same methodology outlined in chapter three, two loop-swap chimeras were 
generated and characterised, in which the putative sugar-substrate binding loop (β2α2 loop) 
sequence from CjeNeuNAcS was installed into the respective positions of both CjePseS and 
CjeLegS in an attempt to confer (or improve) activity with the NeuNAcS substrate ManNAc. 
It should be noted that the generation of these chimeras was completed in parallel to those 
detailed in chapter three.  
4.2 Sequence alignment of multiple sialic acid synthases clades    
          
Dr. Joseph had previously generated a multiple sequence alignment of members of the sialic 
acid synthase family, including those assigned to NeuNAcS, PseS and LegS clades.
86
 
Additionally, a fourth clade, denoted by Dr. Joseph as ‘Type IV sialic acid synthases’ was 
included in the alignment.
86
 This fourth clade encodes putative sialic acid synthases of 
currently unknown function. Unlike other members of the sialic acid synthase family, Type 
IV enzymes do not contain a peptide sequence corresponding to an AFPL domain, and thus 
are fundamentally contrasting to the other sialic acid synthases. 
Interestingly, a number of sialic acid synthases previously characterised as having NeuNAcS 
activity, align within the putative LegS clade. Dr. Joseph suggested that these enzymes may 
possess dual-functionality, with the ability to utilise both the LegS precursor, and ManNAc in 
catalysis.
86
 This is feasible as CjeLegS was shown to exhibit activity with both the LegS 
precursor, and ManNAc albeit very poor.
11, 86
 Because of the commercial unavailability of the 
natural LegS substrate, and difficulty of producing it synthetically, most putative LegS 
enzymes are uncharacterised and denoted as LegS based on sequence comparisons alone. As 
such, the NeuNAcS enzymes that group within the LegS clade have not been confirmed as 
having LegS activity. Here I present a similar multiple sequence alignment, but have 
additionally included members of the NeuNAc 9-PS clade, and excluded ‘Type IV’ 
sequences given the nature of their substrates is unknown (Figure 4.1).  
 77 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Catalytic domain β2α2 loop 
Catalytic domain 
 78 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Catalytic domain 
Catalytic domain 
 79 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Linker AFPL domain 
Catalytic domain 
 80 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1. Sequence alignment of members of the sialic acid family showing four distinct clades. The first of 
these is that including bacterial NeuNAcS (blue). The second group includes mammalian NeuNAc 9-PS (green). 
A third group contains sequences most similar to that of enzymes previously characterised as PseS (orange). The 
fourth group contains sequences which align most closely with enzymes previously shown to have LegS activity 
(purple). Orthologues which have previously been functionally characterised are indicated by arrows. It should 
be noted that a number of bacterial enzymes characterised as NeuNAcS align with sequences of the putative 
LegS family (blue arrows). It is possible that these enzymes show bi-functional LegS and NeuNAcS activity. 
Domain annotation is based on the structure of NmeNeuNAcS (PDB: 1XUZ) and sequences are coloured 
according to the ClustalX colour scheme. 
The two sequence elements that differ most notably between bacterial NeuNAcS and 
mammalian NeuNAc 9-PS, the β2α2 loop and AFPL domain/linker, are also poorly conserved 
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between LegS and PseS clades. Again, this potentially implicates these regions of sequence 
in sugar-substrate binding. Dr. Joseph identified a conserved Ala-X-Tyr-Gln motif within the 
β2α2 loop sequence of all examined LegS orthologues, where X is a variable residue. 
Homology modelling and substrate docking of CjeLegS did not predict any interactions of the 
β2α2 loop residues with the sugar substrate, however given the poor sequence identity of the 
loop region with the homology model template sequence (NmeNeuNAcS), positioning of this 
loop is likely to be inaccurate.
86
  
Conversely the fully conserved residues of the PseS β2α2 loop are sparsely distributed across 
the entire loop, with no distinct motif formation.
86
 As for LegS, a model of CjePseS was also 
generated and docked with natural substrate in silico, however due to low template sequence 
identity, residues of the β2α2 loop were again poorly modelled.
86
  
Upon closer inspection of the LegS clade sequences, there appears to be further division into 
two smaller conserved groups. The LegS sequences chosen for alignment separate into two 
potential ‘sub-clades’ based on sequence alone (Figure 4.2). The first of these supposed sub-
clades (sub-clade one) includes both of the enzymes characterised as having LegS activity 
(CjeLegS and LpnLegS), while the second sub-clade (sub-clade two) contains three 
sequences which have been previously characterised as having NeuNAcS activity.
4, 55, 86
 It is 
possible that sub-clade two represents a group of bi-functional LegS/NeuNAcS, while the 
other LegS sub-clade represents those with LegS only activity, however this is purely 
speculative. CjeLegS, which is known to have bi-functional LegS/NeuNAcS activity, 
however, groups within the first sub-clade.
86
 Such assumptions of sub-clade separation are 
made under the proviso that the apparent disparity in sequence could be an artefact of the 
particular LegS sequences selected for alignment, or the limited number of sequences 
available for alignment. Further functional information relating to the members of these 
putative sub-clades is required to assist in delineation of the relationship between sequence 
and substrate specificity.  
The significance of these putative sub-clades is speculative however there is considerable 
difference in sequence within, and between these groups. Sequence identity ranges from 44 -
75% within sub-clade one, and 59- 81% within sub-clade two. Between the two putative sub-
clades, identity is lower, ranging between 39 and 58%.  
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Figure 4.2. Phylogenetic tree (top) showing division of LegS sequences into postulated sub-clades one (red 
branches) and two (blue branches). Enzymes previously characterised as having LegS activity are highlighted 
red, and those known to have NeuNAcS activity are highlighted blue. CjeLegS which is characterised as having 
both LegS and NeuNAcS functionality is shown in yellow. Partial sequence alignment (bottom) of putative 
LegS sequences showing sub-clade 1 (red) and sub-clade 2 (blue) β2α2 loop sequences. 
Within the β2α2 loop of putative sub-clade two, is a highly conserved Thr-Thr-Gly motif, 
which is otherwise poorly conserved in the putative LegS only sub-clade (Figure 4.2). 
Interestingly, CjeLegS (which is known to exhibit poor NeuNAcS activity) is the only 
sequence from sub-clade one to retain the threonine pair of this motif. Thr-61 (C. jejuni) of 
this motif is conserved as Asn-74 in NeuNAcS, a residue known to hydrogen bond to the C-6 
hydroxyl of ManNAc.
32
 Retention of a similar polar functionality at this position may allow 
Catalytic domain β2α2 loop 
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the enzymes of sub-clade two (and CjeLegS) to form a similar hydrogen bonding interaction 
with ManNAc. The denoted PseS sequences do not separate into obviously distinct sub-
clades as observed for LegS, consistent with the fact that to date no PseS orthologues have 
been shown to exhibit bi-functional activity. 
4.3 LegS and PseS β2α2 loop-swap chimera design and generation    
  
LegS from C. jejuni is characterised as having both a primary LegS function and secondary 
NeuNAcS function.
11, 86
 This requires the ability to recognise and bind both the Leg precursor 
sugar 2,4-diacetamido-2,4,6-trideoxy-D-mannopyranose, and the NeuNAc precursor, 
ManNAc. The genome of C. jejuni also encodes a dedicated NeuNAcS (Cj1141), which has a 
specificity constant for ManNAc over a 1000-fold greater than that of bi-functional 
CjeLegS.
86
 CjePseS (Cj1317) is thought to be selective only for the sugar substrate 2,4-
diacetamido-2,4,6-trideoxyaltrose. Lack of sequence homology across the β2α2 loop between 
NeuNAcS, LegS and PseS sequences, suggests this region may play a role in selecting for 
and stabilising the respective sugar-substrates that these enzymes preferentially utilise in 
catalysis.  
In order to probe the role of this loop in sugar-substrate selectivity of the aforementioned 
bacterial sialic acid synthases, two chimeric proteins were generated in which a block of 12 
residues from the CjeNeuNAcS β2α2 loop was engineered into the respective positions of 
CjeLegS and CjePseS (Figure 4.3). The residues chosen for substitution are predicted to 
constitute the flexible portion of the CjeNeuNAcS β2α2 loop based on sequence identity with 
NmeNeuNAcS. Additionally, the 12 residues chosen for substitution contain the conserved 
putative NeuNAcS sugar-substrate binding motif (-Pro-Gly-Asn-) identified by Dr. Joseph.
86
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CjeNeuNAcS β2α2 loop 
56-DEMSQEAKNVIPGNANISIYEIMEQC-81 
 
           CjeLegS β2α2 loop        CjePseS β2α2 loop  
45-NCISTKAKKAPYQLKTTANDESQLQMVQKL-74   53-SLTLNSDKEDFIIKGGLWDKRKLYELYESA-82 
 
    CjelegS/NeuNAcS loop-swap chimera               CjePseS/NeuNAcS loop-swap chimera 
 45-NCISTKAKNVIPGNANISILQMVQKL-70     53-SLTLNSDKNVIPGNANISIYELYESA-78 
 
Figure 4.3. Residues from the β2α2 loop of CjeNeuNAcS (blue) were substituted into the respective positions of 
CjeLegS and CjePseS in an attempt to confer activity with the NeuNAcS substrate ManNAc. The ManNAc 
binding residue Asn-74 is indicated with a black circle. 
Because the native sugar substrates of LegS and PseS were unavailable, the resulting 
chimeras were assayed for NeuNAcS activity to determine the effect of loop substitution. It 
was envisaged that installing the CjeNeuNAcS loop residues into CjeLegS would improve 
the already existing ability to utilise ManNAc. Conversely, CjePseS has no bi-functional 
character and so it was hoped that by installing the NeuNAcS loop, a novel ability to utilise 
ManNAc would be conferred.  
4.4 Cloning LegS and PseS loop-swap chimeras      
  
Gene constructs encoding the aforementioned LegS and PseS loop-swap chimeras were 
generated using the same methodology as for the Nme/Hsa loop-swap chimera described in 
chapter three (Section 3.4). The genes encoding wild-type CjeLegS (Cj1327) and CjePseS 
(Cj1317) had previously been cloned from genomic DNA (C. jejuni NCTC 11168) by Dr. 
Joseph.
86
 Forward and reverse primers encoding the two halves of the CjeNeuNAcS loop 
residues to be inserted into the LegS and PseS scaffolds were designed (Table 6.4), and used 
to amplify pre and post-loop fragments which were subsequently extended using bridging 
primers. The resulting overlapping fragments were then extended using gene primers 
containing additional generic gateway sequences (Table 6.4). The completed linear 
constructs, with CjeNeuNAcS loop residues installed, were ligated into Gateway® destination 
vector pDEST
TM
17 and sequence verified before proceeding to expression trials. 
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4.5 Expression and purification of LegS and PseS loop-swap chimeras   
    
The pDEST
TM
17 vectors bearing the loop-swap chimeras were transformed into E. coli BL21 
(DE3) Star cells and E. coli BL21 (DE3) pBB540/pBB542 (Chaperone 3) cells for 
comparative expression testing. In order to test inducible expression of the target proteins, an 
induced culture (containing 0.5 mM IPTG) and non-induced culture of each cell line were 
grown overnight. Both chimeras were shown by SDS-PAGE to be over-expressed following 
induction with IPTG, and soluble in both cell lines. Again, chaperone 3 cells yielded the 
greatest quantity of soluble protein, and thus this cell line was chosen for upscaled expression 
and purification. The expressed proteins were purified using a similar protocol as described 
for wild-type HsaNeuNAc 9-PS (Section 2.4) (Figure 4.4A).  
Following purification, mass spectrometry confirmed both chimeras were of the correct 
molecular mass (Appendix B), and circular dichroism (CD) was used to ensure the retention 
of wild-type like secondary structure, and correct folding in solution (Figure 4.4B, 4.4C). 
  
 
 
 
 
  
 
 
 
 
 
Figure 4.4. A) SDS-PAGE gel showing kDa molecular weight markers (M), purified PseS loop-swap chimera 
(1), and purified LegS loop-swap chimera (2). B) Comparison of CD spectra of wild-type CjeLegS and LegS 
loop-swap chimera. C) Comparison of CD spectra of wild-type CjePseS and PseS loop-swap chimera. 
A B 
C 
M 1 2 
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4.6 Activity assessment of LegS and PseS loop-swap chimeras with ManNAc  
    
Following purification, the two aforementioned bacterial sialic acid synthase loop-swap 
chimeras were assayed for activity with ManNAc using the continuous UV-Vis assay. The 
assay conditions used were the same as those established previously by Dr. Joseph for 
characterisation of wild-type CjeLegS and CjePseS.
86
 Under these conditions, no activity was 
detectable for either chimera. Furthermore, no NeuNAc formation was detected for either 
chimera after 24 hours, using the previously described NMR assay (Figure 4.5 & 4.6). 
 
 
 
 
 
 
 
 
Figure 4.5. PRESAT NMR activity assay for LegS loop-swap chimera with 5 mM PEP and 5 mM ManNAc. 
No product formation is detectable after 24 hours. 
 
 
 
 
 
 
 
Figure 4.6. PRESAT NMR activity assay for PseS loop-swap chimera with 5 mM PEP and 5 mM ManNAc. No 
product formation is detectable after 24 hours. 
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4.7 PEP binding studies         
  
The disappointing lack of activity observed for both chimeras in the presence of ManNAc 
and PEP warranted further investigation into the effects of loop substitution on substrate 
binding. To this end the PEP binding properties of the resulting chimeras were assessed by 
ITC (Figure 4.6).  
The LegS loop-swap chimera was clearly shown to retain the ability to bind PEP, in fact the 
calculated dissociation constant for PEP was considerably lower than that of wild-type 
CjeLegS, suggesting improved PEP binding affinity. The enthalpic and entropic components 
of PEP binding appear to be similar to that of the wild-type enzyme (Table 4.1).  
Wild-type CjePseS was shown to have a similar Kd (PEP) to that of CjeLegS, and a similar 
overall change in free energy associated with PEP binding (Table 4.1). The specific 
thermodynamic parameters reported here for wild-type CjePseS should however be viewed 
with scepticism as a number of erroneous data points had to be removed in order to fit the 
model. These anomalous data points most likely result from air trapped within the sample 
cell. When the same PEP titration was completed with the PseS loop-swap chimera, only a 
heat of dilution signal was observed, suggesting total abolition of PEP binding.   
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Figure 4.6. Raw injection peaks and integrated binding isotherms for titrations of A) 1 mM PEP into 150 µM 
wild-type CjeLegS, B) 1 mM PEP into 150 µM LegS loop-swap chimera, C) 1 mM PEP into 150 µM wild-type 
CjePseS and D) 1 mM PEP into 150 µM PseS loop-swap chimera. All proteins were incubated with 1 mM 
MnCl2 prior to titration with PEP. 
A B 
C D 
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Table 4.1. Calculated thermodynamic parameters of PEP binding  
4.8 Structural studies           
   
Dr. Joseph observed that wild-type CjeLegS and CjePseS exist primarily as dimeric species 
in solution, under the conditions used for analytical gel filtration.
86
 NmeNeuNAcS, which is 
known to adopt a functional domain-swapped homo-dimeric arrangement, shares high 
sequence identity with these enzymes and thus it is not surprising that they also exist as 
functional dimers. Analytical gel filtration was used to elucidate the native quaternary 
structures of the generated LegS and PseS loop-swap chimeras in solution. It is possible that 
disruption of native quaternary structure by introduction of CjeNeuNAcS loop residues is 
responsible for the inactivity of these chimeras (Figure 4.7).  
 
 
 
 
 
 
 
Figure 4.7. Semi-logarithmic plots showing elution volume of LegS and PseS loop-swap chimeras relative to 
molecular weight standards. Standards used include: thyroglobulin (669 kDa), beta amylase (200 kDa), alcohol 
dehydrogenase (150 kDa), ovalbumin (43 kDa) and conalbumin (75 kDa). 
The PseS loop-swap chimera eluted from the column as a distinct, single peak at 13.6 mL. 
This elution volume gives an experimental molecular weight of approximately 75.9 kDa, 
which is in close agreement with the theoretical molecular weight of the dimeric species 
 Wild-type CjeLegS LegS loop-swap chimera  Wild-type CjePseS PseS loop-swap chimera 
Kd (PEP) μM 
 
20 ± 1.5 6.1 ± 0.5 19 ± 1.0 - 
∆H cal/mol 18240 ± 430 13990 ± 180 5710 ±120 - 
∆S cal/mol/deg 83 ± 8.3 71 ± 7.1 41 ± 4.1 - 
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(Table 4.2). The LegS loop-swap chimera also eluted as a single peak, however elution was 
much earlier than expected, at 12.5 mL. This elution volume corresponds to an approximate 
molecular weight of 125 kDa, which is more than three times the calculated monomeric mass. 
This observation suggests that the LegS loop-swap chimera predominantly adopts an 
oligomeric arrangement in solution with a molecular mass most consistent with that of a 
trimeric species.  
Table 4.2. Experimental parameters determined for loop-swap chimeras by analytical gel filtration 
 
Small angle X-ray scattering (SAXS) data was obtained for both LegS and PseS loop-swap 
chimeras in the presence and absence of PEP (Figure 4.8). The scattering data obtained for 
LegS in the absence of PEP is of relatively poor quality with low signal to noise at high q. In 
the presence of PEP, scattering data is significantly improved. The scattering profile of the 
LegS loop-swap chimera in the presence of 1 mM PEP differs in shape from that of the 
unliganded enzyme considerably at q ~0.1, indicative of change in the overall shape of the 
protein (Figure 4.8A).
89
 This may be attributed to a conformational change induced by PEP 
binding, as observed for NmeNeuNAcS.
77
 The fact that the scattering profile becomes better 
defined upon addition of PEP provides further evidence for PEP induced structural 
stabilisation. Based on ITC data, it is established that this chimera retains wild-type like PEP 
binding affinity. The scattering data for both unliganded and PEP bound LegS loop-swap 
chimera fits very poorly with the theoretical scattering profile predicted for NmeNeuNAcS 
based on crystallographic coordinates (Figure 4.8A).  
The scattering profile of the PseS loop-swap chimera is not significantly changed by the 
addition of PEP (Figure 4.8B). Assuming CjePseS is subject to the same PEP induced 
conformational rearrangement observed for NmeNeuNAcS, the lack of change in scattering 
profile suggests that this chimera has lost the ability to bind PEP. This reinforces the lack of 
PEP binding observed by ITC. Unlike the LegS loop-swap chimera, scattering data obtained 
 
Elution volume 
(mL) 
Elution vol/void 
vol 
Experimental 
molecular mass 
(Da) 
Theoretical 
dimeric mass 
(Da) 
Theoretical 
trimeric mass 
(Da) 
LegS loop-swap chimera 12.5 1.65 125300 73562 110343 
PseS loop-swap chimera 13.6 1.79 75900 76425 114636 
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for the PseS loop-swap chimera fits more closely with the theoretical scattering calculated for 
NmeNeuNAcS based on crystallographic coordinates. This may suggest an overall structural 
commonality with NmeNeuNAcS, and retention of the domain-swapped oligomeric 
conformation in solution. 
   
 
 
 
 
 
Figure 4.8. A) Small-angle X-ray scattering profiles of LegS loop-swap chimera in presence of 1 mM Mn
2+
 
(red) and 1 mM Mn
2+ 
+ 1 mM PEP (blue) fit to the theoretical scattering profile predicted for NmeNeuNAcS 
(black line). B) SAXS profiles of PseS loop-swap chimera in presence of 1 mM Mn
2+
 (red) and 1 mM Mn
2+ 
+ 1 
mM PEP (blue) fit to the theoretical scattering profile predicted for NmeNeuNAcS (black line). 
Table 4.3. Experimental parameters obtained by small angle X-ray scattering (SAXS)  
Structural parameters LegS loop-swap chimera PseS loop-swap chimera 
 
1 mM MnCl2 1mM MnCl2 + PEP 1 mM MnCl2 1mM MnCl2 + PEP 
I(0) (cm
-1
) [from P(r)] 0.03 ± 0.01 0.09 ± 0.01 0.07 ± 0.01 0.07 ± 0.01 
Rg (Å) [from P(r)] 38.8 ± 1 39.8 ± 1 33.8 ± 1 33.2 ± 1 
I(0) (cm
-1
) (from Guinier) 0.03 ± 0.01 0.09 ± 0.01 0.07 ± 0.01 0.07 ± 0.01 
Dmax (Å) 135 ± 7 134 ± 7 116 ± 6 111 ± 6 
Rg (Å) (from Guinier) 39.5 ± 0.6 40.1 ± 0.7 33.9 ± 0.6 32.4 ± 0.2 
Porod volume estimate (Å
3
) 168300 ± 17000 208900 ± 21000 115300 ± 12000 114900 ± 11000 
Dry dimeric volume calculated 
from sequence (Å
3
) 
88340  88340  91810  91810  
Calculated monomeric molecular 
mass from sequence (Da) 
36781 36781 38213 38213 
Molecular mass from Porod 
volume (Da) (From MoW) 
138000 171300 94530 94180 
A B 
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The calculated porod volumes derived from scattering data for the LegS loop-swap chimera 
vary considerably between the PEP bound and unliganded form (Table 4.3). In the absence of 
PEP, a porod volume of 168300 Å
-3 gives an approximate molecular mass of 138 kDa 
(calculated using MoW), which is most consistent with the theoretical mass of a tetrameric 
species. In the presence of PEP, this value increases to approximately 171 kDa which is more 
similar to that of a species with five subunits. There are several possible explanations for this 
observation. A combination of higher oligomeric state species may exist in solution, with 
PEP shifting the position of the oligomeric equilibrium to favour that of the higher molecular 
weight species. Size-exclusion chromatography used prior to analyses may not be able to 
fully resolve multiple species and therefore the final scattering profile may include 
contributions from more than one oligomeric state. Alternatively, the sample may be 
monodisperse for a single high molecular weight species but because of the poor-quality of 
scattering data, the derived porod volumes and molecular weights are not accurate enough to 
assign specific quaternary states to unliganded and PEP bound forms. What is apparent 
however is that introduction of the CjeNeuNAcS loop residues has somehow destabilised the 
native dimeric quaternary structure of CjeLegS, which may account for the loss of activity 
with ManNAc. Delineating the specific effect of loop substitution on the global solution 
structure of CjeLegS will require repetition of this SAXS experiment in order to obtain a 
higher quality data-set. Additionally, analytical ultracentrifugation (AUC) could be employed 
to further investigate the oligomeric arrangement of this chimera in solution. 
Conversely, the structural parameters determined for the PseS loop-swap chimera are largely 
unchanged between PEP bound and unliganded forms. This provides further evidence for the 
absence of PEP binding. The calculated porod volume of the PseS loop-swap chimera gives 
an approximate molecular mass most consistent with a dimeric species (Table 4.3). Unlike 
the LegS loop-swap chimera, SAXS demonstrates that the PseS loop-swap chimera retains 
wild-type like quaternary structure, corroborating the aforementioned analytical gel filtration 
results. 
4.9 Attempted crystallisation         
    
The LegS and PseS loop-swap chimeras were screened for crystals using commercially 
available crystallisation conditions (Molecular Dimensions PACT, JCSG and Clear Strategy I 
& II). Protein was screened at a range of concentrations (2, 5 10 mg/mL) in the presence and 
absence of ligands, however crystals of diffraction quality were not obtained.  
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4.10 Discussion          
        
Sequence analysis reveals a number of distinct sialic acid synthase clades exist across phyla. 
These sequence homology derived clades can be loosely annotated based on the function of 
known examples from within each clade, but such functional information remains sparse. 
Bacterial NeuNAcS and mammalian NeuNAc 9-PS are two distinct and obvious sialic acid 
synthase families, with a number of fully characterised enzymes from both. These families 
differ primarily by the sugar-substrates they utilise in catalysis. For NeuNAcS and NeuNAc 
9-PS, the difference lies in the presence or absence of a phosphate moiety at C-6 of the 
hexose sugar-substrate. The bacterial sialic acid synthases, LegS and PseS also utilise 
variable sugar substrates in catalysis however selection is based upon substitution of 
functional groups and inversion of stereochemistry at multiple centres, rather than 
phosphorylation state (Figure 4.9).  
 
 
 
 
Figure 4.9. The structurally variable sugar-substrates of the bacterial sialic acid synthases. The NeuNAcS sugar-
substrate ManNAc (left), the LegS sugar-substrate 2,4-diacetamido-2,4,6-trideoxy-D-mannopyranose (centre) 
and the PseS sugar-substrate 2,4-diacetamido-2,4,6-trideoxyaltrose (right). 
The genome of Campylobacter jejuni encodes all three of the aforementioned bacterial sialic 
acid synthases (NeuNAcS, LegS, PseS), suggesting a distinct and specific enzyme is required 
for the biosynthesis of each of the respective bacterial sialic acids.
11
 This becomes convoluted 
by the fact that the product of the gene encoding LegS functionality in C. jejuni also exhibits 
poor NeuNAcS activity and thus can be considered bi-functional.
11, 86
 The C. jejuni genome 
also contains a gene encoding a dedicated NeuNAcS enzyme, with much better catalytic 
properties than the aforementioned CjeLegS.
54
 The minimal NeuNAcS activity observed for 
CjeLegS suggests that LegS may represent an evolutionary prototype, which would likely 
have been promiscuous with respect to its sugar-substrate.
86
 This ancestral LegS would have 
subsequently become specialised for catalysis with specific sugar-substrates. Legionaminic 
and pseudaminic acid are directly linked to basic bacterial cellular functions, including 
maturation and functionalisation of flagellar proteins required for motility and 
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pathogenicity.
11, 44, 50
 These roles are arguably more fundamental to survival and proliferation 
than the molecular mimicry role provided by NeuNAc and so it seems intuitive that the 
enzymes of legionaminic and pseudaminic acid biosynthesis should precede those of 
NeuNAc biosynthesis evolutionarily.  
The additional advantage of de-novo NeuNAc biosynthesis for purposes of immune evasion 
would then provide the selection pressure required for specialisation of an ancestral LegS 
type enzyme toward that of modern day bacterial NeuNAcS. It is possible that enzymes 
currently characterised as NeuNAcS may exhibit residual LegS activity, which would provide 
evidence for divergence from a promiscuous LegS-like ancestor. Assaying for LegS activity 
with the appropriate sugar-substrate would be required to determine if this is indeed the case. 
Furthermore, assessment of bacterial viability following knockout of PseS, LegS and 
NeuNAcS genes from C. jejuni may provide some insight into the relative importance of 
these enzymes in conferring survival advantage to the species, and thus help confirm which 
clade represents the evolutionary prototype. The presence of archael sequences across the 
sialic acid synthase clades supports divergence from an ancestral precursor early in 
evolution,
90
 as opposed to the otherwise proposed origin of bacterial sialic acid synthases 
through lateral gene transfer from mammals.
31
 
Regardless of the origin of sugar-substrate specificity, sequence information would lead us to 
believe that the mechanism of sugar-substrate differentiation involves variation in sequence 
about the β2α2 loop of the catalytic barrel of these enzymes. Poor sequence homology 
between the β2α2 loops of the alternate bacterial sialic acid synthases, but high conservation 
within each clade suggests a functional adaptation involving this loop. Given that these 
enzymes differ only by the sugar-substrates they utilise, one can assume the involvement of 
the loop region in discrimination between substrates. As described in chapter three, 
introduction of the human NeuNAc 9-PS β2α2 loop into the NmeNeuNAcS scaffold was 
unsuccessful at conferring novel activity with the mammalian substrate. It is expected that 
failure to achieve this was in part due to relatively low sequence homology between 
NmeNeuNAcS and HsaNeuNAc 9-PS (29%). In this chapter I describe the generation of an 
additional two loop-swap chimeras in which the β2α2 loop from CjeNeuNAcS was installed 
into the respective positions of CjeLegS and CjePseS. These bacterial sialic acid synthases 
share considerably higher sequence identity with one another, than bacterial NeuNAcS shares 
with mammalian NeuNAc 9-PS. CjeNeuNAcS and CjeLegS are 36.7 % identical at the 
amino acid level, while CjeNeuNAcS and CjePseS share 32.6% identity (Appendix A). It was 
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envisaged that this increased sequence identity between loop ‘donor’ and loop ‘acceptor’ 
enzymes would increase the likelihood of successful transfer of improved or novel activity. 
Both LegS and PseS loop-swap chimeras were successfully cloned, expressed and purified to 
homogeneity as soluble protein. These novel proteins were shown to be correctly folded in 
solution, and maintained wild-type like secondary structure composition. Unfortunately, both 
were inactive with respect to the sugar-substrate ManNAc. Further analysis revealed the PseS 
loop-swap chimera had completely compromised PEP binding ability, with no binding event 
detectable by ITC or SAXS. The lack of a crystal structure or robust model of the wild-type 
enzyme makes it extremely difficult to delineate potential interactions between the β2α2 loop 
residues and PEP binding residues. It is however apparent that substitution of the PseS loop 
residues with those of CjeNeuNAcS has had a drastic effect on PEP binding. Because this 
loop-swap chimera maintains a wild-type like quaternary arrangement in solution, loss of 
PEP binding is assumed to be the primary cause of inactivity. 
Interestingly, the LegS loop-swap chimera retains full (if not improved) PEP binding capacity 
and thus represents the first of the chimeras described in this thesis to do so. This may be due 
to the relatively high sequence identity between CjeLegS and CjeNeuNAcS (36.7%). The 
substituted CjeNeuNAcS loop residues are obviously capable of compensating the loss of the 
wild-type residues with respect to whatever role they play in PEP binding. Despite 
maintenance of PEP affinity, the LegS loop-swap chimera has a significantly destabilised 
oligomeric state. It is unknown how substitution of the designated loop residues could result 
in such alteration of the quaternary structure however a subtle change in the physico-
chemical properties of the protein surface may be sufficient to elicit this effect. It should be 
noted that the CjeNeuNAcS loop sequence installed in the chimera is four residues shorter 
than the substituted CjeLegS loop sequence. Truncation of this loop by four residues may 
have altered the conformation of adjacent secondary structural elements, thereby disrupting 
contacts between adjoining subunits. Loss of the functional dimeric conformation may be 
responsible for the resulting loss of activity with ManNAc.  
Although inactive with respect to ManNAc, the LegS loop-swap chimera retains PEP binding 
affinity and so may provide a good scaffold for the continued pursuit of improved NeuNAcS 
activity. The next obvious step is to determine if this chimera is able to bind the sugar-
substrate. This may be accomplished through ITC titrations with the non-reactive ManNAc 
analogue rManNAc. If this chimera is indeed able to bind rManNAc, it is likely that key 
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catalytic residues are displaced within the active site. Given what we know about the 
importance of active residues interacting across dimer interfaces in both NmeNeuNAcS and 
HsaNeuNAc 9-PS, it is possible that disruption of quaternary structure here has yielded a 
catalytically incompetent active site.
86
 The AFPL domain and linker region are known to not 
only contribute catalytic residues to the active site of the adjacent monomer, but also provide 
considerable stabilisation of dimeric quaternary structure through inter-domain interactions as 
shown for NmeNeuNAcS.
77
 Perturbation of inter-domain interactions through substitution of 
the β2α2 loop sequence may be responsible for the disruption of quaternary structure, and 
therefore loss of catalysis. Access to high-resolution crystal structures of these enzymes 
would provide the molecular insight required to delineate the sugar-substrate binding modes, 
and identify the cause of inactivity following substitution of β2α2 loop-sequences. 
Crystallisation of these proteins should be prioritised in future work.   
To conclude, variation observed in the β2α2 loop sequence between the various bacterial sialic 
acid synthases is likely the result of evolutionary specialisation from a once promiscuous 
ancestral enzyme. Interchanging the central portion of the β2α2 loop between these enzymes 
failed to interchange their sugar-substrate specificity due to unforeseen and confounding 
implications with PEP binding and quaternary structure destabilisation. Artificially recreating 
the variation in sugar-substrate specificity achieved by evolution over hundreds of millions of 
years is apparently no trivial task. 
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Chapter 5: Discussion and concluding remarks 
“Sialic acids are not only the most interesting molecules in the world, but also the most 
important”.91  
This claim, while obviously subjective, is certainly arguable in the context of mammalian 
sialic acids. These compounds are expressed by almost every mammalian cell and tissue type, 
at all stages of development, and the range of functions they provide is not only extremely 
diverse, but also absolutely fundamental to cellular function.
1, 4, 92
 It is of no surprise that the 
biosynthesis of the most common mammalian sialic acid NeuNAc has evolved to become a 
highly efficient process.  
This efficiency is achieved in part, through utilisation of the phosphorylated sugar-substrate 
ManNAc 6-P by NeuNAc 9-PS, the central enzyme of NeuNAc biosynthesis in mammals. 
The analogous bacterial enzyme alternatively utilises the non-phosphorylated sugar ManNAc 
in catalysis. Chapter two of this thesis details the characterisation of human NeuNAc 9-PS, 
(HsaNeuNAc 9-PS) and exploration of its active site architecture using homology modelling 
and directed mutagenesis. This work has exposed a number of key features of the human 
enzyme which allow it to efficiently bind its phosphorylated sugar-substrate, including a Thr-
Lys phosphate binding pair which was identified as potentially important for stabilisation of 
ManNAc 6-P. Other related PEP-utilising aldolases including DAH7PS employ a similar 
motif for binding phosphorylated sugar substrates.
67
 What is particularly interesting about 
HsaNeuNAc 9-PS however, is that the lysine residue of the identified pair is not adjacent to 
the threonine in sequence, but instead is recruited from the opposite chain of the functional 
dimeric enzyme and extends across the dimer interface to fulfil its role. This finding 
rationalises the domain-swapped homo-dimeric arrangement that HsaNeuNAc 9-PS was 
shown to form in solution. Furthermore, an abundance of positively charged residues across 
the putative sugar-substrate binding β2α2 loop possibly acts in combination with specific 
phosphate binding residues to provide an electrostatic environment which favours binding 
and stabilisation of polyanionic ManNAc 6-P.  
Adoption of a phosphorylated sugar-substrate with an inherently higher binding affinity 
confers considerable catalytic efficiency to the mammalian enzyme. Such advantage is 
evident in the vastly improved specificity constant of the human enzyme for its sugar 
substrate, relative to that of the bacterial enzyme for unphosphorylated ManNAc.
32
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The homology model generated for HsaNeuNAc 9-PS, and interactions predicted by induced-
fit substrate docking, were partially corroborated through mutagenesis of predicted sugar-
substrate binding residues. Delineation of the precise sugar-substrate binding mode however 
will require access to a high-resolution crystal structure. While crystals of diffraction quality 
were not obtained during this study, a number of positive crystallisation leads were identified 
and provide a good starting point for the pursuit of a HsaNeuNAc 9-PS crystal structure. If 
achieved, this would represent the first structure of a NeuNAc 9-PS, and the second only 
structure of any sialic acid synthase. 
Certain pathogenic bacteria also express NeuNAc on their own cell surfaces, allowing 
immune system evasion by mimicking the surface physiology of their mammalian host’s 
cells.
7
 As previously mentioned, bacterial and mammalian sialic acid synthases differ 
primarily in the nature of the sugar-substrates they utilise in catalysis.
4
 Bacterial NeuNAcS 
catalyses the condensation of PEP with ManNAc, whereas mammalian NeuNAc 9-PS 
catalyses the condensation of PEP with the phosphorylated derivative ManNAc 6-P. 
Interestingly, these enzymes are entirely exclusive for their respective sugar-substrates. 
Bioinformatic analysis of bacterial and mammalian sialic acid synthases reveals the 
sequences corresponding to the β2α2 loop and AFPL domain/linker regions are most variable 
between these two clades, but are highly conserved within each clade.
86
 This alludes to an 
evolutionary divergence of these sequences to facilitate alternate functions. The β2α2 loop and 
AFPL domains are known to contribute sugar-substrate binding residues in both 
NmeNeuNAcS and HsaNeuNAc 9-PS, and thus peptide sequence variation across these 
regions is likely indicative of involvement in selection for and stabilisation of their respective 
sugar-substrates.
32
 Unlike the β2α2 loop of mammalian NeuNAc 9-PS, which is rich in 
conserved cationic residues, the bacterial β2α2 loop does not possess such positive charge 
character. This can be rationalised in that the bacterial sugar-substrate ManNAc lacks the C-6 
phosphate group, and is neutral at physiological pH, meaning electrostatic stabilisation is 
unnecessary. Variance in electrostatic properties across the sugar-substrate binding site of 
mammalian and bacterial enzymes may reflect a mechanism of selecting for phosphorylated 
and unphosphorylated forms of the sugar-substrate.  
While the β2α2 loop and AFPL domains are likely to be involved in discriminating between 
bacterial and mammalian sugar-substrates, the sugar-substrate specificity of NmeNeuNAcS 
could not be altered to that of the human enzyme by simply substituting these regions of 
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interest. Low sequence identity between the two enzymes makes this a difficult task, with 
unforeseen disruption to PEP binding and quaternary structure hindering success.  
In bacterial systems, NeuNAc is also utilised in catabolic pathways as a source of carbon, 
nitrogen and energy (Figure 3.22).
7, 88
 The first step of NeuNAc catabolism involves lyase 
cleavage of NeuNAc to pyruvate and ManNAc. ManNAc is subsequently phosphorylated to 
ManNAc 6-P which eventually enters glycolysis as fructose 6-phosphate.
7
 As bacterial 
NeuNAcS is specific only for unphosphorylated ManNAc, phosphorylation at C-6 would 
effectively commit ManNAc to the catabolic pathway, preventing futile return to the 
NeuNAc pool.  
The absolute specificity for the unphosphorylated sugar-substrate also makes bacterial 
NeuNAcS a promising target for inhibition with novel antibiotic compounds. Because the 
bacterial and mammalian enzymes are specific for their respective sugar-substrates, it is 
unlikely that sugar-substrate or transition-state analogues designed to bind bacterial 
NeuNAcS, would have any inhibitory effect on the mammalian enzyme. Inhibition of 
bacterial NeuNAcS may provide a novel approach to the early stage treatment of infections 
otherwise resistant to common antibiotics. Disabling the de-novo NeuNAc biosynthesis 
pathway in pathogenic bacteria would effectively destroy the pathogen’s molecular disguise, 
and expose them to the host’s immune system for clearance. 
In addition to NeuNAc, several species of pathogenic bacteria synthesise a number of unique 
sialic acids not observed in the animal kingdom.
10-11, 48
 Legionaminic and pseudaminic acid 
are two such ‘bacterial sialic acids’, both of which are required for the glycosylation and 
function of cell surface structures including flagella, in a number of motile pathogenic 
bacteria.
44, 48
 Involvement in the sialylation of flagellar proteins directly links these sugar 
compounds to the motility and virulence of these species.
11, 47
 Legionaminic and pseudaminic 
acid are biosynthesised by condensation of PEP with 2,4-diacetamido-2,4,6-trideoxy-D-
mannopyranose and 2,4-diacetamido-2,4,6-trideoxyaltrose respectively. These sugar-
substrates differ from one another by inversion of stereochemistry, and from ManNAc by 
variation in the nature and stereochemistry of the hexose-ring substituents (Figure 4.9). The 
aforementioned condensation reactions are catalysed by members of the evolutionarily 
related sialic acid synthase family. How these enzymes selectively recognise and bind the 
appropriate hexose sugar-substrate in vivo remains unknown, however multiple sequence 
alignment again suggests involvement of the β2α2 loop and AFPL domain/linker. It seems 
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likely that these regions, which are poorly conserved between the different sialic acid 
synthase clades, became specialised through divergent evolution from a promiscuous 
ancestral enzyme capable of utilising multiple sugar substrates in catalysis.
90
 Legionaminic 
acid synthase (LegS) may represent an extant relic of this ancestral enzyme as CjeLegS is bi-
functional in nature, and exhibits low levels of activity with ManNAc.
86
 A straight forward 
substitution of the β2α2 loop residues of CjeLegS and CjePseS with those from CjeNeuNAcS 
failed to improve activity with ManNAc, suggesting sugar-substrate selectivity results from a 
far more complex set of interactions between the β2α2 loop and other structural elements. 
Solving the crystal structures of these bacterial sialic synthases will allow identification of the 
specific sugar-substrate binding residues, and will aid in tracking the evolutionary changes 
which have allowed these enzymes to become specific for their respective substrates. 
Delineation of binding modes and key active site contacts may additionally provide the basis 
for design of bacterial sialic acid synthase inhibitors as novel antibiotic compounds. The 
absence of these enzymes in mammals and their critical role in motility and pathogenicity 
makes LegS and PseS ideal candidates for drug-targeting. 
It is remarkable to think that the modern day sialic acid synthases are capable of recognising 
and binding the correct hexose sugar-substrates in vivo, considering the plethora of 
structurally similar compounds present in the cellular environment. This ability to 
discriminate between subtle structural differences in sugar-substrate makes these central 
enzymes of sialic acid biosynthesis a paradigm of molecular recognition. By further 
understanding the ways in which this specificity is achieved on a molecular level, we will 
begin to expose ways in which these enzymes can be exploited toward therapeutic or 
biosynthetic advantage. 
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Chapter 6: Materials and methods 
6.1 Computational tools         
                       
6.1.1 Protein structure visualisation        
  
Protein structures were visualised, and figures created, using PyMOL (version 1.5, 
Schrödinger LLC).
93
 
6.1.2 Sequence alignments         
       
Pairwise and multiple sequence alignments were generated using the ClustalOmega server.
83-
84
 Alignment outputs were visualised using JalView.
94
  
6.1.3 Phylogenetic trees          
   
The multiple alignment outputs from ClustalOmega were entered into Figtree for generation 
and visualisation of phylograms.
95
 
6.1.4 Homology modelling and induced-fit substrate docking of HsaNeuNAc 9-PS  
             
A model of HsaNeuNAc-9-PS was built by homology modelling using Prime.
96-98
 The model 
was constructed using the comparative method with the crystal structure of NmeNeuNAcS as 
the template (PDB ID: 1XUZ). Both monomers were built at the same time to generate the 
dimer structure. The ligands bound in the active site of NmeNeuNAcS (PEP and rManNAc) 
were retained in the homology model of HsaNeuNAc-9-PS. The dimer was then minimised 
with Prime, to optimise bond length and bond angles, and to remove steric clashes.  
The structure of the ligand ManNAc 6-P was built and prepared in Maestro and LigPrep 
respectively.
99-100
 The modelling of ManNAc 6-P to the active site of HsaNeuNAc 9-PS was 
conducted with the Induced-Fit Docking protocol from Schrodinger Suite 2012.
101-104
 Since 
the ManNAc binding loop in the homology model shows different conformations in each 
monomer, induced-fit docking of ManNAc 6-P was conducted in each of the monomers. The 
centre of the grid was defined as centroid of the workspace ligand, i.e. the ManNAc molecule 
bound in the homology model, since ManNAc 6-P was expected to bind in the same pocket 
in the active site as ManNAc in NmeNeuNAcS. For the initial docking, the Van der Waals 
radii of the atoms of the ManNAc 6-P molecule and the enzyme homology model were 
scaled by a factor of 0.5. The 20 best solutions of the initial docking were kept. Residues 70-
78 (on the ManNAc binding loop) as well as all residues on the homology model within a 5 Å 
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distance of the respective docked pose were refined. The ligands were re-docked to the top 20 
newly generated structures if the energy was within 30 kcal/mol of that of the best pose. 
6.2 General laboratory methods         
                          
6.2.1 Water           
        
All water used in these experiments was purified using a Millipore Milli-Q system. Water for 
all molecular biology applications was autoclave sterilised prior to use. 
6.2.2 Buffer preparation         
             
All buffers were pH adjusted using a Mettler Toledo SevenCompact
TM
 220 pH probe which 
was calibrated daily prior to use. pH adjustments were made using 1/10 M HCl and 1/10 M 
NaOH at the appropriate temperature. All buffers were filtered (0.2 µm) under vacuum and 
refrigerated until required. 
6.2.3 Removal of metal ions          
          
Divalent metal ions were removed from buffers by treatment with Chelex 100 Resin (Bio-
Rad). 5 g of resin was added per 100 mL solution and stirred for 1 hour at room temperature. 
Chelex-treated buffers were then re-pH adjusted prior to removal of chelex resin by filtration 
(0.2 µm) under vacuum.  
6.2.4 Enzyme substrate preparation        
            
Substrates (PEP, ManNAc, ManNAc 6-P, Man 6-P) used for all kinetic assays were prepared 
as 10 or 100 mM stock solutions in the appropriate assay buffer, and filtered prior to use. 
Because PEP is highly acidic, the stock solution was pH adjusted before use. Accurate 
substrate concentrations were determined prior to kinetic assays, by measuring (in triplicate) 
the change in absorbance at 232 nm following enzymatic catalysis of the limiting substrate. 
Wild-type NmeNeuNAcS was used for determination of PEP and ManNAc concentration, 
and wild-type HsaNeuNAc 9-PS for ManNAc 6-P and Man 6-P. A control sample lacking 
substrates was used to measure the change in absorbance upon enzyme addition. The total 
change in absorbance (∆A) upon completion of the enzyme catalysed reaction [(starting 
absorbance + enzyme absorbance) - (final absorbance)] could be used to calculate the 
concentration of the limiting substrate with the Beer-Lambert equation using the extinction 
coefficient of PEP (ε = 2.8 × 103 M−1 cm−1). 
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6.2.5 Antibiotics          
            
All proteins described in this thesis were expressed from the Gateway® expression vector 
pDEST
TM
17 which carries ampicillin (Amp) resistance. Amp was added to all growth media 
to a final concentration of 0.1 mg/mL. Chaperone 3 cells used for all protein expression 
additionally carry additional resistance to chloramphenicol (Cam) and spectinomycin (Spec). 
These antibiotics were added to all protein expression growth media at concentrations of 
0.025 mg/mL and 0.1 mg/mL respectively. Stock solutions of Cam (1000x) were dissolved in 
absolute ethanol at 25 mg/mL and stock solutions of Spec (100x) were dissolved in Milli-Q at 
10 mg/mL. Antibiotics were filter sterilised and stored at -80 °C, and freeze-thawed a 
maximum of two times. 
6.2.6 Culture media          
       
Lysogeny-broth (LB) agar was prepared by dissolving LB (Lennox L) (20 g/L) and agar (15 
g/L) base in Milli-Q water and sterilised by autoclaving. The LB-agar solution was then 
heated in a microwave oven until boiling, and left to cool in a 60 °C oven. The LB-agar 
solution was then further cooled to 50 °C before antibiotic(s) were added immediately prior 
to pouring into round petri dishes. LB media for plasmid extraction, pre-cultures and protein 
expression cultures were prepared by dissolving 20 g/L LB (Lennox L) base in Milli-Q water 
and sterilised by autoclaving. Antibiotic(s) were added immediately prior to use. 
6.3 Cloning and transformation        
           
6.3.1 Primer design          
       
All DNA primers used in this study were designed either by hand or using PrimerX 
(www.bioinformatics.org/primerx), and synthesised by Invitrogen. Lyophilized primers were 
re-suspended in sterilised TE buffer (10 mM Tris, 0.1 mM EDTA, pH 8.0) to a final 
concentration of 100 μM.   
6.3.2 Gateway® cloning technology        
        
All cloning and sub-cloning of genes was completed using Gateway® cloning technology 
(Life Technologies). The Gateway® system allows sub-cloning between expression systems 
without the use of traditional ligation sites and restriction enzymes. This system requires the 
installation of generic Gateway® 5’ and 3’ flanking sequences using sequence specific 
Gateway® primers. These 5’ and 3’ add-ons contain att-B sites which include recognition 
 104 
 
sequences for the enzymes which catalyse their specific recombination into Gateway® donor 
vectors.  
The gene containing generic gateway sequences is then incubated with a Gateway® donor 
vector (dsDNA plasmid) and an enzyme mixture known as BP clonase® II. This combination 
of enzymes catalyses the recombination and insertion of the gene containing generic att-B 
sites, into att-P recognition sites present in the donor vector sequence (BP reaction). The gene 
of interest, inserted into the donor vector is referred to as the entry vector. The Gateway® 
donor vector pDONR
TM
221 was used for all initial cloning steps.  
Once ligated into the entry vector, the target gene can be easily transferred into any 
Gateway® destination vector. All Gateway® destination vectors contain att-R recombination 
sequences and the enzyme mixture LR clonase® II is used to catalyse the insertion of the 
target gene, from entry vector, to destination vector (LR reaction). Expression of the target 
gene takes place from the destination vector. Destination vectors typically include additional 
elements such as inducible promoters and purification affinity-tag sequences, which are 
coupled to the target gene to facilitate selective expression and purification. 
The destination vector pDEST
TM
17 was used for expression of all proteins during this study. 
The pDEST
TM
17 plasmid vector couples the gene of interest to an inducible T7 bacteriophage 
promoter site, and an N-terminal histidine-tag (His-tag) for purification with immobilised 
metal affinity chromatography (IMAC). The pDEST
TM
17 plasmid vector carries ampicillin 
resistance, which is used as a selective marker for cells expressing the gene of interest.  
6.3.3 Sub-cloning wild-type HsaNeuNAc 9-PS      
          
An E. coli codon optimised synthetic gene encoding HsaNeuNAc 9-PS was purchased from 
Life Technologies. This gene was purchased pre-ligated into the entry vector pDONR
TM
221. 
Lyophilized pDONR
TM
221 bearing HsaNeuNAc 9-PS gene (5 μg dry weight) was re-
suspended with 50 μl sterilised TE buffer (10 mM Tris, 0.1 mM EDTA, pH 8.0) to a final 
concentration of 100 ng/μl  The LR reaction was then used to transfer the gene of interest into 
pDEST
TM
17 destination vector for expression. For LR reaction, 1 μl of entry clone 
(pDONR
TM221), 1 μl pDESTTM17 vector and 6 μl TE buffer were incubated with 2 μl LR 
Clonase® II mixture at room temperature for 1 hour. The reaction mixture was then 
incubated with 1 μl Proteinase K for 10 minutes at 37 ˚C. The reaction product (pDESTTM17 
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vector bearing HsaNeuNAc 9-PS gene) was used for transformation into competent plasmid 
propagation cell lines (Section 6.3.8).  
6.3.4 PCR protocol          
   
All polymerase chain reactions (PCR) were completed using a Veriti®96-well Thermal 
Cycler (Applied Biosystems). PCR was performed using PfuUltra High-Fidelity DNA 
Polymerase (Agilent). A 50 μL reaction mixture was made for each reaction using the 
manufacturer’s recommended protocol (unless otherwise stated) as shown in Table 6.1. The 
thermal cycling parameters used are outlined in Table 6.2. PCR products were purified where 
necessary, using E-Gel® CloneWell™ gels (Life Technologies).  
Table 6.1.  PCR reaction mixtures for PfuUltra DNA polymerase. 
 
 
Table 6.2. Cycling parameters used for PfuUltra DNA polymerase.  
Cycle step Temp Time Cycles 
Initial denaturation 95 ˚C 2 minutes 1 
Denaturation,  annealing and 
extension 
95 ˚C 30 seconds 
30 Primer Tm - 5 ˚C 30 seconds 
72  ˚C 1 minute 
Final extension 72  ˚C 10 minutes 1 
PfuUltra Reaction components Volume 
Reaction buffer (commercial) 5 µL 
Autoclaved milli-Q 40.6 µL 
dNTP mix (25 mM each dNTP) 0.4 µL 
DNA template (100 ng/µL) 1 µL 
Forward primer (100 ng/µL) 1 µL 
Reverse primer (100 ng/µL) 1 µL 
PfuUltra DNA Polymerase (2.5U/ µL) 1 µL 
Total reaction volume 50 µL 
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6.3.5 Chimera cloning          
           
The gene constructs encoding the β2α2 loop-swap chimeras were generated using a 7-step 
overlap extension PCR methodology outlined in section 3.4. All PCR steps were completed 
using PfuUltra high-fidelity DNA polymerase according to the manufacturer’s protocol 
(Section 6.3.4). Forward and reverse primers encoding the loop residues to be installed were 
designed and used to initially extend pre and post-loop fragments from the appropriate 
templates. The resulting linear fragments were then further extended with ‘bridging primers’ 
to introduce a 30 bp overlap between pre- and post-loop fragments. The overlapping 
fragments were then extended using nested gene primers containing generic gateway 
sequences to generate the complete linear constructs, with novel loop sequences installed. All 
primers used for Nme/Hsa β2α2 loop-swap and double-chimera cloning are shown in table 
6.3, and those used for cloning LegS and PseS loop-swap chimeras are shown in table 6.4. 
The Nme/Hsa AFPL domain-swap chimera was designed and cloned by Dr. Joseph as 
reported elsewhere.
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Table 6.3. DNA primers (5’-3’) used for cloning Nme/Hsa chimeras. Start codons are shown in blue, stop 
codons in red. Overlapping sequences for generic gateway extension are underlined. Sequence corresponding to 
NmeNeuNAcS is highlighted grey, and HsaNeuNAc 9-PS in green. Att-B sites for gateway recombination are 
shown in orange. 
 Nme/Hsa loop-swap chimera  Nme/Hsa double-chimera 
Template used Wild-type NmeNeuNAcS pDEST
TM
17 AFPL chimera construct pDEST
TM
17 
Forward nested gene 
primer  
GGCAGCGGCGGCATGCAAAACAACAACGA GGCAGCGGCGGCATGCAAAACAACAACGA 
Reverse nested gene 
primer  
GAAAGCTGGGTGTTATTCAATATCAGT 
GAAAGCTGGGTGTTAGCTTTTGATTTTTTTGCC 
Forward loop primer  
AAACATTCATGGGGTAAAACCTATGAAATTATGG
AACGTTGC 
AAACATTCATGGGGTAAAACCTATGAAATTATGG
AACGTTGC 
Reverse loop primer  
GCTGGTATACGGACGTTCCAGGGCCTCATCAGAC
ATTTCGTC 
GCTGGTATACGGACGTTCCAGGGCCTCATCAGAC
ATTTCGTC 
Forward bridging 
primer  
CGTCCGTATACCAGCAAACATTCATGGGGT CGTCCGTATACCAGCAAACATTCATGGGGT 
Reverse bridging 
ACCCCATGAATGTTTGCTGGTATACGGACG ACCCCATGAATGTTTGCTGGTATACGGACG 
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primer  
Forward generic 
gateway primer  
GGGGACAAGTTTGTACAAAAAAGCAGGCTTCGAA
AACCTGTATTTTCAGGGCAGCGGCGGC 
GGGGACAAGTTTGTACAAAAAAGCAGGCTTCGAA
AACCTGTATTTTCAGGGCAGCGGCGGC 
Reverse generic 
gateway primer  
GGGGACCACTTTGTACAAGAAAGCTGGGT GGGGACCACTTTGTACAAGAAAGCTGGGT 
 
Table 6.4. DNA primers (5’-3’) used for cloning LegS and PseS loop-swap chimeras. Start codons are shown in 
blue, stop codons in red. Overlapping sequences for generic gateway extension are underlined. Sequence 
corresponding to CjeNeuNAcS is highlighted grey, CjeLegS in yellow and CjePseS purple. Att-B sites for 
gateway recombination are shown in orange. 
 CjeLegS loop-swap chimera  CjePseS loop-swap chimera 
Template used CjeLegS (Cj1327) pDEST
TM
17 CjePseS (Cj1317) pDEST
TM
17 
Forward nested gene 
primer  GGCAGCGGCGCGATGAAAAAAACTTTAATCAT 
GGCAGCGGCGCGATGCAAATAGGAAATTTTAACA
CCG 
Reverse nested gene 
primer  
GAAAGCTGGGTGTTACTCACGGATAAGCTCATCT
TCT 
GAAAGCTGGGTGTCATTGGAAATCTCCTTGTTTT
AAA 
Forward loop primer  
AATGCAAATATTAGCATTCTTCAAATGGTGCAAA
AACTC 
AATGCAAATATTAGCATTTATGAGCTTTATGAAA
GTGCA 
Reverse loop primer  
ACCCGGTATAACATTTTTAGCCTTTGTGCTGATA
CAGTT 
ACCCGGTATAACATTTTTATCGCTATTTAGTGTG
AGGCT 
Forward bridging 
primer  
AATGTTATACCGGGTAATGCAAATATTAGC AATGTTATACCGGGTAATGCAAATATTAGC 
Reverse bridging 
primer  
GCTAATATTTGCATTACCCGGTATAACATT 
 
GCTAATATTTGCATTACCCGGTATAACATT 
 
Forward generic 
gateway primer  
GGGGACAAGTTTGTACAAAAAAGCAGGCTTCGAA
AACCTGTATTTTCAGGGCAGCGGCGGC 
GGGGACAAGTTTGTACAAAAAAGCAGGCTTCGAA
AACCTGTATTTTCAGGGCAGCGGCGGC 
Reverse generic 
gateway primer  
GGGGACCACTTTGTACAAGAAAGCTGGGT GGGGACCACTTTGTACAAGAAAGCTGGGT 
 
The completed linear constructs encoding the respective chimeras were then ligated into the 
Gateway® entry vector pDONR
TM
221 using the Gateway® BP reaction. 1 μl pDONRTM221, 
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1 μl loop swap PCR product and 6 μl sterilised TE buffer were incubated with 2 μl BP 
clonase® II enzyme mixture at 25 ˚C for one hour. The reaction mixture was incubated with 
1 μl Proteinase K for an additional 10 minutes at 37 ˚C to terminate the reaction and then 
stored on ice until required for transformation. 
The BP reaction products (pDONR
TM
221 vectors bearing genes of interest) were transformed 
into ONE SHOT® TOP10 E. coli plasmid propagation cells (Life Technologies) for plasmid 
propagation and purification (Section 6.3.8). Following purification of plasmid from pre-
cultured ONE SHOT® TOP10 cells, the chimera gene constructs were verified by 
sequencing and transferred into expression vector pDEST
TM
17 using the LR reaction as 
previously described in section 6.3.3. 
6.3.6 Site-directed mutagenesis        
        
Variants of HsaNeuNAc 9-PS were generated by site-directed mutagenesis. Primers used for 
mutagenesis are listed in Table 6.5. All mutagenesis was completed using the pDEST
TM
17 
bearing HsaNeuNAc 9-PS vector as a template, with PfuUltra DNA polymerase protocol 
(Section 6.3.4). 
 
Table 6.5. Mutagenic primer sequences. Substituted codons are underlined. 
Oligonucleotide Primer sequence (5’- 3’) 
 
 
 
 HsaK290A (Fwd) CCGTGTGAAATGGCCTGTAATGAAGCACTGGGTAAAAGCGT   
 HsaK290A (Rev) ACGCTTTTACCCAGTGCTTCATTACAGGCCATTTCACACGG   
HsaK74A (Fwd) GGAACGTCCGTATACCAGCGCACATTCATGGGGTAAAACC   
HsaK74A (Rev) GGTTTTACCCCATGAATGTGCGCTGGTATACGGACGTTCC 
HsaT80A (Fwd) CATTCATGGGGTAAAGCGTATGGTGAACATAAA 
 HsaT80A (Rev) TTTATGTTCACCATACGCTTTACCCCATGAATG 
 
 
6.3.7 Agarose gel electrophoresis        
     
Agarose gel electrophoresis was used to ensure PCR and mutagenesis products were 
successfully amplified and of the correct molecular weight. 30 mL of agarose gel was 
prepared by combining 0.3 g agarose, 29.4 mL milli-Q water and 600 μl 50x TAE buffer (2 
M Tris, 50 mM EDTA, 17.5% acetic acid). Agarose was dissolved by microwaving, then left 
to cool to 60˚C before adding 3 μl SYBR Safe DNA gel stain (10000x concentrate in 
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DMSO). The DNA gel was poured and refrigerated until set. 10 μl of each PCR product and 
2 μl loading dye was loaded onto the gel and run at 85 V for 50 minutes. The running buffer 
used was prepared by making 5 mL TAE buffer (50x) up to 250 mL with milli-Q water. 
6.3.8 Transformation into plasmid propagation cell lines and plasmid purification 
     
All pDEST
TM
17 or pDONR
TM
221 vectors containing genes of interest were initially 
transformed into competent E. coli ONE SHOT® TOP10 cells for plasmid propagation. For 
transformation, 2 μl of vector was added to 100 μl of ONE SHOT® TOP10 cells and 
incubated on ice for 20 minutes. Cells were then heat-shocked at 42 ˚C for 30 seconds and 
returned to ice for 2 minutes. 250 μl of SOC media (2 % tryptone, 0.5 % yeast extract, 10 
mM NaCl, 2.5 mM KCl, 10 mM MgSO4, 20 mM glucose) was added, and the transformation 
mixture incubated at 37 ˚C for one hour. 100 μl and 20 μl aliquots of the incubated mixture 
were then plated on LB agar, supplemented with 0.1 mg/mL amp. Plates were incubated 
overnight at 37 ˚C. Colonies from the transformation plates were selected and used to 
inoculate 5 mL LB cultures supplemented with ampicillin, which were then incubated 
overnight whilst shaking at 180 rpm, 37 ˚C in preparation for plasmid extraction. 
5 mL of pre-cultured ONE SHOT® TOP10 cells bearing propagated vector were harvested 
by centrifugation (13000 g, 1 minute) and the cell pellet used for plasmid extraction. 
Purification of the propagated vector from ONE SHOT® TOP10 cells was completed using a 
High-Pure Plasmid Isolation kit (Roche), according to the manufacturer’s instructions. 
Following extraction, the concentration of plasmid was measured by absorbance at 260 nm, 
and then vectors were sequenced to ensure the gene construct of interest was complete. 
Purified pDONR
TM
221 was then used for LR reaction (Section 6.3.3), while purified 
pDEST
TM
17 was used for transformation into expression cell lines. 
6.3.9 Transformation into expression cell lines      
   
Purified pDEST
TM
17 was used for transformation into competent expression cell-lines using 
the same method detailed in section 6.3.8.  
6.3.10 Colony PCR          
           
After transformation of E. coli ONE SHOT® TOP10 cells with pDONR
TM
221 plasmids, 
promising candidates for sequencing were identified with colony PCR. This procedure uses 
the forward gene specific DNA sequencing primer and reverse T7 terminator sequencing 
primer (GCTAGTTATTGCTCAGCGG) to confirm that the sub-cloned gene had been inserted 
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into the vector in the correct orientation. This was confirmed by the amplification of an 
appropriately sized DNA fragment from the colony PCR - subsequently visualised on agarose 
gel. 
PCR reactions were set up using Taq DNA Polymerase (Invitrogen) and following the 
manufacturer's instructions for reaction components and cycling parameters. Template DNA 
was provided as a toothpick scraping of an E. coli TOP10 colony from an agar plate of 
suitably-transformed cells. 
6.3.11 Glycerol stock preparation        
  
All E. coli cells transformed with plasmid vector were stored as glycerol stocks for use 
throughout this study. 250 μl 60 % (w/w) glycerol was added to 750 μl of the pre-cultured 
cells and flash frozen in liquid nitrogen prior to storage at -80˚C. 
6.3.12 DNA sequencing         
    
All recombinant expression vectors were sequenced prior to transformation into expression 
cell lines to ensure the gene constructs of interest were complete and free of unintended 
mutations. All sequencing was completed at the University of Canterbury School of 
Biological Sciences sequencing facility using an Applied Biosystems 3130xl Genetic 
Analyzer. Plasmid samples sent for sequencing were approximately 50 ng/μl. Forward and 
reverse T7 primers at a final concentration of 3.2 μM were used for sequencing pDESTTM17 
vectors, while M13 primers were used for sequencing pDONR
TM
221 vectors. Sequencing 
results were analysed using CLC sequence viewer 6 (Qiagen). 
6.4 Protein expression and purification        
       
6.4.1 Expression cell lines         
           
Expression of all recombinant proteins was tested in both E. coli BL21 (DE3) Star cells 
and/or E.coli BL21 (DE3) pBB540/pBB542 (Chaperone 3) cells. The highest yield of soluble 
protein was achieved for all proteins described in this study, when expressed in chaperone 3 
cells and so this cell-line was used for all up-scaled expression.  
6.4.2 Protein expression for purification       
           
Scrapings from chaperone 3 cell glycerol stocks were used to inoculate 100 mL LB pre-
cultures supplemented with appropriate antibiotics (Section 6.2.5). 100 mL pre-cultures were 
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incubated at 37 ˚C overnight whilst shaking at 180 rpm. The pre-cultured cells were then used 
to inoculate 2 L of LB, and achieve a starting optical density (OD) of ~0.1 at 600 nm. 2 L 
cultures were grown at 37 ˚C until OD600 was approximately 0.4, at which time the growth 
temperature was reduced to 23 ˚C. When OD600 reached 0.5-0.6, over-expression of protein 
was induced by addition of 0.5 mM isopropyl-β-D-thiogalactopyranoside (IPTG), and the cell 
culture grown overnight at 23 ˚C. Cells were harvested by centrifugation in 1 L bottles 
(14000 g, 15 minutes) and the cell pellet stored at -80˚C until required for purification. 
6.4.3 Cell lysis           
   
Harvested cell pellets were re-suspended in 50 mL low-salt buffer (500 mM NaCl, 50 mM 
K2HPO4, pH 8), and lysed on ice using sonication. Lysis was achieved with four rounds of 
sonication (35 pulse, 70-80 power, for 5 minutes) using an Omni Ruptor 4000 ultrasonic 
homogenizer.  
For smaller volume cultures (i.e 5 mL), including those used for initial expression testing, 
lysis was achieved using Bugbuster® protein extraction reagent (Novagen) instead of 
sonication. Cell pellets were resuspended in a smaller volume of buffer (approximately 1 mL) 
containing Bugbuster® reagent. 0.5 μL of Benzonase nuclease® (Novagen) was added to 
break down DNA, and the solution shaken at 25 °C for 20-30 min. 
Lysed cells were then centrifuged (21000 g, 40 minutes) to separate soluble and insoluble 
fractions. The soluble fraction was retained and kept on ice prior to purification. 
6.4.4 Purification protocol         
        
All proteins described in this study were purified using a common method, involving rounds 
of immobilised metal-affinity chromatography (IMAC) and size-exclusion chromatography. 
All chromatography steps were completed using a BioRad Biologic DuoFlow 
Chromatography system with QuadTec UV-Vis detector. Protein elution was monitored at 
280 nm throughout purification. Given the range of recombinant proteins expressed purified 
in this study, the same buffers could not always be used. The following buffers were used for 
purification of the majority of wild-type and variant proteins: 
Low-salt buffer (Talon equilibration): 500 mM NaCl, 50 mM K2HPO4 (pH 8). 
High-salt buffer (Talon elution): 500 mM NaCl, 50 mM K2HPO4 (pH 8), 200 mM imidazole.  
Size-exclusion buffer: 20 mM BTP (pH 7.5), 150 mM NaCl. 
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6.4.5 Immobilised metal-affinity chromatography       
       
The soluble crude lysate was filtered and loaded onto a Tricorn 10/50 Talon immobilized 
metal (cobalt) affinity chromatography (IMAC) column. IMAC is used for isolation of 
recombinant proteins with N or C-terminal poly-histidine tags. The six histidine residues of 
the tag selectively chelate Co
2+
 ions immobilized within the column resin, while untagged 
proteins elute in the flow through. The column bound His-tagged proteins can then be eluted 
with high concentrations of imidazole, which displaces the histidine imidazole functionality. 
The Talon column was pre-equilibrated with five column volumes of low-salt buffer, prior to 
sample injection. The column was then washed with ten column volumes of 100 % low-salt 
buffer, and the bound His-tagged protein eluted with six column volumes of 100 % high-salt 
buffer. Sample injection was completed at 1 mL/min while all buffer steps were completed at 
3 mL/min. The tagged-protein eluted as a single peak with a distinct imidazole shoulder. 
Elution fractions were collected, and buffer exchanged into low-salt buffer using a GE 
Healthcare HiPrep 26/10 desalting column (at 3 mL/min), or manually using a 15 mL 
Vivaspin Turbo 10K MWCO centrifugal concentrator to reduce imidazole concentration.  
6.4.6 TEV protease cleavage         
          
The desalted fractions were then incubated with recombinant tobacco etch virus (TEV) 
protease for one hour at 25 ˚C then overnight at 4˚C to cleave the N-terminal His-tag. TEV 
protease selectively hydrolyses the polypeptide chain between glutamine and glycine of the 
TEV cleavage consensus sequence (Glu-Asn-Leu-Tyr-Phe-Gln/Gly) which links the His-tag 
and the target protein sequence. TEV protease was added at a ratio of 1:100 to the substrate 
protein (by mass, as determined by absorbance).  
A second round of IMAC was then used to separate the cleaved target protein from free His-
tags and TEV, which contains a non-cleavable His-tag. The TEV incubation mixture was re-
filtered and applied to the Talon column, and run using the same protocol as for the first 
IMAC step (Section 6.4.5). The cleaved protein eluted in flow-through fractions while TEV 
protease and free His-tags were eluted with high-salt buffer. The flow-through fractions were 
pooled and concentrated to a volume <15 mL for size-exclusion chromatography. 
6.4.7 Size-exclusion chromatography        
      
Size-exclusion chromatography was used as a final polishing step. The concentrated protein 
was re-filtered and applied to a Superdex 200 26/60 size-exclusion chromatography (SEC) 
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column for the final step of purification. The column was pre-equilibrated with one column 
volume of SEC buffer (as specified) at 1 mL/min prior to sample injection. The column was 
then washed with an additional column volume at 1 mL/min.  
6.4.8 SDS-PAGE          
   
The purification process was monitored using sodium dodecyl sulphate - polyacrylamide gel 
electrophoresis (SDS-PAGE). Samples were taken at each stage of purification, and diluted 
three-fold with milli-Q water. 15 μl of the diluted sample, 1 μl of 0.5 M DTT and 5 μl of 
Novex Bolt
TM
 SDS sample buffer were mixed and boiled. When excessive DNA 
contamination was problematic, samples were incubated with 0.5 μl Benzonase® nuclease 
for 5 minutes prior to boiling. 10 μl of the boiled samples were loaded onto pre-cast Novex 
Bolt
TM
 10 % Bis-Tris Plus mini-gel. 11 μl of Novex pre-stained protein standard was loaded 
adjacent to the sample wells. The gel was run in 1x MOPS running buffer, at 165 V for 45 
minutes.  
The gel was then stained for ~1 hour (1 g Coomassie Blue, 400 mL methanol, 100mL glacial 
acetic acid 500 mL milli-Q water), then transferred to de-stain (400 mL methanol, 100 mL 
glacial acetic acid and 500 mL milli-Q) for ~1 hour. De-stained gels were visualised and 
photographed using the BioRad Gel Doc XR system. 
6.4.9 Protein concentration determination       
     
All protein concentrations (mg/mL) were determined by absorbance at 280 nm using a 
NanoDrop spectrophotometer. The spectrophotometer was blanked with the appropriate 
buffer before making absorbance measurements in triplicate. Extinction coefficients (M
-1
 cm
-
1 
at 280 nm) used for absorbance measurements are listed in table 6.6. Coefficient values 
were calculated based on protein amino acid sequence using ProtParam tool on the ExPASy 
proteomics server.  
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Table 6.6. Calculated protein extinction coefficients. *The difference in extinction coefficient of wild-type 
HsaNeuNAc 9-PS and point mutant variants is negligible and thus mutant extinction coefficients are not listed 
here. 
Protein Extinction coefficient (M
-1
 cm
-1 
at 280 nm) 
HsaNeuNAc 9-PS* 31400 
Nme/Hsa loop-swap chimera 28880 
Nme/Hsa double-chimera 23380 
CjeLegS loop-swap chimera 7450 
CjePseS loop-swap chimera 17420 
 
6.4.10 Protein concentration and buffer exchange       
          
Purified protein was concentrated to the desired final concentration using a 15 mL Vivaspin 
Turbo 10K MWCO centrifugal concentrator (4000 g, variable spin times). All concentrator 
units were rinsed before use with Milli-Q water. Protein solutions were buffer exchanged 
where necessary by repeatedly concentrating in a MWCO device and diluting with the new 
buffer.  
6.4.11 Removal of metal from proteins        
        
For assays requiring metal free apo-enzyme, protein was incubated with 10 mM EDTA for 30 
minutes at 4˚C, prior to buffer exchange into EDTA-free chelexed buffer. Alternatively, 
EDTA treated protein was dialysed against EDTA-free chelexed buffer using 10 kDa MWCO 
Slide-A-Lyzer dialysis cassettes (Thermo Scientific). Protein was dialysed against 1000-fold 
volume of EDTA-free buffer for 8 hours at 4˚C. The dialysis buffer was then replaced with 
fresh solution before continuing with dialysis overnight, with stirring to maximise solute 
exchange. 
6.4.12 Enzyme storage         
   
Purified protein of the desired concentration was flash frozen with liquid nitrogen as 100 μl 
or 200 μl aliquots, and stored at -80˚C until required. 
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6.5 Protein characterisation          
  
6.5.1 Mass spectrometry          
  
The molecular mass of all purified proteins was confirmed by mass spectrometry. Protein was 
buffer exchanged into 5 mM ammonium bicarbonate, and diluted to a final concentration of 1 
mg/mL for analysis. All measurements were made by electrospray ionisation using a Bruker 
maXis 3G (Ultra High Resolution Time of Flight) Tandem Mass Spectrometer. 
6.5.2 Kinetic assay          
     
The kinetic parameters of wild-type and variant enzymes were determined using a continuous 
UV-visible assay monitoring the consumption of PEP at 232 nm (ε = 2.8 × 103 M−1 cm−1) 
with a Varian Cary 100 UV Visible spectrophotometer.  
For HsaNeuNAc 9-PS wild-type and variants, quartz cuvettes (1 mL) containing 50 mM BTP 
(pH 7.5), 1 mM MgCl2, 0.3 mM PEP and variable concentrations of ManNAc 6-P or Man 6-P 
were incubated for 10 minutes at 37 ˚C. For all chimeric proteins, quartz cuvettes (1 mL) 
containing 50 mM BTP (pH 7.5), 1 mM MnCl2 and variable concentrations of PEP and 
ManNAc or ManNAc 6-P were incubated for 10 minutes at 25 ˚C. The enzymatic reactions 
were initiated by addition of 5 μL of purified enzyme for a final concentration of 0.025-0.05 
mg/mL and the initial reaction rates determined (in triplicate) by least-squares fit.  
Michaelis−Menten steady-state approximations were utilized to determine kinetic parameters 
with nonlinear fitting in GraFit (Erithacus Software). For chimera activity tests where 
residual activity was expected to be low, enzyme concentration was increased up to a final 
maximum concentration of 1 mg/mL.       
              
6.5.3 NMR activity assay         
   
PRESAT NMR was used for assessment of low-level enzyme activity, with a Varian 400 
MHz spectrometer. 5 mM PEP, 1 mM MgCl2, 15% D2O, 20 mM BTP (pH 7.5), 100 mM 
NaCl and 5 mM ManNAc or ManNAc 6-P were combined to a final volume of 1 mL and 
added to a 5 mm NMR tube. A blank PRESAT spectra was measured (64 scans) before 
adding 5 μL of enzyme at 15 mg/mL to initiate the reaction. Subsequent PRESAT spectra 
were measured at specific hourly time intervals following addition of enzyme. Activity was 
qualified by the proportional disappearance of substrate proton resonances and appearance of 
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product resonances. Scouting experiments were run as part of each spectra measurement in 
order to maximise water-suppression efficiency. 
6.5.4 Circular dichroism         
  
Circular Dichroism (CD) spectroscopy was used to ensure all recombinant proteins were 
correctly folded following purification, and retained wild-type like secondary structure 
composition. All CD measurements were performed using a JASCO J-815 
Spectropolarimeter. CD spectra were recorded in triplicate from 190 to 260 nm using a 0.5 
nm data pitch, 1 s response and 1 nm bandwidth at 25˚C. Protein for CD was diluted to 0.03 
mg/mL with milli-Q water. A 3 mL quartz cuvette with 1 cm path length was used for each 
measurement. Blank spectra were recorded for milli-Q water alone for each experiment 
before addition of protein, and subtracted from the protein spectra obtained. 
6.5.5 Differential scanning fluorimetry       
           
Protein melt temperatures were measured in the absence and presence of ligands by 
differential scanning fluorimetry (DSF) using an iCycler iQ5 Multicolour Real-Time PCR 
Detection System (Bio-Rad). Protein samples containing 0.1 mg/mL purified protein, 50 mM 
BTP (pH 7.5), 10 x SYPRO orange dye and the appropriate ligand or metal to a final 
concentration of 1 mM (where necessary) were aliquoted as 25 μL triplicates into a 96-well 
microplate. A blank sample was similarly prepared for each condition, with buffer in place of 
the protein. The melt proceeded in 0.2 °C increments from 20 - 95 °C, with a 20 s dwell time 
after each temperature rise. Measurements of fluorescence were made at the end of each 
dwell time.  
For analysis, an Excel spreadsheet with custom VBA-scripted macro was created by Dr. 
Timothy Allison to toggle and dynamically display melt and derivative curves for each 
sample. The melt temperatures were calculated as the temperature of maximum inflection of 
the melting curve after subtracting absorbance of the blank well. Error bars associated with 
DSF plots represent the standard deviation between triplicate measurements. 
6.5.6 Analytical gel filtration         
       
Native protein molecular masses were determined by analytical gel filtration on a Superdex 
200 10/300 column (GE Healthcare) equilibrated with 20 mM BTP (pH 7.5) containing 150 
mM NaCl. The elution volume of blue dextran (2000 kDa) was designated as the column 
void volume, and the column was then equilibrated with 1 mg/mL of known molecular 
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weight standards (Sigma Aldrich) including thyroglobulin (669 kDa), beta amylase (200 
kDa), alcohol dehydrogenase (150 kDa), ovalbumin (43 kDa), conalbumin (75 kDa) and 
carbonic anhydrase (29 kDa). Protein samples of 3 mg/mL were then run at 0.2 mL/min and 
the native molecular mass calculated as function of elution volume relative to elution volume 
of the molecular weight standards.        
  
6.5.7 Isothermal titration calorimetry       
          
The thermodynamic parameters of ligand binding for wild-type and variants of HsaNeuNAc 
9-PS were measured by isothermal titration calorimetry (ITC) using a VP-ITC unit operating 
at 298 K (MicroCal; GE Healthcare). Prior to use, protein was treated with 1 mM EDTA, and 
then buffer exchanged into chelexed 20 mM BTP (pH 7.5) with 150 mM NaCl. Stock 
solutions of ligand were then made using the same buffer, and pH adjusted to match the 
protein solution. All solutions were filtered and degassed under vacuum, and protein 
concentration was measured by UV absorption. For PEP binding experiments, 2 mM PEP 
was titrated into 90 μM protein with a background of 1 mM MgCl2. For ManNAc 6-P binding 
experiments, 5 mM ManNAc 6-P was titrated into 90 μM protein with a background of 1 mM 
MgCl2. Experiments were performed with a starting sample volume of 1.4 mL in the cell. 
Each titration proceeded via 57 injections of ligand: one 2 μL injection followed by 56 
injections of 5 μL.  
ITC titrations of wild-type NmeNeuNAcS and all chimeric proteins were completed using an 
ITC200 unit operating at 298 K (MicroCal; GE Healthcare) using the same sample 
preparation as described above however samples were not degassed in this case. For PEP 
binding experiments, 1 mM PEP was titrated into 150 μM protein with a background of 1 
mM MnCl2. Experiments were performed with a starting sample volume of 200 μL in the 
cell. Each titration proceeded via 20 injections of ligand: one 0.5 μL injection followed by 19 
injections of 2 μL.                                                               
 
Heats of dilution experiments (ligand titrated into buffer + 1 mM metal) were measured 
independently and subtracted from the integrated data before curve-fitting in Origin 7.0 with 
the standard one-site model supplied by MicroCal.                                             6.5.8 Small-angle X-ray scattering data collection 
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6.5.8 Small-angle X-ray scattering data collection 
Small angle X-ray Scattering (SAXS) measurements were performed at the Australian 
Synchrotron SAXS/WAXS beamline equipped with a Pilatus detector (1 M, 
170 mm × 170 mm, effective pixel size of 172 μm × 172 μm). The wavelength of the X-rays 
was 1.033 Å. The sample–detector distance was 1575 mm, which provided a q range of 0.01–
0.555Å
− 1
 [where q is the magnitude of the scattering vector, which is related to the scattering 
angle (2θ) and the wavelength (λ) as follows: q = (4π/λ)sinθ]. Data were collected from a 1.5 
mm glass capillary at 25 ˚C at 2 second intervals.  
Scattering data was collected for all proteins (~10 mg/ml) following elution from a size-
exclusion chromatography column (Superdex 200 5/150), pre-equilibrated with 20 mM BTP 
(pH 7.5) with 150 mM NaCl, in both the presence and absence of 1 mM PEP and 1mM 
MnCl2. Two-dimensional intensity plots from the peak of the size-exclusion chromatography 
run were radially averaged, normalized to sample transmission, and background subtracted.  
6.5.9 Small-angle X-ray scattering data processing      
   
Scattered intensity (I) was plotted versus q. All samples were devoid of an increase in 
intensity at low q (indicative of aggregation) unless otherwise mentioned. All Guinier plots 
were linear for qRg   < 1.3 unless otherwise mentioned. One-dimensional profiles were 
background subtracted, and Guinier fits were made using PRIMUS.
105
 Fourier transform was 
performed using PRIMUS to yield the function P(r), which gives both the relative 
probabilities of distances between scattering centres and the maximum dimension of the 
scattering particle Dmax. Theoretical scattering curve of HsaNeuNAc 9-PS homology model 
was generated from atomic coordinates and compared with experimental scattering curves 
using CRYSOL.
78 Similarly, theoretical scattering of wild-type NmeNeuNAcS was generated based 
on crystallographic coordinates (PDB: 1XUZ) and compared with the scattering profiles obtained for 
the chimeric proteins using CRYSOL. 
6.5.10 Crystallisation trials         
     
Crystal screens were either completed by hanging-drop vapour diffusion using 24-well VDX 
plates (Hampton Research) or using a Mosquito Crystal® (TTP Labtech) crystallisation robot 
on a 96-well sitting drop iQ plate (TTP Labtech). For 24-well plate screens, a final drop 
volume of 2 µL was used, consisting of 1 µL protein solution (in SEC buffer) and 1 µL 
reservoir solution (total reservoir volume of 500 µL). For 96-well sitting drop plates, a final 
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drop volume of 400 nL (equal parts protein and condition) and reservoir volume of 40 µL 
was used. Crystallisation screening trays were incubated at 20 ˚C or 4 ˚C indefinitely. 
Protein for crystallisation was taken from the middle two fractions of the SEC elution peak 
following purification, and used immediately where possible. Protein crystallisation trials 
were attempted in the presence and absence of MgCl2/MnCl2 and PEP, which was added by 
buffer exchanging protein into SEC buffer with additional ligands present at 1 mM.  
Proteins were screened at varied concentrations between 1 and 10 mg/mL (final concentration 
in drop) using commercially available crystallisation screening conditions. Protein 
crystallisation conditions used include: Molecular Dimensions Morpheus, JCSG-plus, PACT 
premier, Clear Strategy I, Clear Strategy II and ProPlex HT-96 screens.  
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Chapter 7. Appendices 
7.1 Appendix A.  Sequence alignments       
       
HsaNeuNAc-9-PS   MPLELEL-CPGRWVGGQHPCFIIAEIGQNHQGDLDVAKRMIRMAKECGADCAKFQKSELE   59 
NmeNeuNAcS       MQNNNEFKIGNRSVGYNHEPLIICEIGINHEGSLKTAFEMVDAAYNAGAEVVKHQTHIVE   60 
                 *  : *:    * ** :*  :**.*** **:*.*..* .*:  * :.**: .*.*.  :* 
 
 
HsaNeuNAc-9-PS   FKFNRKALERPYTSKHSWGKTYGEHKRHLEFSHDQYRELQRYAEEVGIFFTASGMDEMAV  119 
NmeNeuNAcS       DEMSDEAKQVI--PGNADVSIY-EIMERCALNEEDEIKLKEYVESKGMIFISTPFSRAAA  117 
                  ::. :* :      .:  . * *  .:  :..::  :*:.*.*. *::* :: :.. *. 
 
 
HsaNeuNAc-9-PS   EFLHELNVPFFKVGSGDTNNFPYLEKTAKKGRPMVISSGMQSMDTMKQVYQIVKPLNPNF  179 
NmeNeuNAcS       LRLQRMDIPAYKIGSGECNNYPLIKLVASFGKPIILSTGMNSIESIKKSVEIIREAGVPY  177 
                   *:.:::* :*:***: **:* :: .*. *:*:::*:**:*::::*:  :*::     : 
 
 
HsaNeuNAc-9-PS   CFLQCTSAYPLQPEDVNLRVISEYQKLFPDIPIGYSGHETGIAISVAAVALGAKVLERHI  239 
NmeNeuNAcS       ALLHCTNIYPTPYEDVRLGGMNDLSEAFPDAIIGLSDHTLDNYACLGAVALGGSILERHF  237 
                 .:*:**. **   ***.*  :.: .: ***  ** * *      .:.*****..:****: 
 
 
HsaNeuNAc-9-PS   TLDKTWKGSDHSASLEPGELAELVRSVRLVERALGSPTKQLLPCEMACNEKLGKSVVAKV  299 
NmeNeuNAcS       TDRMDRPGPDIVCSMNPDTFKELKQGAHALKLARGGKKDTIIAGEKPTKDFAFASVVADK  297 
                 *      * *  .*::*  : ** :..: :: * *. .. ::  *   ::    ****.  
 
 
HsaNeuNAc-9-PS   KIPEGTILTMDMLTVKVGEPKGYPPEDIFNLVGKKVLVTVEEDDTIMEELVDNHGKKIKS  359 
NmeNeuNAcS       DIKKGELLSGDNLWVKRPGNGDFSVNEYETLFGKVAACNIRKGAQIKKTDIE--------  349 
                 .* :* :*: * * **      :  ::  .*.** .  .:.:   * :  ::         
 
 
1: HsaNeuNAc-9-PS  100.00  28.7   % 
2: NmeNeuNAcS      28.7    100.00 % 
 
Figure 7.1. Pairwise alignment of HsaNeuNAc 9-PS and NmeNeuNAcS. Catalytic barrel residues are blue, β2α2 
loop residues red, linker region residues yellow and AFPL domain residues green. Domain annotation is based 
on the structure of NmeNeuNAcS (PDB 1XUZ).  
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CjePseS          --MQIGNF-NTDKKVFIIAELSANHAGSLEMALKSIKAAKKAGADAIKIQTYTPDSLTLN 57 
CjeNeuNAcS       MQIKIDKLTISQKNPLIIPEIGINHNGSLEIAKLMVDAAKRAGAKIIKHQTHIVEDEMSQ 60 
CjeLegS          -----------MKKTLIIAEAGVNHNGDLNLAKKLIEIAADSGADFVKFQSFKAKNCIST 49 
                             *: :** * . ** *.*::*   :. *  :**. :* *:.  ..     
 
 
CjePseS          SDK-EDFIIKGGLWDKRKLYELYESAKTPYEWHSQIFETAQNEGILCFSSPFAKEDVEFL  116 
CjeNeuNAcS       EAKNVI----PG-NANISIYEIMEQCALNYKDELALKEYVEKQGLVYLSTPFSRAAANRL  115 
CjeLegS          KAKKAPYQLKTT-ANDESQLQMVQKLELDLKAHKELILHAKKCNIAFLSTPFDLESVDLL  108 
                 . *            . .  :: :.     : .  :   .::  :  :*:**    .: * 
 
 
CjePseS          KRFDPIAYKIASFEANDENFVRLIAKEKKPTIVSTGIATEEELFKICEIFKEE--KNPDL  174 
CjeNeuNAcS       EDMGVSAYKIGSGECNNYPLIKHIAQFKKPMIISTGMNSIESIKPTVKILRDY---EIPF  172 
CjeLegS          NELGLKIFKIPSGEITNLPYLKKIAKLNKKIILSTGMANLGEIEEALNVLCKNGAKRQNI  168 
                 : :    :** * * .:   :: **: :*  *:***: .  .:    ::: .    .  : 
 
 
CjePseS          VFLKCTSTYPTAIEDMNLKGIVSLKEKFNVEVGLSDHSFGFLAPVMAVALGARVIEKHFM  234 
CjeNeuNAcS       VLLHTTNLYPTPSHLVRLQAMLELYKEFNCLYGLSDHTTNNLACIGAIALGASVLERHFT  232 
CjeLegS          TLLHCTTEYPAPFNEVNLKAMQSLKDAFKLDVGYSDHTRGIHISLAAVALGACVIEKHFT  228 
                 .:*: *. **:  . :.*:.: .* . *:   * ***:      : *:**** *:*:**  
 
 
CjePseS          LDKSIESEDSKFSLDFDEFKAMVDAVRQAESALGDGKLDLDEKVLK-NRVFARSLYASKD  293 
CjeNeuNAcS       DTMDRKGPDIVCSMDESTLKDLINQTQEMVLLRGDNNKNPLKEEQVTIDFAFASVVSIKD  292 
CjeLegS          LDKNMSGPDHKASLEPQELKMLCTQIRQIQKAMGDGIKKASKSEQKNINIVRKSLVAKKD  288 
                   . .. *   *:: . :* :    ::     **   .  :.      .   *: : ** 
 
 
CjePseS          IKKGEMFSEENVKSVRPSF-GLHPKFYQELLGKKASKDIKFGDALKQGDFQ       343 
CjeNeuNAcS       IKKGEILSMDNIWVKRPSKGGISAKDFEAILGKRAKKDIKNNIQLTWDDFE       343 
CjeLegS          IKKGEIFSEGNLTTKRPAN-GISAMRYEEFLGKIATKNYKEDELIRE----       334 
                 *****::*  *:   **:  *:    :: :*** *.*: *    :       
 
PERCENTAGE IDENTITY MATRIX:         1: CjePseS      100.00   32.6     35.2   % 
           2: CjeNeuNAcS   32.6     100.00   36.7   % 
           3: CjeLegS      35.2     36.7     100.00 % 
 
 
Figure 7.2. Multiple alignment of C. jejuni sialic acid synthases. Catalytic barrel residues are blue, β2α2 loop 
residues red, linker region residues yellow and AFPL domain residues green. Domain annotation is based on the 
structure of NmeNeuNAcS (PDB 1XUZ).  
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7.2 Appendix B. Mass spectrometry derived molecular weights    
          
Protein Experimental mass (Da) Theoretical mass from sequence (Da) Error (%) 
Wild-type HsaNeuNAc 9-PS 40494.6 40495.7 0.003 
HsaK290A 40436.8 40437.5 0.002 
HsaK74A 40437.5 40437.5 0.00 
HsaT80A 40465.1 40465.7 0.002 
Nme/Hsa loop-swap chimera 39067.3 39069.4 0.005 
Nme/Hsa double-chimera 40020.8 40022.9 0.005 
LegS loop-swap chimera 36780.2 36781.0 0.002 
PseS loop-swap chimera 38211.5 38212.6 0.003 
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